```
FILE 'HCAPLUS' ENTERED AT 18:01:21 ON 02 JUL 2008
          13810 S GUAR OR GALACTOMANNAN
L2
             79 S FLUOROURACIL OF FLUORODEOXYURIDINE OR FLUOROPYRIMIDINE OF CIS
L3
           2637 S LEUCOVORIN
L4
              0 S L1 AND L2
L5
              0 S L1 AND L2 AND L3
L6
             0 S L4 AND (PY<2004 OR AY<2004 OR PRY<2004)
L7
              0 S L5 AND (PY<2004 OR AY<2004 OR PRY<2004)
     FILE 'STNGUIDE' ENTERED AT 18:01:32 ON 02 JUL 2008
     FILE 'HCAPLUS' ENTERED AT 18:02:04 ON 02 JUL 2008
L8
          22775 S FLUOROURACIL OR FLUORODEOXYURIDINE OR FLUOROPYRIMIDINE OF CIS
L9
             38 S L1 AND L8
L10
             6 S L1 AND L8 AND L3
L11
             18 S L9 AND (PY<2004 OR AY<2004 OR PRY<2004)
L12
             2 S L10 AND (PY<2004 OR AY<2004 OR PRY<2004)
    FILE 'HCAPLUS' ENTERED AT 18:09:45 ON 02 JUL 2008
L13
        235409 S INTERFERON OR INTERLEUKIN
L14
            38 S L1 AND L13
L15
              3 S L1 AND L3 AND L13
            23 S L14 AND (PY<2004 OR AY<2004 OR PRY<2004)
L16
L17
             1 S L15 AND (PY<2004 OR AY<2004 OR PRY<2004)
```

=> file hcaplus COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 1.89 1.89

FILE 'HCAPLUS' ENTERED AT 15:30:03 ON 02 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jul 2008 VOL 149 ISS 1 FILE LAST UPDATED: 1 Jul 2008 (20080701/ED)

 ${
m HCAplus}$ now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s guar or galactomannan

11663 GUAR

3183 GALACTOMANNAN

L1 13810 GUAR OR GALACTOMANNAN

»> s chemotherapeutic or fluorouracil or fluoropyrimidine or methotrexate or (ARA-c) or hydroxyurea or vinblastine or vincestine or vindesine or chorambucill or streptozocin or cisplatin or dacarbazine or doxorubicin or cyclophosphamide or bisulfan or prednisone or paclitaral

> 22968 CHEMOTHERAPEUTIC 21389 FLUOROURACIL

1420 FLUOROPYRIMIDINE

17958 METHOTREXATE 6608 ARA

3853008 C

3127 ARA-C

(ARA(W)C)

6783 HYDROXYUREA

8154 VINBLASTINE

9557 VINCRISTINE

1215 VINDESINE

2630 CHLORAMBUCIL 1444 STREPTOZOCIN

23605 CISPLATIN

1508 DACARBAZINE

18514 DOXORUBICIN

```
19877 CYCLOPHOSPHAMIDE
           31 BISULFAN
          8061 PREDNISONE
         12210 PACLITAXEL
        129295 CHEMOTHERAPEUTIC OR FLUOROURACIL OR FLUOROPYRIMIDINE OR METHOTR
               EXATE OR (ARA-C) OR HYDROXYUREA OR VINBLASTINE OR VINCRISTINE
              OR VINDESINE OR CHLORAMBUCIL OR STREPTOZOCIN OR CISPLATIN OR
               DACARBAZINE OR DOXORUBICIN OR CYCLOPHOSPHAMIDE OR BISULFAN OR
              PREDNISONE OR PACLITAXEL
=> s cancer or tumor or neopla?
       365017 CANCER
       457299 TUMOR
        549898 NEOPLA?
       841515 CANCER OR TUMOR OR NEOPLA?
=> s cytokine or leucovorin
        116509 CYTOKINE
         2637 LEUCOVORIN
        119110 CYTOKINE OR LEUCOVORIN
=> s intravenous or parenteral or intraarticular or subcutaneous or transdermal or
inhalation or transmucosal or rectal or intrathecal or topical
         43522 INTRAVENOUS
         23116 PARENTERAL
         1071 INTRAARTICULAR
         18795 SUBCUTANEOUS
         15739 TRANSDERMAL
        40356 INHALATION
         1276 TRANSMUCOSAL
         15462 RECTAL
         6894 INTRATHECAL
         50861 TOPICAL
        203405 INTRAVENOUS OR PARENTERAL OR INTRAARTICULAR OR SUBCUTANEOUS OR
              TRANSDERMAL OR INHALATION OR TRANSMUCOSAL OR RECTAL OR INTRATHEC
              AL OR TOPICAL
=> s 11 and 12
          102 L1 AND L2
=> s 11 and 13
         200 L1 AND L3
=> s 11 and 12 and 14
```

L2

1.3

T.4

L5

1.7

T-10

=> s 11 and 13 and 15

=> s 11 and 12 and 15

=> s 11 and 13 and 15

12 L1 AND L2 AND L4

38 L1 AND L3 AND L5

20 L1 AND L2 AND L5

=> fiel stnguide

FIEL IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> file stnguide COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY

FULL ESTIMATED COST

SESSION 2.69 4.58

FILE 'STNGUIDE' ENTERED AT 15:30:20 ON 02 JUL 2008 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION. LAST RELOADED: Jun 27, 2008 (20080627/UP).

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.06 4.64

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 15:30:56 ON 02 JUL 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jul 2008 VOL 149 ISS 1 FILE LAST UPDATED: 1 Jul 2008 (20080701/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 18 and (PY<2003 or AY<2003 or PRY<2003)

22935496 PY<2003 4491181 AY<2003 3959212 PRY<2003

1 L8 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s 19 and (PY<2003 or AY<2003 or PRY<2003)

22935496 PY<2003 4491181 AY<2003 3959212 PRY<2003

L13 16 L9 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s 110 and (PY<2003 or AY<2003 or PRY<2003)

22935496 PY<2003 4491181 AY<2003 3959212 PRY<2003

10 L10 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s 111 and (PY<2003 or AY<2003 or PRY<2003)

22935496 PY<2003 4491181 AY<2003 3959212 PRY<2003

16 L11 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> file stnguide

L14

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 2.69 7.33

FILE 'STNGUIDE' ENTERED AT 15:31:08 ON 02 JUL 2008 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION. LAST RELOADED: Jun 27, 2008 (20080627/UP).

=> file hcaplus

COST IN U.S. DOLLARS SINCE FILE TOTAL SESSION ENTRY FULL ESTIMATED COST 0.06 7.39

FILE 'HCAPLUS' ENTERED AT 15:31:43 ON 02 JUL 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jul 2008 VOL 149 ISS 1 FILE LAST UPDATED: 1 Jul 2008 (20080701/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 112 t.i abs bib

- L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration
- AB The present invention relates to a method for augmentation of epithelial concentration and systemic exposure of therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux transporter systems by using a vaginal or buccal drug delivery compns. and/or devices. Specifically, the invention relates to a method for augmentation of intraepithelial concentration and/or systemic bioavailability for delivery of anti-viral and/or anti-cancer therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux systems by using a vaginal or buccal drug delivery of these drugs into the systemic circulation by delivering such drug to a subject in need thereof vaginally or buccally in an especially formulated composition increasing the drug's bioavailability by providing means for increasing the drug solubility and permeability through the vaginal or buccal mucosa.
- AN 2007:175576 HCAPLUS <<LOGINID::20080702>>
- DN 146:258964
- TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration
- IN Pauletti, Giovanni M.; Harrison, Donald C.; Desai, Kishorkumar J.
- PA USA SO U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 208,209. CODEN: USXXCO
- DT Patent
- LA English
- FAN.CNT 12

FAN.	CNT 12																	
	PATENT				KIN	D :	DATE			APPL		ION I			D.	ATE		
						-												
PI	US 2007	10036	834		A1		2007	0215		US 2	006-	5221:	26		2	0060	915 -	<
	AU 7652	69			B2		2003	0911		AU 2	001-	5419:	2		2	0010	703 -	<
	US 2003	0049	302		A1		2003	0313		US 2	002-	2266	67		2	0020	B21 ·	<
	US 6982	091			B2		2006	0103										
	US 2006	0002	966		A1		2006	0105		US 2	005-	2082	09		2	0050	818 -	<
	AU 2006	2925	07		A1		2007	0329		AU 2	006-	2925	07		2	0060	915	
	CA 2622	746			A1		2007	0329		CA 2	006-	2622	746		2	0060	915	
	WO 2007	0355	15		A2		2007	0329		WO 2	006-	US36	087		2	0060	915	
	WO 2007	0355	15		A3		2007	0927										
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KN,	KP,	
		KR,	KZ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	
		MW.	MX,	MY,	MZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RS,	
		RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SV,	SY,	TJ,	TM,	TN,	TR,	TT,	TZ,	
		UA,	UG,	US,	UZ,	VC,	VN,	ZA,	ZM,	ZW								
	RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	
		IS,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	BJ,	
		CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG,	BW,	GH,	
							NA,											

```
PRAI US 2001-3158779 P 20010829 <--
US 2002-226667 A1 20020821 <--
US 2005-208209 A2 20050818
US 2005-717680P P 20050915
AU 1998-76976 A3 19980610 <--
W0 2006-US36087 W 20060915
```

=> d 113 1-16 ti abs bib

- L13 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Foam prepared from nanoemulsions for administration to the skin

AB The present invention provides a foamable composition for administration to the skin, body surface, body cavity or nucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water nano emulsion composition includes: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1-% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; and (c) a liquefied or compressed gas propellant at a concentration of 3-25% by weight of the total composition,

water and

optional ingredients are added to complete the total mass to 100%. Upon release from an aerosol container, the foamable composition forms and expanded foam suitable for topical administration. The present invention further provides methods of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface using such foamable compns.; and to methods of producing such foams having an improved bubble size.

AN 2008:708760 HCAPLUS <<LOGINID::20080702>>

- TI Foam prepared from nanoemulsions for administration to the skin
- IN Tamarkin, Dov; Besonov, Alex; Eini, Meir; Danziger, Jorge
- PA Foamix Ltd., Israel
- SO U.S. Pat. Appl. Publ., 35pp., Cont.-in-part of U.S. Ser. No. 389,742.
- CODEN: USXXCO
- DT Patent
- LA English
- FAN.CNT 26

	PATEN	r NO.			KIN		DATE			APPL					D.	ATE		
						-												
PI	US 20	080138	3296		A1		2008	0612		US 2	007-	9756	21		2	0071)19 <-	
	WO 20	040372	25		A2		2004	0506		WO 2	003-	TB55	27		2	0031	024 <-	
	WO 20						2004								_			
			AG,						D7	DD	DC.	DD	DV	D7	CZ	CH	CM	
	**																	
			CR,															
			HR,															
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NO,	ΝZ,	OM,	PH,	
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	ΤJ,	TM,	TN,	TR,	TT,	TZ,	
		UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	zw							
	R	W: GH,	GM.	KE.	LS.	MW.	MZ.	SD.	SL.	SZ.	TZ.	UG,	ZM.	ZW.	AM,	AZ.	BY,	
			KZ,															
			FR.															
			ВJ,															
	TTC 20						2005											
	US 20050069566 A1						2005										425 <-	
	ZA 2005003298 A																	
	US 20060140984 A1						2006										222 <-	
	US 20060233721 A1 20061						1019		US 2	006-	3897	42		2	0060	327 <-		
	AU 2006201878 A						2007	0927		AU 2	006-	2018	78		2	0060.	504 <-	
PRAI	PRAI IL 2002-152486 A						2002	1025	<-	_								
	US 2002-429546P						2002	1129	<-	-								

```
US 2003-492385P P 20030804
W0 2003-1B5527 W 20031024
US 2004-911367 A2 2004804
US 2005-717058P P 20050914
US 2005-532618 A2 20051222
US 2006-389742 A2 20060327
```

- L13 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Polypropylene glycol alkyl ether foamable pharmaceutical carrier vehicle and pharmaceutical compositions thereof comprising surfactant and liquid hydrocarbon gas propellant
- AB The present invention teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent water and a liquefied hydrocarbon gas propellant; and pharmaceutical compns. thereof. Thus, concns. of active agents (in wt%) in foamable compns. were as follows: hydrocortisone acetate 1, betamethasone valerate 0.12, clobetasol proprionate 0.05, acyclovir 5, ciclopirox 1, clindamycin 1-2, azelaic acid 15, metronidazol 0.25-2, diclofenac 1, tacrolinus 0.2, caffeine 5, clotrimazole 1, lidocaine base 2, terbinafine HCl 1, gentamycin 0.1,
- dexpanthenol 5, urea 5-10, ammonium lactate 12-17.5, povidone-iodine 10.
 AN 2008:417770 HCAPLUS <<LOGINID::20080702>>
- DN 148:410765
- TI Polypropylene glycol alkyl ether foamable pharmaceutical carrier vehicle and pharmaceutical compositions thereof comprising surfactant and liquid hydrocarbon gas propellant
- IN Freidman, Doron; Tamarkin, Dov; Feiman, Naomi; Schuz, David; Berman, Tal PA Foamix Ltd., Israel
- SO PCT Int. Appl., 115pp.
 - CODEN: PIXXD2
- DT Patent
- LA English

FAN.	CNT	26																	
		TENT				KIN		DATE			APPL						ATE		
PI		2008															0070		
		W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BH,	BR,	BW,	BY,	BZ,	CA,	
			CH,	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DO,	DZ,	EC,	EE,	EG,	ES,	FI,	
			GB,	GD,	GE,	GH,	GM,	GT,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	
			KM,	KN,	KP,	KR,	KZ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LY,	MA,	MD,	ME,	
			MG,	MK,	MN,	MW.	MX,	MY,	MZ,	NA,	NG,	NI,	NO.	NZ,	OM,	PG,	PH,	PL,	
			PT.	RO.	RS.	RU.	SC.	SD,	SE.	SG.	SK.	SL,	SM.	sv.	SY.	TJ.	TM.	TN.	
			TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	ZA,	ZM,	ZW					
		RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	
			IS,	IT,	LT,	LU,	LV,	MC,	MT,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	
			ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG,	BW,	
			GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	
			BY,	KG,	KZ,	MD,	RU,	TJ,	TM										
	US	2007	0020	213		A1		2007	0125		US 2	006-	4889	89		20	3060.	719 -	<
	US	2007	0253	911		A1		2007	1101		US 2	007-	7178	97		20	0070	313 -	<
PRAI	US	2006	-811	627P		P		2006	0607										
	US	2006	-482	596		A		2006	0707										
	US	2006	-488	989		A		2006	0719										
	US	2007	-717	897		A		2007	0313										
	IL	2002	-152	486		A		2002	1025	<-	-								
	US	2002-429546P						2002		<-	_								
		3 2003-492385P						2003	0804										
		2003						2003											
	WO	WO 2003-IB5527				W		2003	1024										
	US 2003-530015P					P													
	US 2004-835505					A2		2004	0428										
	US	2004	-911	367		A2		2004	0804										

US	2004-922358	A2	20040820
US	2005-78902	A2	20050311
US	2005-124676	A2	20050509
US	2005-700702P	P	20050719
US	2005-532618	A2	20051222
US	2006-781868P	P	20060313
US	2007-897638P	P	20070126
US	2007-899176P	P	20070202

- L13 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Foamable compositions, kits and drug delivery methods for treating hyperhidrosis
- AB The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and/or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and/or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis. Thus, oil-in-water foamable composition comprised (in wt%): azelaic acid 15.00. mineral oil 5.60, iso-Pr palmitate 5.60, sorbitan stearate 2.00, PPG15-stearyl ether 1.00, stearic acid 0.85, glyceryl monostearate 0.45, xanthan qum 0.26, methocel K100M 0.26, preservative 0.25, propellant 10.00, and water to 100.
- AN 2007:1237305 HCAPLUS <<LOGINID::20080702>>
- DN 147:491650
- TI Foamable compositions, kits and drug delivery methods for treating
- hyperhidrosis
- IN Tamarkin, Dov; Eini, Meir; Zlatkis, Ella
- PA Foamix Ltd., Israel
- SO U.S. Pat. Appl. Publ., 38pp., Cont.-in-part of U.S. Ser. No. 532,618.
- DT Patent
- LA English
- FAN.CNT 26

		ENT :				KIN		DATE			APPL	ICAT					ATE		
PI	US WO	2007 2004 2004	0253 0372	911 25		A1 A2		2007 2004 2004	1101 0506		US 2	007-	7178	97		2	0070	313 <- 024 <-	
		W:	AL, CU, HU, LU, RO, US,	AM, CZ, ID, LV, RU, UZ,	AT, DE, IL, MA, SC, VC,	AU, DK, IN, MD, SD, VN, MZ,	AZ, DM, IS, MG, SE, YU,	DZ, JP, MK, SG, ZA,	EC, KE, MN, SK, ZM,	EE, KG, MW, SL, ZW	ES, KP, MX, TJ,	FI, KR, MZ, TM,	GB, KZ, NO, TN,	GD, LC, NZ, TR,	GE, LK, OM, TT,	GH, LR, PH, TZ,			
			KG, FI, BF,	KZ, FR, BJ,	MD, GB, CF,	RU, GR, CG,	TJ, HU, CI,	TM, IE, CM,	AT, IT, GA,	BE, LU, GN,	BG, MC, GQ,	CH, NL, GW,	CY, PT, ML,	CZ, RO, MR,	DE, SE, NE,	DK, SI, SN,	EE, SK, TD,	ES, TR, TG	
		2005						2005											
		2005						2005			US 2							311 <-	
		2005						2006			ZA 2							425 <-	
		2006				A1		2006			US 2							222 <-	
		2006				A1		2007			AU 2							504 <-	
		20070292359 2008038140				A1		2007			US 2							607 <-	
	WO	2008	0381	40		A2		2008	0403		WO 2	007-	IB34	63		2	0070	507	

```
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
            CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
            GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
            KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
            MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
            PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
            TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
            GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM
    US 20080044444
                       A1
                             20080221
                                        US 2007-825406
                                                               20070705 <--
    US 20080152596
                       A1
                             20080626
                                       US 2007-894767
                                                              20070820
PRAI IL 2002-152486
                      A
                             20021025 <--
                      P
    US 2002-429546P
                             20021129 <--
                      P
    US 2003-492385P
                             20030804
    WO 2003-IB5527
                      W
                             20031024
    US 2004-911367
                      A2 20040804
                      A2
A2
P
    US 2005-78902
                             20050311
    US 2005-532618
                             20051222
    US 2006-781868P
                             20060313
                      P
P
    US 2007-897638P
                             20070126
    US 2007-899176P
                             20070202
    US 2003-497648P
                       P
                             20030825
                      P
    US 2003-530015P
                            20031216
                      A2
    US 2004-835505
                            20040428
                      A2
    US 2004-922358
                             20040820
    US 2005-124676
                       A2
                            20050509
    US 2005-696878P
                      P
                             20050706
                      P
                            20050719
    US 2005-700702P
                      P
                            20060607
    US 2006-811627P
                     P 20060705
A2 20060706
    US 2006-818634P
    US 2006-481596
    US 2006-482596
                             20060707
                      A
    US 2006-488989
                       A2
                            20060719
                       A2 20070112
    US 2007-653205
    US 2007-717897
                       A2
                            20070313
    US 2007-811140
                       A1
                             20070607
```

- L13 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration
- AB The present invention relates to a method for augmentation of epithelial concentration and systemic exposure of therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux transporter systems by using a vaginal or buccal drug delivery compos. and/or devices. Specifically, the invention relates to a method for augmentation of intrappithelial concentration and/or systemic bioavailability for delivery of anti-viral and/or anti-cancer therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux systems by using a vaginal or buccal drug delivery of these drugs into the systemic circulation by delivering such drug to a subject in need thereof vaginally or buccally in an especially formulated composition increasing the

bioavailability by providing means for increasing the drug solubility and permeability through the vaginal or buccal mucosa.

DN 146:258964

AN 2007:175576 HCAPLUS <<LOGINID::20080702>>

- Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration
- Pauletti, Giovanni M.; Harrison, Donald C.; Desai, Kishorkumar J. IN

KIND DATE

- PA
- SO U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 208,209.

APPLICATION NO

DATE

- Patent
- T.A English

FAN.CNT 12 PATENT NO

		LENI.			VIM	_	DAIL					TON			D	AIE		
ΡI		2007			A1	_	2007	0215				5221			2	0060	015	/
		7652		054	B2		2003					5419			2			
		2003		202	A1		2003								2			
		6982		302	B2		2003			05 2	002-	2200	0 /		2	0020	52I	·
		2006		000	A1						005	2002	0.0			0050	010	
		2006					2006					2082 2925				0050		<
				0 /	A1		2007									0060		
		2622			A1		2007					2622				0060		
		2007			A2		2007			WO Z	006-	US36	08/		21	0060	115	
	WO	2007			A3		2007											
		W:					AU,											
							DE,											
							HU,											
							LR,											
							NG,											
							SK,				SY,	TJ,	TM,	TN,	TR,	TT,	TZ,	
							VN,											
		RW:					CZ,											
							MC,											
							GN,											
							NA,					UG,	ZM,	ZW,	AM,	AZ,	BY,	
							TM,				OA							
PRAI		2001					2001											
		2002					2002		<	-								
		2005					2005											
	US 2005-717680P P				2005													
	AU 1998-76976 A3					1998		<	-									
	WO 2006-US36087 W					2006	0915											

- L13 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TΙ Antibiotic kit and compositions
- AB The present invention relates to a therapeutic kit to provide an effective dosage of an antibiotic including an aerosol packaging assembly. The assembly includes a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition of an antibiotic; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixts. at 2-50%, a surfactant, 0.01-5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at 3-25% by weight of the total composition 2006:1256641 HCAPLUS <<LOGINID::20080702>> AN
- DN 146:50262
- Antibiotic kit and compositions
- TN Friedman, Doron; Besonov, Alex; Tamarkin, Dov; Eini, Meir
- PA Foamix Ltd., Israel
- SO U.S. Pat. Appl. Publ., 31pp., Cont.-in-part of U.S. Ser. No. 532,618. CODEN: USXXCO

L PAIN .	PA:	ENT				KIN		DATE			APPL						ATE	
PI	US WO	2006 2004 2004	0269 0372 0372	485 25 25		A1 A2 A3		2006 2004 2004	1130 0506 1229		WO 2	006- 003-	4484 IB55	90 27		2	0060 0031	607 < 024 <
		W:						AU, DK,										
								IN,										
								MD,										
								SD,					ТJ,	TM,	TN,	TR,	TT,	TZ,
		D						VN,										D.17
		RW:						MZ, TM,										
								IE,										
								CM,										
		2005	0069	566		A1		2005	0331		US 2	004-	9113	67		2	0040	804
		2006				A1		2006			US 2							222 <
		2006				A2		2007			AU 2	006-	3393	11		2	0060	607
		2611		11		A1 A1		2007			CA 2	006-	2611	577		2	0060	607
		2007		96		A2		2007			CA 2	006-	IB39	75			0060	
	WO	2007	0993	96		A3		2008	0313									
		W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
								DE,										
								ID,										
								NZ,										
								SY,										
				VN,														
		RW:						CZ,										
								GN,										
								NA,										
				KZ,	MD,	RU,	ТJ,	TM,										
	EP	1919			D.C.	A2	011	2008			EP 2				on.		0060	
		R:						CZ,										
				HR,			шо,	ш.,	IIC,	мы,	г.,	11,	no,	UL,	υ1,	OIC,	111,	AL,
	US	2007				A1		2007	1220		US 2	007-	7325	47		2	0070	404 <
	WO	2008				A2		2008			WO 2						0070	
		W:						AU,										
								HN,										
								LC,										
								MZ,										
								SE,						SY,	TJ,	TM,	TN,	TR,
		DW.	TT,					UZ, CZ,						ED	CD	CD	****	TE
		Ew.	IS,					MC,										
								GA,										
								MZ,		SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,
DD 2 7	***	0000			KΖ,			TJ,										
PRAI		2002				P P		2002		<-	_							
		2003				TaZ		2003										
		2004				A2		2004										
		2005				A2 P A2		2005										
	US	2005	-532	618		A2		2005	1222									

```
IL 2002-152486 A 20021025 <--
US 2003-497648P P 20030825
US 2003-530015P P 20031216
US 2004-835505 A2 20040428
US 2004-922358 A2 20040820
US 2004-922358
US 2005-41921 A2 20050124 US 2006-789186P P 20060404 US 2006-448490 A2 20060607 WO 2006-1B3975 W 2006-607
US 2006-861620P
US 2007-880434P
                                          P
                                                        20061129
                                          P
                                                        20070112
```

- L13 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TΤ Foamable oil in water emulsion composition comprising polymer AB

The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water emulsion composition includes: an oil globule system, selected from the group consisting of oil bodies; and sub-micron oil globules, about 0.1% to about 5% by weight of an agent, selected from the group consisting of a surface-active agent, having an HLB value between 9 and 16; and a polymeric agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, water and optional ingredients are added to complete the total mass to 100%. Upon release from an aerosol container, the foamable composition forms and expanded foam suitable for topical administration. For example, emulsion composition was prepared comprising mineral oil 5.6%, iso-Pr myristate 5.6%, glyceryl monostearate 0.45%, PEG-40 stearate 2.6%, stearyl alc. 0.85%, Xanthan gum 0.26%, methocel K100M 0.26%, Polysorbate

80 0.90%, water 74.88%, preservative 0.60 and propellant 8%.

2006:1094143 HCAPLUS <<LOGINID::20080702>>

AN 145:426012

DN

- ΤI Foamable oil in water emulsion composition comprising polymer
- Tamarkin, Dov; Friedman, Doron; Besonov, Alex; Eini, Meir IN

PA Foamix Ltd., Israel

- SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 532,618. CODEN: USXXCO
- DT Patent
- LA English EAN CMT 26

PAN.		TENT	NO.			KIN	D	DATE			APPL	ICAT	ION I	NO.		D	ATE		
PI	WO	2006 2004 2004	0372	25		A1 A2		2006 2004 2004	0506				3897 IB55	42 27				327 <- 024 <-	
	110	W: AE, AG, CO, CR, GM, HR, LS, LT, PL, PT, UA, UG, RW: GH, GM,			AL, CU, HU, LU, RO,	AM, CZ, ID, LV, RU,	AT, DE, IL, MA, SC,	AU, DK, IN, MD, SD,	AZ, DM, IS, MG, SE,	DZ, JP, MK, SG,	EC, KE, MN, SK,	EE, KG, MW, SL,	ES, KP, MX,	FI, KR, MZ,	GB, KZ, NO,	GD, LC, NZ,	GE, LK, OM,	GH, LR, PH,	
		RW:	GH, KG, FI,	GM, KZ, FR,	KE, MD, GB,	LS, RU, GR,	MW, TJ, HU,		SD, AT, IT,	SL, BE, LU,	SZ, BG, MC,	TZ, CH, NL,	CY, PT,	CZ, RO,	DE, SE,	DK, SI,	EE, SK,	ES, TR,	
		20050069566				A1		2005											
		2005003298				A		2006					3298					125 <-	
		20060140984 1 2006201878				A1		2006						18				222 <-	
	WO	2006 2007 2007	1020	52		A1 A2 A3		2007 2007 2008	0913					78 70			00609	504 <- 914	

```
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
             KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
            MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
             RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
     US 20080138296
                         A1
                               20080612
                                         US 2007-975621
                                                                 20071019 <--
PRAI IL 2002-152486
                         Α
                               20021025 <--
     US 2002-429546P
                        P
                               20021129 <--
     US 2003-492385P
                        P
                               20030804
     WO 2003-IB5527
                               20031024
                        147
     US 2004-911367
                         A2
                               20040804
     US 2005-717058P
                         P
                               20050914
     US 2005-532618
                         A2
                               20051222
     US 2006-389742
                         Α
                               20060327
L13 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
     Nanoparticulate megestrol formulations containing surface stabilizer
     The present invention is directed to nanoparticulate compns. comprising
    megestrol. The megestrol particles of the composition have an effective
```

- ΤI
- average
 - particle size of <2000 nm. Thus, a formulation contained megestrol 5, HPMC 1, and dioctyl sodium sulfosuccinate 0.05%.
- ΔN 2005:36425 HCAPLUS <<LOGINID::20080702>>
- DM 142:120565
- ΤI Nanoparticulate megestrol formulations containing surface stabilizer
- TN Hovey, Douglas; Pruitt, John; Ryde, Tuula
- PA Elan Pharma International Ltd., USA
- SO U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 412,669. CODEN: USXXCO
- DT Patent
- LA English
- FAN.CNT 2

	PATENT			KIN		DATE				ICAT					ATE	
PI	US 2005 US 2003 US 7101	000870 021949	7		2	2003	0113 1127 0905	1	US 2	004-	8786	23		2	0040	629 < 414 <
	US 2004 CA 2508	010588		A1 A1	2	2004	0603									423 < 423 <
	WO 2004															423 <
	W: AE, AG, AI CO, CR, CU		, AL,	AM,	ΑT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		GM, H														
		LS, L														
		PH, P										ΤJ,	TM,	TN,	TR,	TT,
		TZ, U														
	RW:	GH, G														
		KG, K														
		FI, F														
		BF, B														
		231071														
	EP 1613	276		A1	- 2	2006	0111	1	EP 2	003-	7241	96		2	0030	423
	R:	AT, B	E, CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		IE, S	I, LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK	

```
JP 2005510726 T 20060330 JP 2004-570751 20030423 <--
EP 1935407 A1 20080625 EP 2008-4947 20030423 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LIT, LU, MC, NL, PT, RO, SE, ST, SK, TR
US 20050233001 A1 20051020 US 2005-93149 20050330 <--
US 20080152885 A1 20080626 US 2007-979253 20071031 <--
US 2002-437680P P 20020412 <--
US 2002-430348P P 20021203 <--
US 2003-412669 A2 20030414
EP 2003-724196 A3 20030423
US 2003-42196 A1 20030423
US 2003-421660 W 20030423
US 2004-878623 A1 20040629
```

- L13 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Liquid dosage compositions of stable nanoparticulate drugs

AB The present invention relates to liquid dosage compns. of stable nanoparticulate drugs. The liquid dosage compns. of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the drug. Thus, an aqueous nanoparticulate colloidal dispersion (NCD) comprising drug 32.5 Copovidone 6.5, and dioctyl sodium sulfosuccinate 0.464 by weight was prepared by milling for 3.8 h under high energy milling conditions. The final mean particle size (by weight) of the drug particle was 161 nm. The concentrated NCD was then diluted with preserved water and glycerol (the osmotically active crystal growth inhibitor) to 0.5-3.0% drug.

- AN 2004:60341 HCAPLUS <<LOGINID::20080702>>
- DN 140:117406
- TI Liquid dosage compositions of stable nanoparticulate drugs
- IN Bosch, William H.; Hilborn, Matthew R.; Hovey, Douglas C.; Kline, Laura J.; Lee, Robert W.; Pruitt, John D.; Ryde, Niels P.; Ryde, Tuula A.; Xu, Shuqian
- PA Elan Pharma International, Ltd, Ire.
- SO PCT Int. Appl., 68 pp.
- CODEN: PIXXD2
- DT Patent
- LA English

PAN.	PATENT NO.		KIND	DATE	APPLICATION NO.	
PI			A1	20040122	WO 2003-US22187	
	W: AE	, AG, AL	, AM, AT	AU, AZ,	BA, BB, BG, BR, BY,	BZ, CA, CH, CN,
	CO	, CR, CU	, CZ, DE	, DK, DM,	DZ, EC, EE, ES, FI,	GB, GD, GE, GH,
	GM	, HR, HU	, ID, IL	, IN, IS,	JP, KE, KG, KP, KR,	KZ, LC, LK, LR,
	LS	, LT, LU	, LV, MA	MD, MG,	MK, MN, MW, MX, MZ,	NI, NO, NZ, OM,
	PG	, PH, PL	, PT, RC	, RU, SC,	SD, SE, SG, SK, SL,	SY, TJ, TM, TN,
	TR	, TT, TZ	, UA, UG	, US, UZ,	VC, VN, YU, ZA, ZM,	ZW
	RW: GH	, GM, KE	LS, MW	, MZ, SD,	SL, SZ, TZ, UG, ZM,	ZW, AM, AZ, BY,
	KG	, KZ, MD	, RU, TJ	, TM, AT,	BE, BG, CH, CY, CZ,	DE, DK, EE, ES,
	FI	, FR, GB	, GR, HU	, IE, IT,	LU, MC, NL, PT, RO,	SE, SI, SK, TR,
	BF	, BJ, CF	, CG, CI	, CM, GA,	GN, GQ, GW, ML, MR,	NE, SN, TD, TG
	CA 2492488		A1	20040122	CA 2003-2492488	20030716 <
	AU 2003261	167	A1	20040202	AU 2003-261167	20030716 <
	EP 1551457		A1	20050713	EP 2003-764723	20030716 <
	R: AT	, BE, CH	, DE, DE	, ES, FR,	GB, GR, IT, LI, LU,	NL, SE, MC, PT,
	IE	, SI, LT	LV, FI	, RO, MK,	CY, AL, TR, BG, CZ,	EE, HU, SK
	JP 2005536	512	T	20051202	JP 2004-521891	20030716 <
PRAI				20020716	<	
	WO 2003-US	22187	W	20030716		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L13 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Combination of immediate release and controlled release pharmaceuticals
 AB Disclosed are compns, exhibiting a combination of immediate release and
 - controlled release characteristics. The compose comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least 1 active ingredient having a microparticulate particle size. Using a math. model, pharmacokinetic profiles were developed after single oral doses of a pharmaceutical formulation containing a drug having a single defined particle size. Small particles dissolve faster than larger particles, but that they also decay more rapidly. As a consequence, larger drug particles provide the longest blood plasma levels, although these same particles
 - 2003:300863 HCAPLUS <<LOGINID::20080702>>
- DN 138:326560
- TI Combination of immediate release and controlled release pharmaceuticals IN Cooper, Eugene R.; Ruddy, Stephen B.
- PA USA

MA

SO PCT Int. Appl., 45 pp.

exhibit slow dissoln.

- CODEN: PIXXD2
- DT Patent LA English
- FAN.CNT 1

E PAIN.	PA:	TENT					D	DATE			APPL	ICAT	ION I	. OI		D	ATE		
PI	WO	2003	0308	72		A2			0417 0731		WO 2	002-	US32	314		2	0021	011 <	
		W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
									DM,										
									IS,										
									MG,										
									SG,				ТJ,	TM,	TN,	TR,	TT,	TZ,	
									YU,										
		RW:							SD,										
									AT,										
									LU,							Br,	ы,	CF,	
	03	2463							GW,							2	0021	011 <	
		2002																011 <	
		2002																011 <	
		6908									00 2	002	2005.	20		-	0021	/11 /	
											EP 2	002-	8009	9.3		2	0021	011 <	
		1443						2007								_			
									FR,	GB.	GR.	IT.	LI.	LU.	NL.	SE.	MC.	PT.	
			IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	SK			
	JΡ	2005508939				T		2005	0407		JP 2	003-	5339	05		2	0021	011 <	
	AT	371442				T		2007	0915		AT 2	002-	8009	93		2	0021	011 <	
	ES	2292848				Т3		2008	0316		ES 2	002-	8009	93		2	0021	011 <	
PRAI																			
	WO	2002	-US3	2314		W		2002	1011	<-	-								

- L13 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Treatment of inflammatory skin conditions
 - B The invention relates to the use of one or more antimicrobial metals, most preferably silver, preferably formed with atomic disorder, and preferably in a nanocryst. form, for the treatment of inflammatory skin conditions. The nanocryst antimicrobial metal of choice may be used in the form of a nanocryst. coating of one or more antimicrobial metals, a nanocryst.

powder of one or more antimicrobial metals, or a solution containing dissolved species from a nanocryst. powder or coating of one or more antimicrobial metals. Thus, a com. CM-cellulose/pectin gel (DuoDERM) was combined with nanocryst. silver powder prepared to produce a gel with 0.1%silver. A logarithmic reduction test was performed as follows in the gel by using Pseudomonas aeruginosa. The logarithmic reduction for this mixture was 6.2, indicating a significant bactericidal effect. 2002:832637 HCAPLOS <LOGINID:20081032>>

ADDITORTION NO

DATE

AN 2002:83263° DN 137:316115

TI Treatment of inflammatory skin conditions

MIND DATE

IN Burrell, Robert Edward; Yin, Hua Qing

Nucryst Pharmaceuticals Corp., Can.

SO PCT Int. Appl., 58 pp. CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 24

		TENT						DATE				ICAT					ATE		
PI	WO	2002	0853	87		A2											0020	423	<
		W:	AE, CO, GM, LS, PL, UA, GH,	AG, CR, HR, LT, PT, UG, GM,	AL, CU, HU, LU, RO, US, KE,	AM, CZ, ID, LV, RU, UZ, LS,	AT, DE, IL, MA, SD, VN, MW,	AU, DK, IN, MD, SE, YU, MZ,	AZ, DM, IS, MG, SG, ZA, SD,	BA, DZ, JP, MK, SI, ZM, SL,	EC, KE, MN, SK, ZW SZ,	EE, KG, MW, SL,	ES, KP, MX, TJ,	FI, KR, MZ, TM,	GB, KZ, NO, TN,	GD, LC, NZ, TR,	GE, LK, OM, TT,	GH, LR, PH, TZ,	
								FR,											
		2002	0192	298		A1													
		7008						2006											
		2445															0020	423	<
		2002									AU 2	002-	2528	81		20	0020	423	<
		2002																	
		1383									EP 2	002-	7219	04		20	0020	423	<
	ΕP	1383																	
		R:						ES,					LI,	LU,	NL,	SE,	MC,	PT,	
		0001						RO, 2004											
	3.00	2004 3222	3299	30		1		2004									0020		
	AI	2261	/4 CEO			T		2006									0020		
		2006						2006									0051		
DDAT		2000						2000				005-	2040	00		21	,051.	122	\
LIMI		2001																	
	WO	2002	-CA5	49		W		2002	0423	<-	-								

- L13 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Preparation of aqueous clear solution dosage forms with bile acids
- AB Compns. for pharmaceutical and other uses comprise clear aqueous solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aqueous solution The compns. comprise (1) water, (ii) a bile acid component in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and (iii) either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a

range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition may further contain

a pharmaceutical compound, such as insulin, heparin, bismuth compds.,

amantadine and rimantadine. For example, solution dosage forms that did not show any precipitation at any pH were prepared containing ursodeoxycholic acid (UDCA) 22

g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g, bismuth citrate 4 g. citric acid or lactic acid as needed, and purified water to make 1 L.

AN 2002:185616 HCAPLUS <<LOGINID::20080702>>

- DN 136:252482
- TI Preparation of aqueous clear solution dosage forms with bile acids IN Yoo, Seo Hong
- PA USA SO
- U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U.S. 6,251,428. CODEN: USXXCO
- DT Patent
- LA English
- FAN.CNT 5

		TENT NO										LICAT					TE		
PI	US	200200 730376	315	58		A1		2002	0314 1204	Ţ		2001-							<
		625142									JS	1999-	3575	49		19	990	720	<
	US	200301	8693	33		A1						2002-					021	204	<
		716629							0123										
	US	200501	5840	8 (A1		2005	0721	τ	JS	2004-	9969	45		20	041	124	<
		200432										2004-							
	CA	258816	8			A1		2006	0601	(CA	2004-	2588	3168		20	041	124	
	EP	181931	8			A1		2007	0822	1	EΡ	2004-	8120	94		20	041	124	
		R: A	T, 1	ΒE,	BG,	CH,	CY,	, CZ,	DE,	DK,	EE	, ES,	FI,	FR,	GB,	GR,	HU,	IE,	
		I	s, :	IT,	LI,	LU,	MC,	, NL,	PL,	PT,	RO	, SE,	SI,	SK,	TR				
	CN	101065 200401 200852 200620	110			A		2007	1031	(CN	2004-	8004	14467		20	041	124	
	BR	200401	921	3		A		2007	1218	1	BR	2004-	1921	.3		20	041	124	
	JP	200852	1800)		T		2008	0626		JP	2007-	5430	06		20	041	124	
	ΑU	200620	331	5		A1		2006	0824	ž	ΑU	2006-	2033	15		20	060	803	<
	US	200700	7282	28		A1		2007	0329	τ	JS	2006-	5221	.62		20	060	915	<
	IN	2007CN	025	32		A		2007	0907		IN	2007-	CN25	32		20	070	612	
	KR	200709	8823	1		A		2007	1005	1	KR	2007-	7143	61		20	070	622	
		200800									JS	2007-	9345	05		20	071	102	<
PRAI		1998-9							0724										
		1999-3							0720										
	US	2000-1	8026	58P		P			0204										
		2001-3							0205										
		2001-7						2001			-								
		2004-9																	
		2004-U							1124								_		

RE.CNT 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L13 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- Tannins in method of isolating mucilaginous polysaccharides and uses for ΤI the polysaccharides thus obtained
- AB The present invention provides a method of isolating mucilaginous polysaccharides from plants, cereals, cell cultures, or fungi such as mushrooms known to have mucilaginous or protein-bound polysaccharides with desirable biol. properties. The mucilaginous polysaccharides present in aqueous solution or tissue exts. are treated with tanning to form a complex

which

is then separated from the solution The complex is then treated one or more times with either solvents or other substances in solution to remove the bounded tannins from the complex thereby and releasing the isolated polysaccharide. The polysaccharides prepared according to the present method retain properties that are substantially similar to those of the

native polysaccharide as it is found in the resp. plant or cell. The polysaccharides thus prepared are used in a variety of products, e.g., in cosmetics, pharmaceuticals, and food products. This process is particularly suitable for isolating acetylated mannose polymers from aloe plants and beta glucans.

2000:493312 HCAPLUS <<LOGINID::20080702>> AN

DN 133:101738

- Tannins in method of isolating mucilaginous polysaccharides and uses for the polysaccharides thus obtained
- IN Vittori, Natale
- Pλ Vito-Mannan Polysaccharide L.L.C., USA
- PCT Int. Appl., 45 pp. SO
- CODEN: PIXXD2
- DT Patent
- LA. English
- FAN. CNT 1

FAN.CI	PATENT	NO.			KIN	D	DATE			APPL	ICAT	ION I	NO.		Dž	ATE		
	(O 200	00415	41							WO 2	000-	US75	9		20	0000	111 <	:
		AE, CZ, IS, MG,	AL, DE, JP, MK,	AM, DK, KE, MN,	AT, DM, KG, MW,	AU, EE, KP, MX,	AZ, ES, KR, NO,		GB, LC, PL,	GD, LK, PT,	GE, LR, RO,	GH, LS, RU,	HR, LT, SD,	HU, LU, SE,	ID, LV, SG,	IL, MA,	IN, MD,	
	CA 232	: GH, DK, CI, 8092	GM, ES, CM,	KE, FI, GA,	LS, FR, GN, A1	MW, GB, GW,	SD, GR, ML, 2000	SL, IE, MR, 0720	SZ, IT, NE,	TZ, LU, SN, CA 2	UG, MC, TD,	ZW, NL, TG 2328	AT, PT, 092	BE, SE,	CH, BF,	CF,	CG,	
Į	JS 648	4456 AT, IE, 2942	BE, SI,	CH,	A3 DE, LV, B1	DK, FI,	2002 ES, RO 2002	0911 FR, 1119	GB,	GR, US 2	IT,	LI, 4811	LU,	NL,	SE,	MC,	111 <	<
PRAI (MX 200 JS 199 VO 200	9-115	619P		P		1999	0112	<-	-	000-1	PA99	66		20	1001	011 <	:

- L13 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- Improved formulation for topical non-invasive application in
- A formulation comprises mol. arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of the pores is smaller than the average penetrant diameter, provided

that

the penetrants can transport agents or cause permeation through the pores after penetrants have entered pores. The formulation comprises at least 1 consistency builder in an amount that increases the formulation to maximally $5~\mathrm{Nm/s}$ so that spreading over is enabled. The formulation also contains 1antioxidant in an amount that reduces the increase of oxidation index to <100% per 6 mo and/or at least 1 microbicide in an amount that reduces the bacterial count of 1 million germs added/g of total mass of the formulation to <100 in the case of aerobic bacteria, to <10 in the case of entero-bacteria, and to <1 in the case of Pseudomonas aeruginosa or Staphilococcus aureus, after a period of 4 days. Thus, a composition contained soybean phosphatidylcholine 347, Tween-80 623, sodium dodecyl sulfate 30, benzyl alc. 50, clobetasol 17-propionate 25 and pH 6.5 50 mM phosphate buffer 9000 mg.

AN 2000:456858 HCAPLUS <<LOGINID::20080702>>

- DN 133:94512
- TT Improved formulation for topical non-invasive application in

vivo

IN Cevc, Gregor

PA Idea Innovative Dermale Applikationen G.m.b.H., Germany

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent LA English

LA English FAN.CNT 1

	PA:	TENT	NO.			KIN)	DATE			APPI	ICAT	ION	NO.		D.	ATE		
PI		2000	0386 AL, DK, KP, NO,	53 AM, EE, KR, NZ,	AT, ES, KZ, PL,	A1 AU, FI, LC, PT,	AZ, GB, LK, RO,	2000 BA, GE, LR,	0706 BB, GH, LS, SD,	BG, GM, LT,	WO 1 BR, HR, LU,		EP84 CA, ID, MD,	CH, IL, MG,	CN, IS, MK,	CU, JP, MN,	9981 CZ, KE, MW,	223 DE, KG, MX,	
		RW:	GH, FI,	GM, FR,	KE, GB,	LS, GR,	MW,	SD,	SZ, LU,	MC,	NL,	AT, PT, TG							
	ΔII	2356 9925 7708	080			A1	•	2000	0706 0731		CA 1	998- 999-	2356 2513	080 7			9981 9981		
	EP	7708 1140 1140	021			A1		2004 2001 2004	1010		EP 1	.998-	9668	46		1	9981	223	<
			AT, IE,	BE, SI,	CH, LT,	DE, LV,	DK, FI,	ES, RO	FR,	GB,		IT,							
	HU	9816 2001 2001	0044	24				2001 2002 2002	0328			998-					9981 9981		
	JP EE	2002 2001	5333 0034	79 2		T A		2002 2002	1008 1015		EE 2	000-	342			1	9981	223	<
	AT	2207 2723 2226	91			C2 T T3		2003 2004 2005	0815		AT 1 ES 1	998- 998-	9668 9668	46 46		1	9981 9981	223 223	<
	PL HR	1938 2001 2001	24 0003	09		B1 A1 B1		2007 2002 2005	0630		PL 1 HR 2	.967- 2001-	3494 309			1 2	9981 0010	223 502	<
	NO US	2001 2002	0031 0064	64		A A1		2001 2002	0822 0530		NO 2 US 2	2001-	3164 8874	93		2	0010 0010	622 622	<
	MX	7175 2001 1040	PA06			B2 A A1		2005	0604 0128		HK 2	2001-	1022	30		2	0010 0020	622 323	<
PRAI	WO	2007 1998 2001	-EP8	421		A1 A		2007 1998 2001	0809 1223	<-	US 2 -	2006-	6380	91		2	0061		
os		RPAT			2	211		2001	0022										

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Novel pharmaceutical formulation of dehydroepiandrosterone for percutaneous topical application

AB The disclosed formulation is comprised of: (a) 0.1-5 weight dehydroepiandrosterone; (b) 0.5-3% acrylic gel, 1-3% quar gum, or 1-3% cellulose-derived gel; and optionally other ingredients such as hydrophilic gels, estradiol, vitamins, progesterone, minoxidil, hyaluronidase, vasoprotectants, plant exts., etc. The formulation has various pharmacol. applications, e.g. for treating menstrual disorders, mammary and gynecol. neoplasms, lipodystrophy, panniculopathy, circulatory disorders, bruises, muscular pain, obesity, diabetes, osteoporosis, aging, etc.

- AN 1997:204223 HCAPLUS <<LOGINID::20080702>>
- DN 126:190952
- OREF 126:36787a,36790a
- TI Novel pharmaceutical formulation of dehydroepiandrosterone for percutaneous topical application
- IN Cabo Soler, Jose; Calderon Gomez, Jesus; Palacios Gil-Antunano, Santiago
- PA Spain
- SO PCT Int. Appl., 15 pp.
- CODEN: PIXXD2
- DT Patent
- LA Spanish FAN.CNT 1

	PATENT NO.	KIND DATE	APPLICATION NO.	DATE
PI	WO 9703676	A1 19970206	WO 1996-ES153	19960719 <
	W: AU, BR, CA,	CN, JP, MX, US,	AM, AZ, BY, KG, KZ, MD,	RU, TJ, TM
	RW: AT, BE, CH,	DE, DK, ES, FI,	FR, GB, GR, IE, IT, LU,	MC, NL, PT, SE
	ES 2098193	A1 19970416	ES 1995-1471	19950721 <
	ES 2098193	B1 19971201		
	AU 9664196	A 19970218	AU 1996-64196	19960719 <
PRAI	ES 1995-1471	A 19950721	<	
	WO 1996-ES153	W 19960719	<	

- L13 ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Carbohydrate-linked short-chain fatty acids for delivery to the colon.
 AB Delivery to the colon of fatty acids, especially short-chain fatty acids
- (SCFA),
 - can be effected by covalently linking SCFA to a carrier, that is preferably a carbohydrate, by an ester link. The SCFA is protected by its link with the carbohydrate through the small intestine, and where the carbohydrate is digestible in the small intestine such as a digestible starch, the starch can also be protected from digestion in the small intestine by the substitution. Levels of SCFA such as acetate, propionate and butyrate may be elevated to have beneficial effects in the prevention of colonic disorders, such as rectal cancer,
 - diverticulitis, colitis, diarrhea and constipation.
 - AN 1995:756390 HCAPLUS <<LOGINID::20080702>>
 - DN 123:142666
 - OREF 123:25401a,25404a
 - TI Carbohydrate-linked short-chain fatty acids for delivery to the colon.
 - IN Anisson, Geoffrey; Topping, David; Illman, Richard
 - PA Commonwealth Scientific and Industrial Research Organisation, Australia SO PCT Int. Appl., 55 pp.
 - CODEN: PIXXD2
 - DT Patent
- LA English
- FAN.CNT 1

ran.		TENT	NO.			KIN	D	DATE		4	APPL	ICAT:	ION I	NO.		D	ATE		
PI	WO	9513	801 AM, GB,	AT, GE,	HU,	JP,	BG, KE,	1995 BR, KG, PT,	BY, KP,	CA, KR,	CH, KZ,	CN, LK,	CZ, LR,	DE, LU,	DK, LV,	EE, MD,	ES, MG,	MN,	-
		RW:		MW, NL,				BE,											
		2176 2176	719			A1 C		1995			CA 1	994-	2176	719		1	9941	117 <	-
	AU	9481 6959	368			A B2		1995 1998	0606		AU 1	994-	8136	8		1	9941:	117 <	-

	EP	730447	i	11	19960911	EP 1	995-900575	19941117	<
	EP	730447	1	31	20020220				
		R: CH, DE,	ES, FI	R, (GB, IT, LI,	NL, SE			
	JP	09505060		Γ	19970520	JP 1	994-514114	19941117	<
	JP	4071823	1	32	20080402	JP 1	995-514114	19941117	<
	US	5840860		A.	19981124	US 1	996-646294	19960905	<
PRAI	AU	1993-2454		A	19931117	<			
	WO	1994-AH713	1	47	19941117	/			

- L13 ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Method for preparing diagnostic slide coated with immunoreactive substance-sensitized latex and water-soluble polymer
- AB The method comprises coating the slide with a reagent layer containing immunoreactive substance (e.g. antibody or antigen)-sensitized latex, water-soluble polymer (e.g. PVP), and optionally a water-soluble natural compound
- (e.g. cyclodextrin), followed by natural drying to produce a stable and redissolvable coating. Thus, monoclonal anti-mannan antibody was prepared, immobilized on latex, coated on a slide together with PVP, and used for detecting mannan derived from Candida tropicalis.
- AN 1993:599163 HCAPLUS <<LOGINID::20080702>>
- DN 119:199163
- OREF 119:35405a,35408a
- TI Method for preparing diagnostic slide coated with immunoreactive substance-sensitized latex and water-soluble polymer
- IN Kondo, Kenji; Yoshimura, Makoto; Fujii, Masahiko
- PA Kureha Chemical Ind Co Ltd, Japan
- SO Jpn. Kokai Tokkyo Koho, 11 pp.
- CODEN: JKXXAF
- DT Patent
- LA Japanese
- FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05196623	A	19930806	JP 1992-171730	19920606 <
	JP 2631796	B2	19970716		
PRAI	JP 1991-176213	A1	19910620	<	

- => d 114 1-10 ti abs bib
- L14 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
- AB The present invention relates to a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixts, thereof, a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixts, thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a
- liquefied

hydrocarbon gas propellant. Thus, a foaming vehicle composition comprised (1) an oil phase containing diisopropyl adipate (DISPA) 20.00, benzyl alc. 2.000, oleyl alc. 2.000, PPG 15 stearyl ether 2.00, sorbitan stearate 2.00, and stearyl alc. 3.00, and (ii) a water phase containing hydroxypropyl Me cellulose 0.15, xanthan gum 0.15, sucrose ester 3.00, propylene glycol

17.70, and water 30.00%, resp.

2008:226051 HCAPLUS <<LOGINID::20080702>>

DN 148:269446

AN

TI Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof Tamarkin, Dov; Friedman, Doron; Berman, Tal; Ziv, Enbal; Schuz, David

IN

PA Foamix Ltd., Israel SO

U.S. Pat. Appl. Publ., 37pp., Cont.-in-part of U.S. Ser. No. 717,897. CODEN: USXXCO

DT Patent

LA English

FAN.	PA:	26 TENT				KIN		DATE			APPL						ATE	
PI	US WO	2008 2004 2004	0044 0372	444 25		A1 A2 A3		2008 2004 2004	0221 0506		US 2 WO 2	007-	8254	06		2	0070	705 < 024 <
		W:	CO, GM,	CR, HR,	CU, HU,	CZ,	DE, IL,	AU, DK, IN,	DM, IS,	DZ, JP,	EC, KE,	EE, KG,	ES, KP,	FI, KR,	GB, KZ,	GD, LC,	GE, LK,	GH, LR,
			PL,	PT,	RO,	RU,	SC,	MD, SD, VN,	SE,	SG,	SK,	SL,						
			GH, KG, FI, BF,	GM, KZ, FR, BJ,	KE, MD, GB,	LS, RU, GR, CG,	MW, TJ, HU, CI,	MZ, TM, IE, CM,	SD, AT, IT, GA,	SL, BE, LU, GN,	SZ, BG, MC, GQ,	TZ, CH, NL, GW,	CY, PT, ML,	CZ, RO, MR,	DE, SE,	DK, SI, SN,	EE, SK, TD,	ES, TR, TG
		2005				A1		2005			US 2						0040	
		2005				A1 A1		2005 2005			US 2						0040: 0041:	
		2004				A1		2005			US 2							311 <
		2005				A		2006			ZA 2							425 <
	US	2006	0140	984		A1		2006	0629		US 2	005-	5326	18		2	0051	222 <
		2006				A1		2007										504 <
		2007				A1		2007			US 2						0061	
		2007				A1 A1		2007 2007			US 2						0070	313 <
		2008				A2		2008			WO 2						0070	
		W:			AL,			AU,							BW,			
								CZ,										
								GT,										
								LA,										
								MY, SD,										
			TR,					US,							31,	10,	111,	114,
		RW:						CZ,							GB,	GR,	HU,	IE,
								MC,										
								GA,										
								MZ,		SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,
	IIS	2008			ΝΔ,	A1		TJ, 2008			US 2	007-	8946	6.8		2	0070	R 2 N
PRAI						A		2002		<-			0540			-	00,0	020
	US	2002	-429	546P		P		2002	1129	<-	_							
		2003				P		2003										
		2003				W		2003										
		2003				P		2003										
		2004				A2 A2		2004 2004										
		2005		0.2		7.2		2005										
		2005		618		A2		2005										
		2006		634P		A2 P A2		2006										
	US	2007	-653	205		A2		2007	0112									

US	2007-717897	A2	20070313
US	2005-679020P	P	20050509
US	2006-781868P	P	20060313
US	2006-784793P	P	20060321
US	2006-430599	A2	20060509
US	2007-897638P	P	20070126
IIS	2007-899176P	P	20070202

- L14 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration
- AB The present invention relates to a method for augmentation of epithelial concentration and systemic exposure of therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux transporter systems by using a vaginal or buccal drug delivery compns. and/or devices. Specifically, the invention relates to a method for augmentation of intraepithelial concentration and/or systemic bioavailability for delivery of anti-viral and/or anti-cancer therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux systems by using a vaginal or buccal drug delivery of these drugs into the systemic circulation by delivering such drug to a subject in need thereof vaginally or buccally in an especially formulated composition increasing the drug's bioavailability by providing means for increasing the drug solubility and permeability through the vaginal or buccal mucosa.
- AN 2007:175576 HCAPLUS <<LOGINID::20080702>>
- DN 146:258964
- TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration
- IN Pauletti, Giovanni M.; Harrison, Donald C.; Desai, Kishorkumar J.
- PA USA SO U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 208,209. CODEN: USXXCO
- DT Patent
- LA English
- FAN.CNT 12

FAN	PATENT				KIN		DATE			APPL					D.	ATE		
PI	US 200 AU 765	70036 269	834		A1 B2		2007	0911		US 2 AU 2	006- 001-	5221: 5419:	26 2		2	0010	915 < 703 <	
	US 200: US 698:	2091			A1 B2		2003 2006	0103		US 2			-				821 <	
	US 200 AU 200	52925			A1 A1		2006 2007	0329		US 2 AU 2	006-	2925	07		2	00609		
	CA 262: WO 200	70355			A1 A2		2007 2007	0329		CA 2 WO 2						00609 00609		
	WO 200'				AM,		2007 AU,			вв,	BG,	BR,	BW.	BY,	BZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE, HU,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		KR,	KZ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	
		RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SV,								
	RW	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,								
		CF,	CG,	CI,	CM,	GA,	MC, GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG,	BW,	GH,	
		GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	

```
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRAI US 2001-315877P P
                           20010829 <--
    US 2002-226667
                       A1
                             20020821 <--
    US 2005-208209
                       A2
                            20050818
                      P
    US 2005-717680P
                            20050915
    AU 1998-76976
                       A.3
                            19980610 <--
    WO 2006-US36087
                       TaT
                             20060915
```

- L14 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Antibiotic kit and compositions
- AB The present invention relates to a therapeutic kit to provide an effective dosage of an antibiotic including an aerosol packaging assembly. The assembly includes a container accommodating a pressurized product, and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition of an antibiotic; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixts. at 2-50% a surfactant, 0.01-5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at 3-25% by weight of the total composition
- AN 2006:1256641 HCAPLUS <<LOGINID::20080702>>
- DN 146:50262
- TI Antibiotic kit and compositions
- IN Friedman, Doron; Besonov, Alex; Tamarkin, Dov; Eini, Meir
- PA Foamix Ltd., Israel
- SO U.S. Pat. Appl. Publ., 31pp., Cont.-in-part of U.S. Ser. No. 532,618. CODEN: USXXCO
- DT Patent
- LA English

FAN CNT 26

FAN.	PA:	26 FENT				KIN		DATE			APPL						ATE	
PI	WO	2006 2004 2004	0372	25		A2		2004	0506									607 < 024 <
			CO, GM, LS, PL, UA,	CR, HR, LT, PT, UG,	CU, HU, LU, RO, US,	CZ, ID, LV, RU, UZ,	DE, IL, MA, SC, VC,	AU, DK, IN, MD, SD, VN,	DM, IS, MG, SE, YU,	DZ, JP, MK, SG, ZA,	EC, KE, MN, SK, ZM,	EE, KG, MW, SL, ZW	ES, KP, MX, TJ,	FI, KR, MZ, TM,	GB, KZ, NO, TN,	GD, LC, NZ, TR,	GE, LK, OM, TT,	GH, LR, PH, TZ,
		RW:	KG, FI,	KZ, FR,	MD, GB,	RU, GR,	TJ, HU,	MZ, TM, IE, CM,	AT, IT,	BE, LU,	BG, MC,	CH, NL,	CY, PT,	CZ, RO,	DE, SE,	DK, SI,	EE, SK,	ES, TR,
	US	2005																
																		222 <
		2006																
		2006											,,,,			_	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
		2611						2007			C 2	006-	2611	577		2	ากรก	607
		2007																
		2007									2		1000			_		
								AU,		BA.	BB.	BG.	BR.	BW.	BY.	BZ.	CA.	CH.
								DE,										
								ID,										
								LT,										
								NZ,										
								SY,										
						ZM.							-					
		RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,

```
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
                               20080514 EP 2006-847249
    EP 1919449
                                                                  20060607
                         A2
        R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
            BA, HR, MK, RS
                                          US 2007-732547
    US 20070292355
                               20071220
                                                                  20070404 <--
    WO 2008075207
                         A2
                               20080626
                                          WO 2007-IB4459
                                                                  20070404
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
            CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
            GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
            KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG,
            MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
            RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
            TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
            GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM
                               20021129
PRAI US 2002-429546P
                         P
    US 2003-492385P
                         Ρ
                               20030804
    WO 2003-IB5527
                         W
                               20031024
    US 2004-911367
                         A2
                               20040804
    US 2005-688244P
                         P
                               20050607
                         A2
    US 2005-532618
                               20051222
    IL 2002-152486
                         A
                              20021025
                                         <--
                              20030825
    US 2003-497648P
                         P
    US 2003-530015P
                        P
                              20031216
    US 2004-835505
                        A2
                              20040428
    US 2004-922358
                        A2
                              20040820
    US 2005-41921
                        A2
                              20050124
    US 2006-789186P
                        P
                               20060404
    US 2006-448490
                         A2
                              20060607
    WO 2006-IB3975
                         TeZ
                               20060607
    US 2006-861620P
                         P
                               20061129
    US 2007-880434P
                         P
                               20070112
```

- L14 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
- ΤI Liquid dosage compositions of stable nanoparticulate drugs
- AB The present invention relates to liquid dosage compns. of stable nanoparticulate drugs. The liquid dosage compns. of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the drug. Thus, an aqueous nanoparticulate colloidal dispersion (NCD) comprising drug 32.5 Copovidone 6.5, and dioctyl sodium sulfosuccinate 0.464% by weight was prepared by milling for 3.8 h under high energy milling conditions. The final mean particle size (by weight) of the drug particles was 161 nm. The concentrated NCD was then diluted with preserved water and glycerol (the osmotically active crystal growth inhibitor) to 0.5-3.0% drug.
- AN 2004:60341 HCAPLUS <<LOGINID::20080702>>
- DN 140:117406
- Liquid dosage compositions of stable nanoparticulate drugs
- TN Bosch, William H.; Hilborn, Matthew R.; Hovey, Douglas C.; Kline, Laura J.; Lee, Robert W.; Pruitt, John D.; Ryde, Niels P.; Ryde, Tuula A.; Xu, Shuqian
- PA Elan Pharma International, Ltd, Ire.
- SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DT Patent LA English FAN.CNT 18

KIND DATE APPLICATION NO. DATE PATENT NO. WO 2004006959 A1 20040122 WO 2003-US22187 20030716 <--PΙ W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG A1 20040122 CA 2003-2492488 20030716 <--A1 20040202 AU 2003-261167 20030716 <--A1 20050713 EP 2003-764723 20030716 <--CA 2492488 AU 2003261167 EP 1551457 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK 20051202 JP 2005536512 Т 20021202 Jr 20020716 <--JP 2004-521891 20030716 <--P PRAI US 2002-396530P WO 2003-US22187 W 20030716

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation of aqueous clear solution dosage forms with bile acids

AB Compns. for pharmaceutical and other uses comprise clear aqueous solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aqueous solution The compns. comprise (1) water, (ii) a bile acid component in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and (iii) either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a

range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition may further

a pharmaceutical compound, such as insulin, heparin, bismuth compds., amantadine and rimantadine. For example, solution dosage forms that did not show any precipitation at any pH were prepared containing ursodeoxycholic acid

g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g, bismuth citrate 4 g, citric acid or lactic acid as needed, and purified water to make 1 L.

AN 2002:185616 HCAPLUS <<LOGINID::20080702>>

DN 136:252482

TI Preparation of aqueous clear solution dosage forms with bile acids

IN Yoo, Seo Hong

PA USA

SO U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U.S. 6,251,428.

CODEN: USXXCO

DT Patent

LA English

LA English

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PT	US 20020031558	A1	20020314	US 2001-778154	20010205 <

```
US 7303768 B2 20071204 US 251428 B1 20010626 US 1999-357549 19990720 <-- US 20030186933 A1 20031002 US 2002-309603 20021204 <-- US 7166299 B2 20070123
                       B2 20070123
A1 20050721 US 2004-996945
     US 20050158408
                                                                  20041124 <--
     AU 2004325203
                        A1 20060601 AU 2004-325203
                                                                  20041124
     CA 2588168 A1 20060601 CA 2004-2588168
EP 1819318 A1 20070822 EP 2004-812094
                                                                  20041124
                                                                  20041124
         R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
                              20071031 CN 2004-80044467
     CN 101065110 A
                                                                  20041124
BR 2004019213
                        A
                              20071218 BR 2004-19213
                                                                  20041124
                                                                  20041124
                                                                  20060803 <--
                                                                 20060915 <--
                                                                 20070612
                                                                 20070622
                                                                 20071102 <--
```

RE.CNT 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

Anti-itch patch containing analgesics, anesthetics, or corticosteroids AB An adhesive anti-itch patch comprising a flexible backing having a front side and a back side and a therapeutic formulation positioned on the entire surface or on a portion of the front side of the backing is described. The therapeutic formulation includes a medicament, i.e., an antipruritic agent, such as an analgesic, an anesthetic, or a corticosteroid, useful for treating a condition associated with an insect bite, a rash, a skin irritation, poison ivy, poison oak, an inflammatory skin condition, or poison sumac; and a pressure sensitive adhesive. A method for treating a skin condition associated with itching includes applying to the skin surface an adhesive patch of the present invention. For example, therapeutic formulation contained (by weight) lidocaine 2.5%, camphor 3.0%, propylene glycol 8.4%, polyethylene glycol 0.7%, fragrance 0.5%, glycerin 42.4%, Aloe vera 1.0%, algin 22.5%, water 4.0%, and acrylic ester copolymer adhesive 15.0%.

AN 2001:434847 HCAPLUS <<LOGINID::20080702>>

DN 135:66217

TI Anti-itch patch containing analgesics, anesthetics, or corticosteroids IN Rolf, David; Buseman, Teri

PA Lectec Corporation, USA

SO PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DT Patent

LA English

LA ENGLISE FAN.CNT 2

E Pil	PATE		KIND DATE			APPLICATION NO.						DATE						
							-									-		
PΙ	WO 2	0010	0417	46		A1		2001	0614		WO 2	000-1	JS33	498		2	0001	211 <
		W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
			CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FΙ,	GB,	GD,	GE,	GH,	GM,	HR,
			HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,
			LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PL,	PT,	RO,	RU,

```
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
            YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    WO 2001041745
                         A1
                               20010614
                                         WO 2000-US12970
                                                                  20000512 <--
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
            CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
            ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
            LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
            SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,
            AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
            DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
            CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    US 6469227
                        B1
                              20021022 US 2000-569783
                                                                 20000512 <--
PRAI US 1999-170041P
                        P
                               19991210 <--
    US 2000-569783
                        A
                               20000512 <--
                               20000512 <--
    WO 2000-US12970
                         TeT
RE.CNT 3
             THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
             ALL CITATIONS AVAILABLE IN THE RE FORMAT
L14 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
```

- ΤI A method for the improvement of transport across adaptable semi-permeable barriers
- AB The invention relates to a method, a kit and a device for controlling the flux of penetrants across an adaptable semi-permeable porous barrier, the method comprising the steps of: preparing a formulation by suspending or dispersing said penetrants in a polar liquid in the form of fluid droplets surrounded by a membrane-like coating of one or several layers, said coating comprising at least two kinds of forms of amphiphilic substances with a tendency to aggregate; said penetrants being able to transport agents through the pores of said barrier or to enable agent permeation through the pores of said barrier after penetrants have entered the pores, selecting a dose amount of said penetrants to be applied on a predetd. area of said barrier to control the flux of said penetrants across said barrier, and applying the selected dose amount of said formulation containing said penetrants onto said area of said porous barrier. Highly adaptable complex droplets (ultradeformable vesicles or Transfersomes) were prepared containing soybean phosphatidylcholine, Na cholate, 3H-labeled DPPC and phosphate buffer.
- AN 2001:31308 HCAPLUS <<LOGINID::20080702>>
- DN 134:91147
- TΙ A method for the improvement of transport across adaptable semi-permeable barriers
- TN Cevc, Gregor
- PA Idea Innovative Dermale Applikationen G.m.b.H., Germany
- SO PCT Int. Appl., 94 pp.
- CODEN: PIXXD2 DT Patent
- LA English

FAN.	CNT	1																
	PA:	TENT	NO.			KIN	D	DATE			APPL	ICAT	I NOI	NO.		D	ATE	
							_											
PI	WO	2001	0019	62		A1		2001	0111		WO 1	999-	EP46	59		1	9990	705 <
		W:	ΑE,	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,
			DE,	DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,
			JP,	KE,	KG,	KP,	KR,	KΖ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,
			MN,	MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,
			TM,	TR,	TT,	UA,	UG,	US,	UZ,	VN,	YU,	ZA,	zw					
		RW:	GH,	GM,	KE,	LS,	MW,	SD,	SL,	SZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,	DK,

```
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
            CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    AU 9954096
                               20010122 AU 1999-54096
                        A
                                                                  19990705 <--
    CA 2375157
                               20010111 CA 2000-2375157
                                                                  20000705 <--
                         A1
                              20010111 WO 2000-EP6367
    WO 2001001963
                         A1
                                                                  20000705 <--
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
            HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
            SD. SE. SG. SI. SK. SL. TJ. TM. TR. TT. TZ. UA. UG. US. UZ. VN.
            YU. ZA. ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
            CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    EP 1189598
                         A1 20020327 EP 2000-947939
                                                                  20000705 <--
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    HU 2002001454
                         A2
                               20021228
                                          HU 2002-1454
                                                                  20000705 <--
    HU 2002001454
                         A3
                               20040528
    JP 2003503442
                         T
                              20030128
                                           JP 2001-507458
                                                                  20000705 <--
                                          EE 2002-8
AU 2000-61557
RU 2002-101651
    EE 200200008
                        A
                              20030415
                                                                  20000705 <--
    AU 779765
                        B2 20050210
                                                                  20000705 <--
                        C2
                              20050920
    RU 2260445
                                                                  20000705 <--
                              20030831 HR 2001-B81
20050311 IN 2001-DN1133
20020305 NO 2002-32
                        A1
    HR 2001000881
                                                                  20011127 <--
    IN 2001DN01133
                       A
                                                                  20011206 <--
                        A
                                                                  20020104 <--
    NO 2002000032
    US 20030099694
                       A1 20030529
                              20030529 US 2002-37480
20030721 MX 2002-PA53
                                                                  20020104 <---
                        Α
                                                                  20020107 <--
    MX 2002PA00053
    US 20050123897
                        A1 20050609
                                         US 2004-984450
                                                                 20041108 <--
                                          IN 2005-DN3651
                              20070824
    IN 2005DN03651
                        A
                                                                 20050818 <--
                         A
PRAI WO 1999-EP4659
                              19990705 <--
    WO 2000-EP6367
                         W
                              20000705 <--
    IN 2001-DN1133
                         A3
                             20011206 <--
    US 2002-37480
                         A1
                               20020104
                                         <--
RE.CNT 5
             THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
```

ALL CITATIONS AVAILABLE IN THE RE FORMAT L14 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN Improved formulation for topical non-invasive application in

vivo

AB A formulation comprises mol. arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of the pores is smaller than the average penetrant diameter, provided

that

the penetrants can transport agents or cause permeation through the pores after penetrants have entered pores. The formulation comprises at least 1 consistency builder in an amount that increases the formulation to maximally $5\ \mathrm{Nm/s}$ so that spreading over is enabled. The formulation also contains 1antioxidant in an amount that reduces the increase of oxidation index to <100% per 6 mo and/or at least 1 microbicide in an amount that reduces the bacterial count of 1 million germs added/g of total mass of the formulation to <100 in the case of aerobic bacteria, to <10 in the case of entero-bacteria, and to <1 in the case of Pseudomonas aeruginosa or Staphilococcus aureus, after a period of 4 days. Thus, a composition contained soybean phosphatidylcholine 347, Tween-80 623, sodium dodecyl sulfate 30, benzyl alc. 50, clobetasol 17-propionate 25 and pH 6.5 50 mM phosphate buffer 9000 mg.

2000:456858 HCAPLUS <<LOGINID::20080702>> AN

DN 133:94512

Improved formulation for topical non-invasive application in vivo

IN Cevc, Gregor

PA Idea Innovative Dermale Applikationen G.m.b.H., Germany

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent LA English

FAN.CNT 1

FAN.	CNT	1																	
	PATENT NO.						D	DATE			APP	LICAT	CION	NO.		DATE			
PI	WO	2000	0386	 53		A1	_	2000	0706		wo	1998-	EP84	21		1	9981		<
								BA,											
								GE,											
								LR,											
								RU,											
								YU,			-						,		
		RW:						SD,		UG,	ZW	, AT,	BE,	CH,	CY,	DE,	DK,	ES,	
								IT,											
			CM.	GA.	GN.	GW.	ML.	MR.	NE.	SN.	TD	. TG							
	CA	2356	080			A1		2000	0706		CA	1998-	-2356	080		1	9981	223	<
	AU	2356 9925	137			A		2000	0731		AU	1999-	2513	7		1	9981	223	<
	AU	7708	03			B2		2004	0304										
		1140									ΕP	1998-	9668	46		1	9981	223	<
	EP	1140	021			B1		2004	0804										
		R:						ES,	FR,	GB,	GR	, IT,	LI,	LU,	NL,	SE,	MC,	PT,	
			IE,	SI,	LT,	LV,	FI,	RO											
	BR	9816	113			A		2001	1023		BR	1998-	-1611	3		1	9981		
	HU	9816 2001 2001 2002 2001 2207 2723 2226 1938 2001 2001 2001	0044	24		A2		2002	0328		HU	2001-	4424			1	9981	223	<
	HU	2001	0044	24		A3		2002	1228										
	JP	2002	5333	79		T		2002	1008		JP	2000-	5906	07		1	9981		
	EE	2001	0034	2		A		2002	1015		EE	2001-	-342			1	9981		
	RU	2207	844			C2		2003	0710		RU	2001-	1200	08		1	9981		
	AT	2723	91			T		2004	0815		AT	1998-	-9668	46		1	9981		
	ES	2226	203			T3		2005	0316		ES	1998-	-9668	46		1	9981	223	<
	PL	1938	24			B1		2007	0330		PL	1967-	3494			1	9981	223	<
	HK	2001	0003	09		AI		2002	0630		HK	2001-	-309			2	0010	502	<
	HR	2001	0003	09		BI		2005	0630										
	NO	2001	0031	64		A		2001	0822		NO	2001- 2001-	3164			2	0010		
	US	2002 7175	0064	524		AI		2002	0330		US	2001-	-88/4	93		2	0010	622	<
	05	2001	850	101		B2					3.617	2001-	Da.C.	2.1		2	0010	c 2 2	
		1040		424		A1						2001- 2002-							
				111		A1		2005											
DDAT	TITO.	2007	_PD0	121		V AT						2000-	-0500	21		2	0001	212	\
PRAI	IIC	2001	_997	103		7.1		2001											
os	MAI	RPAT	133.	9451	2	AI		2001	0022	-									
DE CI						2 01	ren	DEEE	DENC	DC 3	172 T	TARTE	FOR	THE	e pe	CORD			

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles

AB Gas and gaseous precursor filled microspheres, and foams provide novel topical and s.c. delivery vehicles for various active ingredients, including drugs and cosmetics. Gas and gaseous precursor filled microcapsules were prepared from dipalmitoylphosphatidylcholine.

AN 1998:207280 HCAPLUS <<LOGINID::20080702>>

DN 128:275101

OREF 128:54369a,54372a

TI Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles

IN Unger, Evan C.; Matsunaga, Terry O.; Yellowhair, David

PA

Imarx Pharmaceutical Corp., USA
U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 307,305.
CODEN: USXXAM SO

DT Patent

LA

	English						
FAN.	CNT 21						
	PATENT NO.		KIN	D DATE	APPLICATION NO.		DATE
PI	US 5733572 US 5088499 WO 9109629 W: CA RW: AT		Δ.	19980331	US 1994-346426 US 1990-569828 WO 1990-US7500		19941129 <
	US 5088499		7.	19920231	HS 1990-569828		19900820 <
	WO 9109629		7.1	19910711	WO 1990-HS7500		19901219 <
	W. CA	.TP	nı	15510711	WO 1330 0B7300		13301213 (
	PW - AT	BF C	H DE	DK ES ED	GB, GR, IT, LU, NL,	SE	
	TD OFFO267	DE, C	n, DE,	10020612	TD 1001 503276	OE	10001210 <
	TD 3300356	,	B2	20020729	01 1991 303270		13301213 (
	AT 190170		T	1000015	AT 1001-002057		19901219 <
	EC 2121061		1,3	10000716	EC 1001-002057		19901219 <
	Ch 2069759			20070116	Ch 1991-2069759		19901219 <
	IIS 5228446		Δ.	19930720	HS 1991-717084		19910618 <
	WO 9222247		2.1	19921223	JP 1991-503276 AT 1991-902857 ES 1991-902857 CA 1990-2069759 US 1991-717084 WO 1992-US2615		19920331 /
	W: AU,	CA .T	p ni	13321223	WO 1332 082013		13320331 (
				DK ES ER	GB, GR, IT, LU, MC,	MT.	SE
	AII 9220020	22, 0	, D.,	19930112	AH 1992-20020	,	19920331 <
	AU 667471		B2	19960328	110 1332 20020		13320001 1
	-TP 06508364	1	т	19940922	.TP 1993-500847		19920331 <
	JP 3456584		B2	20031014	01 1330 00001		13300001
	EP 616508		A1	19940928	GB, GR, 11, LU, MC, AU 1992-20020 JP 1993-500847 EP 1992-912456		19920331 <
	EP 616508		B1	20010718			
	EP 616508		B2	20040929			
	R: AT.	BE, C	H, DE,	DK, ES, FR,	GB, GR, IT, LI, LU,	MC,	NL, SE
	AT 203148		T	20010815	GB, GR, IT, LI, LU, AT 1992-912456 ES 1992-912456 CA 1992-2110491 US 1993-76239 US 1993-76230 US 1993-8268 US 1993-160232 US 1993-159687 US 1994-199462 WO 1994-US5633		19920331 <
	ES 2159280		T3	20011001	ES 1992-912456		19920331 <
	CA 2110491		C	20070724	CA 1992-2110491		19920331 <
	US 5469854		A	19951128	US 1993-76239		19930611 <
	US 5580575		A	19961203	US 1993-76250		19930611 <
	US 5348016		A	19940920	US 1993-88268		19930707 <
	US 5542935		A	19960806	US 1993-160232		19931130 <
	US 5585112		A	19961217	US 1993-159687		19931130 <
	US 5769080		A	19980623	US 1994-199462		19940222 <
	WO 9428874		A1	19941222	WO 1994-US5633		19940519 <
	RW: AT,	BE, C	H, DE,	DK, ES, FR,	GB, GR, IE, IT, LU,	MC,	NL, PT, SE
	US 5773024		A	19980630	US 1994-30/305		19940916 <
	CA 2177713		A1	19950608	US 1994-307305 CA 1994-2177713 WO 1994-US13817		19941130 <
	WO 9515118		A1	19950608	WO 1994-US1381/		19941130 <
	W: AU,	CA, C	N, JP	DV DO DD	GB, GR, IE, IT, LU,	wo	NI DE CE
	EP 740528		H, DE,	10061106	EP 1995-908414	PIC,	NL, PI, SE
	EP 740528		B1				19941130 <
						TIT	MC NI DT CE
	JP 09506098	DE, C	п, ре,	19970617	TD 1005_515763	LU,	100/11/20 /
	AT 235228	,	T	20030415	AT 1995-908414		19941130 <
	US 5571497		Δ	19961105	HS 1995-468056		19950606 <
	CN 1180310		A	19980429	CN 1996-193069		19960327 <
	CN 1100310		B	20030226	51. 1550 155005		13300027
	US 6001335		A	19991214	US 1996-665719		19960618 <
	US 5935553		A	19990810	US 1996-758179		19961125 <
	US 6743779		B1	20040601	US 1997-841169		19970429 <
	US 5985246		A	19991116	US 1996-665719 US 1996-758179 US 1997-841169 US 1997-888426 AU 1998-56271		19970708 <
	AU 9856271		A	19980507	AU 1998-56271		19980224 <
	AU 713127		B2	19991125	GB, GR, IE, IT, LI, JP 1995-515763 AT 1995-908414 US 1995-468056 CN 1996-193069 US 1996-655719 US 1996-758179 US 1997-888426 AU 1998-56271		

	AU	9888405	A	19981203	AU	1998-88405	19981012 <
	AU	731072	B2	20010322			
	HK	1013625	A1	20000420	HK	1998-114978	19981223 <
	AU	9910043	A	19990304	AU	1999-10043	19990104 <
	GR	3036877	T3	20020131	GR	2001-401740	20011011 <
PRAI	US	1989-455707	B2	19891222	<		
	US	1990-569828	A2	19900820	<		
	US	1991-716899	B2	19910618	<		
	US	1991-717084	A2	19910618	<		
	US	1993-76239	A2	19930611	<		
	US	1993-76250	A2	19930611	<		
	US	1993-159674	B2	19931130	<		
	US	1993-159687	A2	19931130	<		
	US	1993-160232	A2	19931130	<		
	US	1994-307305	A2	19940916	<		
	WO	1990-U\$7500	W	19901219	<		
	US	1991-716793	A	19910618	<		
	US	1991-750877	A3	19910826	<		
	US	1992-818069	A3	19920108	<		
	WO	1992-US2615	A	19920331	<		
	US	1992-967974	A3	19921027	<		
	US	1993-17683	A3	19930212	<		
	US	1993-18112	B3	19930217	<		
	US	1993-85608	A3	19930630	<		
	US	1993-88268	A3	19930707	<		
	US	1993-163039	A3	19931206	<		
	US	1994-212553	B2	19940311	<		
	AU	1994-70416	A3	19940519	<		
		1994-346426	A	19941129	<		
	AU	1995-21850	A3	19941130	<		
	WO	1994-US13817	W	19941130	<		
		1995-395683	A3	19950228	<		
	US	1995-468056	A3	19950606	<		
		1995-471250	A3	19950606	<		
		1996-640554	B2	19960501	<		
		1996-665719	A3	19960618	<		
	US	1997-785661	B2	19970117	<		

RE.CNT 314 THERE ARE 314 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L14 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
- ΤI Bioadhesive-wound healing composition
- AB The present invention pertains to therapeutic bloadhesive-wound healing compns. useful for treating wounds and increasing the proliferation and resuscitation rate of mammalian cells. The compns. comprise a bioadhesive agent and a therapeutically effective amount of a wound healing composition In one embodiment the wound healing composition comprises (a) pyruvate; (b) an antioxidant; and (c) a mixture of saturated and unsatd. fatty acids. The therapeutic bioadhesive-wound healing compns. may further comprise medicaments such as antiviral agents, antikeratolytic agents, anti-inflammatory agents, antifungal agents, antibacterial agents, immunostimulating agents, and the like. The bioadhesive-wound healing compns. may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the bioadhesive-wound healing compns. and the pharmaceutical products in which the compns. may be used.
- AN 1996:367739 HCAPLUS <<LOGINID::20080702>>
- DN 125:19043
- OREF 125:3725a,3728a
- TI Bioadhesive-wound healing composition
- IN Leung, Sau-Hung S.; Martin, Alain

PA Warner-Lambert Company, USA SO PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 28

	PATENT NO.	KIND DATE	APPLICATION NO.	DATE		
PI	WO 9606640 W: AU, CA, JP,		WO 1995-US8568	19950707 <		
	RW: AT, BE, CH,	DE, DK, ES, FR,	GB, GR, IE, IT, LU, MC,			
	US 5658956		US 1995-445824			
	AU 9530045	A 19960322	AU 1995-30045	19950707 <		
	AU 707353	B2 19990708				
	EP 779820	A1 19970625	EP 1995-926209	19950707 <		
	R: BE, CH, DE,	DK, ES, FR, GB,	GR, IT, LI			
	JP 10505057	T 19980519	JP 1996-508729	19950707 <		
	ZA 9507245	A 19970630	ZA 1995-7245	19950829 <		
PRAI	US 1994-298521	A 19940830	<			
	US 1995-445824	A 19950522	<			
	US 1991-663500	B1 19910301	<			
	US 1993-53922	B2 19930426	<			
	WO 1995-US8568	W 19950707	<			

=> d 115 1-16 ti abs bib

L15 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Foam prepared from nanoemulsions for administration to the skin

AB The present invention provides a foamable composition for administration to the skin, body surface, body cavity or nucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water nano emulsion composition includes: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1-% by weight of at least one stabilizing agent, selected from the group consisting of (i) a non-ionic surfactant, (ii) an ionic surfactant, and (iii) a polymeric agent; and (c) a liquefied or compressed gas propellant at a concentration of 3-25% by weight of the total composition,

water and

optional ingredients are added to complete the total mass to 100%. Upon release from an aerosol container, the foamable composition forms and expanded foam suitable for topical administration. The present invention further provides methods of treating, alleviating or preventing a disorder of the skin, body cavity or mucosal surface using such foamable compns.; and to methods of producing such foams having an improved bubble size.

AN 2008:708760 HCAPLUS <<LOGINID::20080702>>

TI Foam prepared from nanoemulsions for administration to the skin

IN Tamarkin, Dov; Besonov, Alex; Eini, Meir; Danziger, Jorge

PA Foamix Ltd., Israel

SO U.S. Pat. Appl. Publ., 35pp., Cont.-in-part of U.S. Ser. No. 389,742.

DT Patent

LA English

FAN.CNT 26

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080138296	A1	20080612	US 2007-975621	20071019 <
WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <
WO 2004037225	A3	20041229		
	US 20080138296 WO 2004037225	US 20080138296 A1 WO 2004037225 A2	US 20080138296 A1 20080612 WO 2004037225 A2 20040506	US 20080138296 A1 20080612 US 2007-975621 WO 2004037225 A2 20040506 WO 2003-IB5527

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

```
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    US 20050069566
                        A1
                             20050331
                                         US 2004-911367
    ZA 2005003298
                        A
                              20060830
                                         ZA 2005-3298
                                                                20050425 <--
    US 20060140984
                        A1
                              20060629
                                        US 2005-532618
                                                                20051222 <--
    US 20060233721
                        A1
                              20061019
                                        US 2006-389742
                                                                20060327 <--
    AU 2006201878
                        A1
                              20070927
                                         AU 2006-201878
                                                                20060504 <--
PRAI IL 2002-152486
                       A
                              20021025 <--
    US 2002-429546P
                       P
                              20021129 <--
    US 2003-492385P
                       P
                              20030804
    WO 2003-IB5527
                       TeT
                              20031024
    US 2004-911367
                        A2
                              20040804
    US 2005-717058P
                        P
                              20050914
    US 2005-532618
                         A2
                               20051222
    US 2006-389742
                         A2
                              20060327
L15 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
```

- TI Polypropylene glycol alkyl ether foamable pharmaceutical carrier vehicle and pharmaceutical compositions thereof comprising surfactant and liquid hydrocarbon gas propellant
- AB The present invention teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent water and a liquefied hydrocarbon gas propellant; and pharmaceutical compns. thereof. Thus, concns. of active agents (in wt%) in foamable compns. were as follows: hydrocortisone acetate 1, betamethasone valerate 0.12, clobetasol proprionate 0.05, acyclovir 5, ciclopirox 1, clindamycin 1-2, azelaic acid 15, metronidazol 0.25-2, diclofenac 1, tacrolimus 0.2, caffeine 5, clotrimazole 1, lidocaine base 2, terbinafine HCl 1, gentamycin 0.1, dexpanthenol 5, urea 5-10, ammonium lactate 12-17.5, povidone-iodine 10.

 AN 2008:417770 HCAPIUS <<10COINID::20080702>>
- DN 148:410765
- TI Polypropylene glycol alkyl ether foamable pharmaceutical carrier vehicle and pharmaceutical compositions thereof comprising surfactant and liquid hydrocarbon gas propellant
- IN Freidman, Doron; Tamarkin, Dov; Feiman, Naomi; Schuz, David; Berman, Tal
- PA Foamix Ltd., Israel
- SO PCT Int. Appl., 115pp.
- CODEN: PIXXD2
- DT Patent

LA FAN.	English CNT 26																	
	PATENT	NO.			KIN	D	DATE			APPL	ICAT	ION	NO.		DATE			
						_												
PI	WO 2008	0381	40		A2		2008	0403	WO 2007-IB3463							20070607		
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BH,	BR,	BW,	BY,	BZ,	CA,	
		CH,	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DO,	DZ,	EC,	EE,	EG,	ES,	FI,	
		GB,	GD,	GE,	GH,	GM,	GT,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	
		KM,	KN,	KP,	KR,	ΚZ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LY,	MA,	MD,	ME,	
		MG,	MK,	MN,	MW,	MX,	MY,	MZ,	NA,	NG,	ΝI,	NO,	NZ,	OM,	PG,	PH,	PL,	
		PT,	RO,	RS,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SV,	SY,	ΤJ,	TM,	TN,	
		TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	ZA,	ZM,	ZW					
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	
		IS,	IT,	LT,	LU,	LV,	MC,	MT,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	
		BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG,	BW,	

GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

		DI, 10,	1121	rib,	10, 10, 111				
	US	20070020213		A1	20070125	US	2006-488989	20060719 <	<
	US	20070253911		A1	20071101	US	2007-717897	20070313 <	<
PRAI	US	2006-811627P		P	20060607				
	US	2006-482596		A	20060707				
	US	2006-488989		A	20060719				
	US	2007-717897		A	20070313				
	IL	2002-152486		A	20021025	<			
	US	2002-429546P		P	20021129	<			
	US	2003-492385P		P	20030804				
	US	2003-497648P		P	20030825				
	WO	2003-IB5527		W	20031024				
	US	2003-530015P		P	20031216				
	US	2004-835505		A2	20040428				
	US	2004-911367		A2	20040804				
	US	2004-922358		A2	20040820				
	US	2005-78902		A2	20050311				
	US	2005-124676		A2	20050509				
	US	2005-700702P		P	20050719				
	US	2005-532618		A2	20051222				
	US	2006-781868P		P	20060313				
	US	2007-897638P		P	20070126				
	US	2007-899176P		P	20070202				

- L15 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Foamable compositions, kits and drug delivery methods for treating hyperhidrosis
- AB The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and/or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and/or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis. Thus, oil-in-water foamable composition comprised (in wt%): azelaic acid 15.00, mineral oil 5.60, iso-Pr palmitate 5.60, sorbitan stearate 2.00, PPG15-stearyl ether 1.00, stearic acid 0.85, glyceryl monostearate 0.45, xanthan gum 0.26, methocel K100M 0.26, preservative 0.25, propellant 10.00, and water to 100.
- AN 2007:1237305 HCAPLUS <<LOGINID::20080702>>
- DN 147:491650
- TI Foamable compositions, kits and drug delivery methods for treating hyperhidrosis
- IN Tamarkin, Dov; Eini, Meir; Zlatkis, Ella
- PA Foamix Ltd., Israel
- U.S. Pat. Appl. Publ., 38pp., Cont.-in-part of U.S. Ser. No. 532,618. CODEN: USXXCO
- DT Patent
- LA English
- FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PΙ	US 20070253911	A1	20071101	US 2007-717897	20070313 <
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <
	WO 2004037225	A3	20041229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

```
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 20050069566
                         A1
                               20050331
                                           US 2004-911367
     US 20050232869
                         A1
                                20051020
                                           US 2005-78902
                                                                   20050311 <--
     ZA 2005003298
                         Α
                                20060830
                                           ZA 2005-3298
                                                                   20050425 <--
     US 20060140984
                         A1
                                20060629
                                          US 2005-532618
                                                                   20051222 <--
     AU 2006201878
                         A1
                                20070927
                                           AU 2006-201878
                                                                   20060504 <--
     US 20070292359
                         A1
                                20071220
                                           US 2007-811140
                                                                   20070607 <--
     WO 2008038140
                         A2
                               20080403
                                           WO 2007-IB3463
                                                                   20070607
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
             MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
         TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZM, RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
                                           US 2007-825406
     US 20080044444
                         A1
                               20080221
                                                                   20070705 <--
     US 20080152596
                         A1
                                20080626
                                           US 2007-894767
                                                                   20070820
PRAI IL 2002-152486
                          Α
                                20021025
                                          <--
     US 2002-429546P
                          P
                                20021129
                                          /--
     US 2003-492385P
                          Р
                                20030804
     WO 2003-IB5527
                        W
                                20031024
     US 2004-911367
                        A2
                                20040804
     US 2005-78902
                         A2
                                20050311
     US 2005-532618
                        A2
                                20051222
     US 2006-781868P
                        P
                               20060313
     US 2007-897638P
                        P
                               20070126
     US 2007-899176P
                        P
                               20070202
     US 2003-497648P
                               20030825
                        P
     US 2003-530015P
                        P
                               20031216
     US 2004-835505
                        A2
                               20040428
     US 2004-922358
                        A2
                               20040820
     US 2005-124676
                        A2
                               20050509
     US 2005-696878P
                        P
                               20050706
     US 2005-700702P
                        P
                               20050719
     US 2006-811627P
                        P
                               20060607
     US 2006-818634P
                        P
                               20060705
     US 2006-481596
                         A2
                                20060706
     US 2006-482596
                         Α
                                20060707
     US 2006-488989
                         A2
                                20060719
     US 2007-653205
                         A2
                                20070112
     US 2007-717897
                          A2
                                20070313
     US 2007-811140
                          A1
                                20070607
```

L15 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration

- ΔR The present invention relates to a method for augmentation of epithelial concentration and systemic exposure of therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux transporter systems by using a vaginal or buccal drug delivery compns. and/or devices. Specifically, the invention relates to a method for augmentation of intraepithelial concentration and/or systemic bioavailability for delivery of anti-viral and/or anti-cancer therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux systems by using a vaginal or buccal drug delivery of these drugs into the systemic circulation by delivering such drug to a subject in need thereof vaginally or buccally in an especially formulated composition increasing the drug's
 - bioavailability by providing means for increasing the drug solubility and permeability through the vaginal or buccal mucosa.
- AN 2007:175576 HCAPLUS <<LOGINID::20080702>>
- DN 146:258964 тт
- Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration
- IN Pauletti, Giovanni M.; Harrison, Donald C.; Desai, Kishorkumar J.
- PA
- SO U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 208,209. CODEN: USXXCO
- Patent.
- LA. English

FAN. CNT 12

FAN.	PA:	IZ FENT				KIN		DATE				ICAT				D	ATE		
PI	US AU US	2007 7652 2003 6982	0036 69 0049	834 302		A1 B2 A1 B2		2007 2003 2003 2006	0911 0313		US 2 AU 2	006- 001- 002-	5221 5419	26 2		2	0060 0010 0020	703	<
	US AU CA WO	2006 2006 2622 2007	0002 2925 746 0355	966 07 15		A1 A1 A1 A2		2006 2007 2007 2007	0105 0329 0329 0329		AU 2 CA 2	005- 006- 006- 006-	2925 2622	07 746		2	0060	915 915	<
	wo	2007 W: RW:	AE, CN, GE, KR, MW, RU, UA, AT, IS, CF, GM,	AG, CO, GH, KZ, MX, SC, UG, BE, IT, CG, KE,	AL, CR, GM, LA, MY, SD, US, BG, LT, CI, LS,	AM, CU, HN, LC, MZ, SE, UZ, CH, LU, CM, MW,	AT, CZ, HR, LK, NA, SG, VC, CY, LV, GA, MZ,	AU, DE, HU, LR, NG, SK, VN, CZ, MC, GN, NA, TM,	AZ, DK, ID, LS, NI, SL, ZA, DE, NL, GQ, SD,	DM, IL, LT, NO, SM, ZM, DK, PL, GW, SL,	DZ, IN, LU, NZ, SV, ZW EE, PT, ML, SZ,	EC, IS, LV, OM, SY, ES, RO, MR, TZ,	EE, JP, LY, PG, TJ, FI, SE, NE,	EG, KE, MA, PH, TM, FR, SI, SN,	ES, KG, MD, PL, TN, GB, SK, TD,	FI, KM, MG, PT, TR, GR, TR,	GB, KN, MK, RO, TT, HU, BF, BW,	GD, KP, MN, RS, TZ, IE, BJ, GH,	
PRAI	US US US AU	2001 2002 2005 2005 1998 2006	-315 -226 -208 -717 -769	877P 667 209 680P 76		P A1 A2 P		2001 2002 2005	0829 0821 0818 0915 0610	<-	-	Ů.							

- L15 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TT Antibiotic kit and compositions
- The present invention relates to a therapeutic kit to provide an effective AB dosage of an antibiotic including an aerosol packaging assembly. The

assembly includes a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition of an antibiotic; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixts. at 2-50%, a surfactant, 0.01-5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at 3-25% by weight of the total composition 2006:1256641 HCAPLUS <<LOGINID::20080702>>

AN DN 146:50262

TΙ Antibiotic kit and compositions

IN Friedman, Doron; Besonov, Alex; Tamarkin, Dov; Eini, Meir

PA Foamix Ltd., Israel SO

U.S. Pat. Appl. Publ., 31pp., Cont.-in-part of U.S. Ser. No. 532,618. CODEN: USXXCO

DТ Pat.ent. LA English

FAN.		26																	
		TENT :	NO.			KIN		DATE			APPL	ICAT	ION:	NO.		D	ATE		
PI	WO	2006 2004 2004	0372	25		A1 A2 A3		2006 2004 2004	0506		US 2							607 < 024 <	
		W:	CO, GM,	CR, HR,	CU, HU,	CZ, ID,	DE,	AU, DK, IN, MD,	DM, IS,	DZ, JP,	EC, KE,	EE, KG,	ES, KP,	FI, KR,	GB, KZ,	GD, LC,	GE, LK,	GH, LR,	
		RW:	PL, UA,	PT, UG,	RO, US,	RU, UZ,	SC, VC,	SD, VN, MZ,	SE, YU,	SG, ZA,	SK, ZM,	SL, ZW	TJ,	TM,	TN,	TR,	TT,	TZ,	
			KG, FI, BF,	KZ, FR, BJ,	MD, GB,	RU, GR, CG,	TJ, HU, CI,	TM, IE, CM,	AT, IT, GA,	BE, LU, GN,	BG, MC, GQ,	CH, NL, GW,	CY, PT, ML,	CZ, RO, MR,	DE, SE,	DK, SI, SN,	EE, SK, TD,	ES, TR, TG	
	US AU	2005 2006 2006 2006	0140 3393	984 11		A1 A1 A2 A1		2005 2006 2007 2007	0629 0907		US 2 US 2 AU 2	005-	5326	18		2	0040: 0051: 0060:	222 <	
	WO	2611 2007 2007	0993 0993	96		A1 A2 A3		2007 2007 2008	0907 0313		CA 2 WO 2	006-	IB39	75		2	0060 0060	607	
		W:	CN, GE, KZ, MZ,	CO, GH, LC, NA,	CR, GM, LK, NG,	CU, HR, LR, NI,	CZ, HU, LS, NO,	AU, DE, ID, LT, NZ, SY,	DK, IL, LU, OM,	DM, IN, LV, PG,	DZ, IS, LY, PH,	EC, JP, MA, PL,	EE, KE, MD, PT,	EG, KG, MG, RO,	ES, KM, MK, RS,	FI, KN, MN, RU,	GB, KP, MW, SC,	GD, KR, MX, SD,	
		RW:	AT, IS, CF, GM,	BE, IT, CG, KE,	BG, LT, CI, LS,	LU, CM, MW,	CY, LV, GA, MZ,	CZ, MC, GN, NA, TM,	NL, GQ, SD,	PL, GW, SL,	PT, ML, SZ,	RO, MR, TZ,	SE, NE,	SI, SN,	SK, TD,	TR, TG,	BF, BW,	BJ, GH,	
	EP	1919 R:	449 AT, IS,	BE,	BG,	A2 CH, LT,	CY,	2008 CZ, LV,	0514 DE,	DK,	EP 2	006- ES,	FΙ,	FR,		GR,		IE,	
		2007 2008 W:	0292 0752 AE,	355 07 AG,	AL,	A1 A2 AM,		2007 2008 AU, CZ,	0626 AZ,	BA,		007- BG,	IB44 BH,	59 BR,		BY,	0070 BZ,	CA,	

```
GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
            KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG,
            MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
            RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
            TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
            GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM
PRAI US 2002-429546P
                        P
                              20021129 <--
    US 2003-492385P
                         P
                              20030804
    WO 2003-IB5527
                        W
                              20031024
    US 2004-911367
                        A2
                              20040804
    US 2005-688244P
                       P
                              20050607
    US 2005-532618
                        A2
                              20051222
    IL 2002-152486
                              20021025 <--
                        A
    US 2003-497648P
                        P
                              20030825
    US 2003-530015P
                        P
                              20031216
    US 2004-835505
                        A2
                              20040428
    US 2004-922358
                        A2
                              20040820
    US 2005-41921
                        A2
                              20050124
    US 2006-789186P
                        P
                              20060404
    US 2006-448490
                         A2
                              20060607
    WO 2006-IB3975
                         W
                               20060607
    US 2006-861620P
                         Ρ
                               20061129
    US 2007-880434P
                         P
                               20070112
L15 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
```

- ΤI Foamable oil in water emulsion composition comprising polymer
- AB The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water emulsion composition includes: an oil globule system, selected from the group consisting of oil bodies; and sub-micron oil globules, about 0.1% to about 5% by weight of an agent, selected from the group consisting of a surface-active agent, having an HLB value between 9 and 16; and a polymeric agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, water and optional ingredients are added to complete the total mass to 100%. Upon release from an aerosol container, the foamable composition forms and expanded foam suitable for topical administration. For example, emulsion composition was prepared comprising mineral oil 5.6%, iso-Pr myristate 5.6%, glyceryl monostearate 0.45%, PEG-40 stearate 2.6%, stearyl alc. 0.85%, Xanthan gum 0.26%, methocel K100M 0.26%, Polysorbate 80 0.90%, water 74.88%, preservative 0.60 and propellant 8%. 2006:1094143 HCAPLUS <<LOGINID::20080702>>
- AN DN 145:426012
- ΤI Foamable oil in water emulsion composition comprising polymer
- Tamarkin, Dov; Friedman, Doron; Besonov, Alex; Eini, Meir IN
- PA Foamix Ltd., Israel
- SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 532,618.
- CODEN: USXXCO
- Patent
- LA English FAN.CNT 26

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060233721	A1	20061019	US 2006-389742	20060327 <
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <
	WO 2004037225	Δ3	20041229		

```
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                         A1
                               20050331
                                            US 2004-911367
     ZA 2005003298
                         A
                               20060830
                                            ZA 2005-3298
                                                                    20050425 <--
     US 20060140984
                         A1
                               20060629
                                           US 2005-532618
                                                                    20051222 <--
     AU 2006201878
                         A1
                                20070927
                                            AU 2006-201878
                                                                    20060504 <--
     WO 2007102052
                         A2
                                20070913
                                            WO 2006-IB4170
                                                                    20060914
     WO 2007102052
                         A3
                               20080103
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
             KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
             RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
                        A1 20080612 US 2007-975621
    US 20080138296
                                                                   20071019 <--
                         A
                               20021025 <--
PRAI IL 2002-152486
                         P
                               20021129
     US 2002-429546P
                                          <--
                         P
     US 2003-492385P
                               20030804
                         W
     WO 2003-IB5527
                               20031024
     US 2004-911367
                         A2 20040804
                         P
     US 2005-717058P
                               20050914
     US 2005-532618
                         A2 20051222
     US 2006-389742
                         A
                                20060327
L15 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
     Nanoparticulate megestrol formulations containing surface stabilizer
TΙ
AB
     The present invention is directed to nanoparticulate compns. comprising
    megestrol. The megestrol particles of the composition have an effective
average
     particle size of <2000 nm. Thus, a formulation contained megestrol 5,
     HPMC 1, and dioctyl sodium sulfosuccinate 0.05%.
     2005:36425 HCAPLUS <<LOGINID::20080702>>
AN
DN
     142:120565
TI
    Nanoparticulate megestrol formulations containing surface stabilizer
    Hovey, Douglas; Pruitt, John; Ryde, Tuula
IN
PA
     Elan Pharma International Ltd., USA
     U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 412,669.
     CODEN: USXXCO
DT
     Patent
T.A
    English
FAN.CNT 2
     PATENT NO.
                         KIND
                                DATE
                                            APPLICATION NO.
                                                                     DATE
```

A1

A1

20050113

20031127

B2 20060905

A1 20040603

US 2004-878623

US 2003-412669

US 2003-420927 20030423 <--

20040629 <--

20030414 <--

US 20050008707

US 20030219490

US 7101576 US 20040105889

```
20030423 <--
    CA 2508301
                        A1 20040617 CA 2003-2508301
A1 20040617 WO 2003-US12660
    WO 2004050059
                                                                  20030423 <--
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
            TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    AU 2003231071
                         A1
                            20040623 AU 2003-231071
20060111 EP 2003-724196
                                                                 20030423 <--
    EP 1613276
                                                                  20030423
                         A1
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                         т
                               20060330
                                         JP 2004-570751
                                                                  20030423 <--
    JP 2006510726
    EP 1935407
                         A1
                               20080625
                                          EP 2008-4947
                                                                  20030423 <--
        R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR
    US 20050233001
                               20051020
                        A1
                                          US 2005-93149
                                                                  20050330 <--
    US 20080152585
                         A1
                               20080626
                                          US 2007-979253
                                                                  20071031 <--
PRAI US 2002-371680P
                               20020412 <--
                         P
    US 2002-430348P
                        P
                               20021203 <--
                        A2
    US 2003-412669
                               20030414
    EP 2003-724196
                        A3
                               20030423
    US 2003-420927
                         A1
                               20030423
                              20030423
    WO 2003-US12660
                         W
    US 2004-878623
                        A1
                              20040629
L15 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
    Liquid dosage compositions of stable nanoparticulate drugs
TI
    The present invention relates to liquid dosage compns. of stable
AB
    nanoparticulate drugs. The liquid dosage compns. of the invention include
    osmotically active crystal growth inhibitors that stabilize the
    nanoparticulate active agents against crystal and particle size growth of
    the drug. Thus, an aqueous nanoparticulate colloidal dispersion (NCD)
    comprising drug 32.5 Copovidone 6.5, and dioctyl sodium sulfosuccinate
    0.464% by weight was prepared by milling for 3.8 h under high energy milling
    conditions. The final mean particle size (by weight) of the drug particles
    was 161 nm. The concentrated NCD was then diluted with preserved water and
    glycerol (the osmotically active crystal growth inhibitor) to 0.5-3.0%
    drug.
AN
    2004:60341 HCAPLUS <<LOGINID::20080702>>
DN
    140:117406
ΤI
    Liquid dosage compositions of stable nanoparticulate drugs
    Bosch, William H.; Hilborn, Matthew R.; Hovey, Douglas C.; Kline, Laura
TN
    J.: Lee, Robert W.: Pruitt, John D.; Ryde, Niels P.: Ryde, Tuula A.: Xu,
    Shuqian
```

- PA Elan Pharma International, Ltd, Ire.
- SO PCT Int. Appl., 68 pp.
- CODEN: PIXXD2
- DT Patent
- LA English FAN.CNT 18

	PA?	FENT	NO.			KIN	D	DATE			APPL	ICAT	I NOI	NO.		D	ATE	
							-											
PI	WO	2004	0069	59		A1		2004	0122		WO 2	003-	US22	187		2	0030	716 <
		W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,

```
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2492488
                         A1
                               20040122 CA 2003-2492488
                                                                   20030716 <--
                              20040202 AU 2003-261167
20050713 EP 2003-764723
    AU 2003261167
                          A1
                                                                   20030716 <--
     EP 1551457
                         A1
                                                                   20030716 <--
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005536512
                         Т
                              20051202
                                         JP 2004-521891
                                                                   20030716 <--
PRAI US 2002-396530P
                         P
                               20020716 <--
     WO 2003-US22187
                               20030716
RE.CNT 4
             THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
             ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

- L15 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Combination of immediate release and controlled release pharmaceuticals
 AB Disclosed are compns, exhibiting a combination of immediate release and
 - B Disclosed are compns. exhibiting a combination of immediate release and controlled release characteristics. The compns. comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least 1 active ingredient having a microparticulate particle size. Using a math. model, pharmacokinetic profiles were developed after single oral doses of a pharmaceutical formulation containing a drug having a single defined particle size. Small particles dissolve faster than larger particles, but that they also decay more rapidly. As a consequence, larger drug particles provide the longest blood plasma levels, although these same particles
- exhibit slow dissoln.
 AN 2003:300863 HCAPLUS <<LOGINID::20080702>>
- DN 138:326560
- TI Combination of immediate release and controlled release pharmaceuticals
- IN Cooper, Eugene R.; Ruddy, Stephen B.
- PA USA
- SO PCT Int. Appl., 45 pp.
- CODEN: PIXXD2
- DT Patent
- LA English
- FAN.CNT 1

	PAT	ENT:	NO.			KIND DATE					APPL	ICAT	ION I	NO.			ATE		
PI		2003	0308	72				2003 2003			WO 2	002-	JS32	314				011 <	
	WO	W:	AE, CO, GM, LS, PL, UA,	AG, CR, HR, LT, PT, UG,	AL, CU, HU, LU, RO, US,	AM, CZ, ID, LV, RU, UZ,	AT, DE, IL, MA, SD, VC,	AU, DK, IN, MD, SE, VN, MZ,	AZ, DM, IS, MG, SG, YU,	DZ, JP, MK, SI, ZA,	EC, KE, MN, SK, ZM,	EE, KG, MW, SL, ZW	ES, KP, MX, TJ,	FI, KR, MZ, TM,	GB, KZ, NO, TN,	GD, LC, NZ, TR,	GE, LK, OM, TT,	GH, LR, PH, TZ,	
		2463	FI, CG, 495	FR, CI,	GB, CM,	GR, GA, A1	IE, GN,	TM, IT, GQ, 2003	LU, GW, 0417	MC, ML,	NL, MR, CA 2	PT, NE, 002-	SE, SN, 2463	SK, TD, 495	TR,	BF,	BJ,	CF,	
	US US	2002 2003 6908 1443	0137 626			A1 A1 B2 A2		2003 2003 2005 2004	0724 0621			002-	2689	28		2	0021	011 <- 011 <- 011 <-	

```
20070829
    EP 1443912
                       В1
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
    TP 2005508939
                       T
                            20050407 JP 2003-533905
                                                             20021011 <--
                                                             20021011 <--
    AT 371442
                       T
                            20070915
                                       AT 2002-800993
    ES 2292848
                       Т3
                          20080316
                                       ES 2002-800993
                                                             20021011 <--
PRAI US 2001-328405P
                      P
                          20011012 <--
    WO 2002-US32314
                       W
                            20021011 <--
```

- L15 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Treatment of inflammatory skin conditions
 - The invention relates to the use of one or more antimicrobial metals, most preferably silver, preferably formed with atomic disorder, and preferably in a nanocryst. form, for the treatment of inflammatory skin conditions. The nanocryst antimicrobial metal of choice may be used in the form of a nanocryst. coating of one or more antimicrobial metals, or a solution containing dissolved species from a nanocryst. powder or coating of one or more antimicrobial metals. Thus, a com. CM-cellulose/pectin gel (DuoDERM) was combined with nanocryst silver powder prepared to produce a gel with 0.1%silver. A logarithmic reduction test was performed as follows in the gel by using Pseudomonas aeruginosa. The logarithmic reduction for this mixture was 6.2, indicating a significant bactericidal effect.
- AN 2002:832637 HCAPLUS <<LOGINID::20080702>>
- DN 137:316115
- TI Treatment of inflammatory skin conditions
- IN Burrell, Robert Edward; Yin, Hua Qing
- PA Nucryst Pharmaceuticals Corp., Can.
- SO PCT Int. Appl., 58 pp.
- CODEN: PIXXD2
- DT Patent

LA English

PAN.	PA:	TENT						DATE						.00			ATE		
PI	WO	2002 2002	0853	87		A2					WO 2	002-	CA54	9		2	0020	423 <	(
		W:							AZ,										
									DM,										
									IS,										
									MG,										
									SG,			SL,	IJ,	IM,	IN,	TR,	11,	TZ,	
		DW.							ZA, SD,			T 17	TIC	734	77.14	2.77	DE	CII	
		KW:							GB,										
									GA,										
	IIS	2002																	
		7008											0 1 0 0	,		_	0010		
		2445									CA 2	002-	2445	740		2	0020	123 <	:
		2002																423 <	
	AU	2002	2528	81		B2		2007	0726					-		_			
		1383									EP 2	002-	7219	04		2	0020	423 <	(
	EP	1383	522			B1		2006	0405										
		R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
			ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR							
		2004																	
		3222																423 <	
		2261																	
		2006							0420			005-	2845	06		2	0051	122 <	:
PRAI		2001																	
	US	2001	-840	637		A		2001	0423	<-	-								

- L15 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Preparation of aqueous clear solution dosage forms with bile acids
- AB Compns. for pharmaceutical and other uses comprise clear aqueous solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aqueous solution The compns. comprise (1) water, (ii) a bile acid component in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and (iii) either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a

range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition may further contain

a pharmaceutical compound, such as insulin, heparin, bismuth compds., amantadine and rimantadine. For example, solution dosage forms that did not show any precipitation at any pH were prepared containing ursodeoxycholic acid (UDCA) 22

g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g, bismuth citrate 4 g, citric acid or lactic acid as needed, and purified water to make 1 L.

- AN 2002:185616 HCAPLUS <<LOGINID::20080702>>
- DN 136:252482
- TI Preparation of aqueous clear solution dosage forms with bile acids
- IN Yoo, Seo Hong PA USA
- PA USA SO U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U. S. 6,251,428. CODEN: USXXCO
- DT Patent
- LA English

FAN.	CNT	5														
	PAT	TENT	NO.		KIN	DATE		1	APP	LICAT	ION	NO.	DI	TE		
PI	US	2002	20031	558	A1		0314		US	2001-	7781	154	 20	0102	205	<
			3768				1204									
	US	6251	1428		B1		0626			1999-				99907		
			30186						US	2002-	3096	503	20	10212	204	<
			5299													
			0158							2004-						<
										2004-						
										2004-						
	EP									2004-						
		R:								, ES,			GR,	HU,	IE,	
										, SE,						
	CN	1010	06511	0	A	2007	1031	(CN	2004-	8004	14467	20	10411	.24	
	BR	2004	10192	13	A	2007	1218		BR	2004-	1921	13	20	10411	.24	
	JP	2008	35218	00	T	2008	0626		JP	2004- 2007- 2006-	5430	006	20	/0413	24	
	AU	2006	2033	15	A1	2006	0824	4	ΑU	2006-	203	315	20	10608	303	<
			70072							2006-						<
			7CN02							2007-						
										2007-						
			30057							2007-	9345	005	20	0711	.02	<
PRAI			3-940				0724									
			-357				0720									
			-180				0204									
			1-366													
			L-778				0205 1124									
			1-996 1-US3				1124									
	WO	2004	1-053	9507	A.	2004	1124									

RE.CNT 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L15 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Tannins in method of isolating mucilaginous polysaccharides and uses for the polysaccharides thus obtained
- AB The present invention provides a method of isolating mucilaginous polysaccharides from plants, cereals, cell cultures, or fungi such as mushrooms known to have mucilaginous or protein-bound polysaccharides with desirable biol. properties. The mucilaginous polysaccharides present in

aqueous solution or tissue exts. are treated with tannins to form a complex

which

is then separated from the solution The complex is then treated one or more times with either solvents or other substances in solution to remove the bounded tannins from the complex thereby and releasing the isolated polysaccharide. The polysaccharides prepared according to the present method retain properties that are substantially similar to those of the native polysaccharide as it is found in the resp. plant or cell. The polysaccharides thus prepared are used in a variety of products, e.g., in cosmetics, pharmaceuticals, and food products. This process is particularly suitable for isolating acetylated mannose polymers from aloe plants and beta glucans.

- AN 2000:493312 HCAPLUS <<LOGINID::20080702>>
- DN 133:101738
- TI Tannins in method of isolating mucilaginous polysaccharides and uses for the polysaccharides thus obtained
- IN Vittori, Natale
- PA Vito-Mannan Polysaccharide L.L.C., USA
- SO PCT Int. Appl., 45 pp. CODEN: PIXXD2
- DT Patent
- LA English
- FAN.CNT 1

FAN.	CNT	1																	
		TENT						DATE								D.	ATE		
																_			
PI		2000									WO 2	000-1	US75	9		2	0000	111 <	<
	WO	2000	0415	41		A3		2001	1115										
		W:	ΑE,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CR,	CU,	
			CZ,	DE,	DK,	DM,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	HR,	HU,	ID,	IL,	IN,	
			IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	
			MG,	MK,	MN.	MW,	MX,	NO.	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	
			SL,	TJ.	TM.	TR.	TT.	TZ.	UA.	UG,	US.	UZ.	VN.	YU.	ZA.	ZW			
		RW:	GH.	GM.	KE.	LS.	MW.	SD.	SL.	SZ.	TZ.	UG.	ZW.	AT.	BE.	CH.	CY,	DE.	
																	CF,		
			CI,	CM.	GA,	GN,	GW,	ML,	MR.	NE.	SN.	TD,	TG						
	CA	2328												092		2	0000	111 <	<
	EP	1144	456			A2		2001	1017		EP 2	000-	9043	09		2	0000	111 <	<
		1144																	
		R:	AT.	BE.	CH.	DE.	DK.	ES.	FR.	GB.	GR.	IT.	LI.	LU.	NL.	SE.	MC,	PT.	
					LT,				,	,	,	,	,	,	,	,	,	,	
	IIS	6482							1119		IIS 2	000-	4811	11		2	0000	111 <	
		2000						2001										011 <	
DDAT		1999										000 1	. 1155	00		-	0001	011 -	`
FRAI																			
	WO	2000	-us7	59		W		2000	0111	<-	_								

- L15 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Improved formulation for topical non-invasive application in vivo
- AB A formulation comprises mol. arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of the pores is smaller than the average penetrant diameter, provided

the penetrants can transport agents or cause permeation through the pores after penetrants have entered pores. The formulation comprises at least 1 consistency builder in an amount that increases the formulation to maximally 5 Nm/s so that spreading over is enabled. The formulation also contains 1 antioxidant in an amount that reduces the increase of oxidation index to <100% per 6 mo and/or at least 1 microbicide in an amount that reduces the bacterial count of 1 million germs added/g of total mass of the formulation to <100 in the case of aerobic bacteria, to <10 in the case of entero-bacteria, and to <1 in the case of Pseudomonas aeruginosa or Staphilococcus aureus, after a period of 4 days. Thus, a composition contained soybean phosphatidylcholine 347, Tween-80 623, sodium dodecyl sulfate 30, benzyl alc. 50, clobetasol 17-propionate 25 and pH 6.5 50 mM phosphate buffer 9000 mg.

AN 2000:456858 HCAPLUS <<LOGINID::20080702>>

DN 133:94512

TI Improved formulation for topical non-invasive application in vivo

IN Cevc, Gregor

PA Idea Innovative Dermale Applikationen G.m.b.H., Germany

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent LA English

FAN.	CNT	1																	
		FENT				KIN		DATE			APP:	LICAT	ION :	ΝΟ.		D.	ATE		
PT	WO	2000	0386	53		A1		2000	0706		WO.	1998-1	EP84	21		11	9981	223	<
												, BY,							
												, HU,							
												LV,							
												, SI,							
								YU.									,		
		RW:	GH,	GM,	KE,	LS,	MW,	SD,	SZ,	UG,	ZW	, AT,	BE,	CH,	CY,	DE,	DK,	ES,	
			FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL	, PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	
								MR,											
	CA	2356	080			A1		2000	0706		CA :	1998-	2356	080		1	9981	223	<
	ΑU	9925	137			A		2000	0731		AU :	1999-	2513	7		1	9981	223	<
		7708																	
											EP :	1998-	9668	46		1	9981	223	<
	EΡ	1140																	
		R:							FR,	GB,	GR	, IT,	LI,	LU,	NL,	SE,	MC,	PT,	
						LV,													
												1998-							
	HU	2001	0044	24		A2		2002	0328		HU .	2001-	4424			1	9981	223	<
	HU	2001	0044	24		A3		2002			TD .	0000		0.77					
	JP	2002	5333	19		T		2002			JP .	2000-	5906	0 /		1:	9981	223	<
	EE	2001	0034	2		A		2002			EE .	2001-	342			11	3381	223	
	KU 2.T	2207	844			CZ		2003			KU.	2001-	1200	16		11	3381	223	<
	M.I.	2001 2001 2207 2723 2226 1938 2001	313			1.3		2004			EC.	2000- 2001- 2001- 1998- 1998- 1967- 2001-	0660	46		11	9981	223	
	DI	1030	203			13		2007	0330		DI I	1967-	3101	40		11	2201	223	>==
	HD	2001	0003	na		21		2002	0530		HD .	2001-	300			2	0010	502	>
	HB	2001	0003	09		R1		2005	0630			2001 .	505			-	0010	302	-
	NO	2001	0031	64		A		2001			NO.	2001-	3164			2	0010	622	<
	US	2002	0064	524		A1		2002				2001-							
		7175				B2		2007								_			
		2001									MX :	2001-	PA64	24		2	0010	622	<
		1040				A1						2002-							
	US	2007	0184					2007	0809		US :	2006-	6380	91		2	0061	212	<
PRAI	WO	1998	-EP8	421		A		1998	1223	<-	_								
	US	2001	-887	493		A1		2001	0622	<-	-								

OS MARPAT 133:94512

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

- TI Novel pharmaceutical formulation of dehydroepiandrosterone for percutaneous topical application
- AB The disclosed formulation is comprised of: (a) 0.1-5 weight dehydroepiandrosterone; (b) 0.5-3% acrylic gel, 1-3% guar gum, or 1-3% cellulose-derived gel, and optionally other ingredients such as hydrophilic gels, estradiol, vitamins, progesterone, minoxidil, hyaluronidase, vasoprotectants, plant exts., etc. The formulation has various pharmacol. applications, e.g. for treating menstrual disorders, mammary and gynecol. neoplasms, lipodystrophy, panniculopathy, circulatory disorders, bruises, muscular pain, obesity, diabetes, osteoporosis, aging, etc.
- AN 1997:204223 HCAPLUS <<LOGINID::20080702>>
- DN 126:190952
- OREF 126:36787a,36790a
 - I Novel pharmaceutical formulation of dehydroepiandrosterone for percutaneous topical application
- IN Cabo Soler, Jose; Calderon Gomez, Jesus; Palacios Gil-Antunano, Santiago PA Spain
- SO PCT Int. Appl., 15 pp.
- CODEN: PIXXD2
- DT Patent
- LA Spanish
- FAN.CNT 1

	PATENT NO.	KIND DATE	APPLICATION NO.	DATE
PI	WO 9703676	A1 19970206	WO 1996-ES153	19960719 <
	W: AU, BR, CA,	CN, JP, MX, US,	AM, AZ, BY, KG, KZ, MD,	RU, TJ, TM
	RW: AT, BE, CH,	DE, DK, ES, FI,	FR, GB, GR, IE, IT, LU,	MC, NL, PT, SE
	ES 2098193	A1 19970416	ES 1995-1471	19950721 <
	ES 2098193	B1 19971201		
	AU 9664196	A 19970218	AU 1996-64196	19960719 <
PRAI	ES 1995-1471	A 19950721	<	
	WO 1996-ES153	W 19960719	<	

- L15 ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Carbohydrate-linked short-chain fatty acids for delivery to the colon.
- AB Delivery to the colon of fatty acids, especially short-chain fatty acids (SCFA),

can be effected by covalently linking SCFA to a carrier, that is preferably a carbohydrate, by an ester link. The SCFA is protected by its link with the carbohydrate through the small intestine, and where the carbohydrate is digestible in the small intestine such as a digestible starch, the starch can also be protected from digestion in the small intestine by the substitution. Levels of SCFA such as acetate, propionate and butyrate may be elevated to have beneficial effects in the prevention of colonic disorders, such as rectal cancer,

diverticulitis, colitis, diarrhea and constipation.

- AN 1995:756390 HCAPLUS <<LOGINID::20080702>>
- DN 123:142666
- OREF 123:25401a,25404a
- TI Carbohydrate-linked short-chain fatty acids for delivery to the colon.
- IN Anisson, Geoffrey; Topping, David; Illman, Richard
- PA Commonwealth Scientific and Industrial Research Organisation, Australia
- SO PCT Int. Appl., 55 pp.
- CODEN: PIXXD2
- DT Patent

LA English FAN. CNT 1

E MIN.		TENT	NO.			KIN					APPL	ICAT	ION	NO.		D	ATE		
PI			801						0526		WO 1	994-		3				117 <-	
		W:	GB,	GE, NL,	HU,	JP,	KE,	BR, KG, PT,	KP,	KR,	KZ,	LK,	LR,	LU,	LV,	MD,	MG,	MN,	
		RW:	KE,	MW, NL,				BE, BJ,											
		2176				A1		1995			CA 1	994-	2176	719		1	9941	117 <-	
	AU	2176 9481 6959	368			C A B2		2007 1995 1998	0606		AU 1	994-	8136	8		1	9941	117 <-	
	EP	7304	47					1996 2002	0911		EP 1	995-	9005	75		1	9941	117 <-	
					ES,			IT,				004	C 2 4 2 2			1.	0011	110 .	
		0950 4071				T B2		1997 2008										117 <- 117 <-	
		5840				A		1998										905 <-	
PRAI				4				1993				,,,,	0102	, ,		4.	,,,,,	,05 \	
	WO	1994	-AU7	13		W		1994	1117	<-	-								

- L15 ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
- Method for preparing diagnostic slide coated with immunoreactive substance-sensitized latex and water-soluble polymer
- AB The method comprises coating the slide with a reagent layer containing immunoreactive substance (e.g. antibody or antigen)-sensitized latex, water-soluble polymer (e.g. PVP), and optionally a water-soluble natural compound

(e.g. cyclodextrin), followed by natural drying to produce a stable and redissolvable coating. Thus, monoclonal anti-mannan antibody was prepared, immobilized on latex, coated on a slide together with PVP, and used for detecting mannan derived from Candida tropicalis.

AN 1993:599163 HCAPLUS <<LOGINID::20080702>>

DN 119:199163

OREF 119:35405a,35408a

CODEN: JKXXAF

- TI Method for preparing diagnostic slide coated with immunoreactive substance-sensitized latex and water-soluble polymer
- IN Kondo, Kenji; Yoshimura, Makoto; Fujii, Masahiko
- PA Kureha Chemical Ind Co Ltd, Japan
- SO Jpn. Kokai Tokkyo Koho, 11 pp.
- DT Patent

LA	Jap	anese
FAN.	CNT	1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05196623	A	19930806	JP 1992-171730	19920606 <
	JP 2631796	B2	19970716		
PRAI	JP 1991-176213	A1	19910620	<	

=> file stnguide

SINCE FILE COST IN U.S. DOLLARS TOTAL. ENTRY SESSION FULL ESTIMATED COST 127.82 135.21

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 15:32:07 ON 02 JUL 2008
```

THE 'SINGUIDE' ENTERED AT 15:32:07 ON 02 DUE 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 27, 2008 (20080627/UP).

=> s guar or galactomannan

11663 GUAR

3183 GALACTOMANNAN

L1 13810 GUAR OR GALACTOMANNAN

=> s fluorouracil of fluorodeoxyuridine or fluoropyrimidine of cisplatin

21389 FLUOROURACIL

1919 FLUORODEOXYURIDINE

74 FLUOROURACIL OF FLUORODEOXYURIDINE

(FLUOROURACIL(1W)FLUORODEOXYURIDINE)

1420 FLUOROPYRIMIDINE

23605 CISPLATIN

5 FLUOROPYRIMIDINE OF CISPLATIN

(FLUOROPYRIMIDINE(1W)CISPLATIN)

L2 79 FLUOROURACIL OF FLUORODEOXYURIDINE OR FLUOROPYRIMIDINE OF CISPLA TIN

=> s leucovorin

L3 2637 LEUCOVORIN

=> s 11 and 12

L4 0 L1 AND L2

=> s 11 and 12 and 13

L5 0 L1 AND L2 AND L3

=> s 14 and (PY<2004 or AY<2004 or PRY<2004)

23986121 PY<2004 4778946 AY<2004

4249769 PRY<2004

L6 0 L4 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s 15 and (PY<2004 or AY<2004 or PRY<2004)

23986121 PY<2004

4778946 AY<2004 4249769 PRY<2004

.7 0 L5 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE TOTAL

SESSION ENTRY 2.69 3.11

TOTAL

3.17

SESSION

SINCE FILE

ENTRY

0.06

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 18:01:32 ON 02 JUL 2008 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION. LAST RELOADED: Jun 27, 2008 (20080627/UP).

=> file hcaplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 18:02:04 ON 02 JUL 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jul 2008 VOL 149 ISS 1 FILE LAST UPDATED: 1 Jul 2008 (20080701/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

- => s fluorouracil or fluorodeoxyuridine or fluoropyrimidine of cisplatin
 - 21389 FLUOROURACIL
 - 1919 FLUORODEOXYURIDINE
 - 1420 FLUOROPYRIMIDINE
 - 23605 CISPLATIN
 - 5 FLUOROPYRIMIDINE OF CISPLATIN

(FLUOROPYRIMIDINE (1W) CISPLATIN)

L8 22775 FLUOROURACIL OR FLUORODEOXYURIDINE OR FLUOROPYRIMIDINE OF CISPLA TIN

=> s 11 and 18

38 L1 AND L8

=> s 11 and 18 and 13

1.10 6 L1 AND L8 AND L3 => s 19 and (PY<2004 or AY<2004 or PRY<2004)

23986121 PY<2004 4778946 AY<2004 4249769 PRY<2004

18 L9 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s 110 and (PY<2004 or AY<2004 or PRY<2004)

23986121 PY<2004 4778946 AY<2004 4249769 PRY<2004

2 L10 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS SINCE FILE TOTAL. ENTRY SESSION 2.69 5.86

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 18:02:11 ON 02 JUL 2008 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION. LAST RELOADED: Jun 27, 2008 (20080627/UP).

=> d 111 1-18 ti abs bib

L11 ANSWER 1 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:v

- Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration
- The present invention relates to a method for augmentation of epithelial concentration and systemic exposure of therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux transporter systems by using a vaginal or buccal drug delivery compns. and/or devices. Specifically, the invention relates to a method for augmentation of intraepithelial concentration and/or systemic bioavailability for delivery of anti-viral and/or anti-cancer therapeutic agents having a substrate affinity for cytochrome P 450 enzymes and membrane efflux systems by using a vaginal or buccal drug delivery of these drugs into the systemic circulation by delivering such drug to a subject in need thereof vaginally or buccally in an especially formulated composition increasing the drug's bioavailability by providing means for increasing the drug solubility and
- permeability through the vaginal or buccal mucosa. 2007:175576 HCAPLUS <<LOGINID::20080702>> AN
- 146:258964 DN
- Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration
- Pauletti, Giovanni M.; Harrison, Donald C.; Desai, Kishorkumar J. TN
- PΆ
- SO. U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 208,209. CODEN: USXXCO

DT Patent LA English FAN.CNT 12

NO. DATE
26 20060915 <
2 20010703 <
67 20020821 <
09 20050818 <
07 20060915
746 20060915
087 20060915
BW, BY, BZ, CA, CH,
EG, ES, FI, GB, GD,
KE, KG, KM, KN, KP,
MA, MD, MG, MK, MN,
,,,,
FR. GB. GR. HIL TE.
,,,,
BW, BY, BZ, CA, C EG, ES, FI, GB, C KE, KG, KM, KN, K

- L11 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Nanoparticle compositions comprising antibodies for targeted delivery
- AB The present invention is directed to compns. of one or more nanoparticulate active agents, at least one PEG-derivatized surface stabilizer, and at least one antibody or fragment thereof, and methods of using such compns. for targeting delivery of the one or more active agents to a desired site. The one or more active agents preferably have a particle size of $\leq 2~\mu$. The targeted delivery can be used, e.g., for disease diagnosis, imaging, or drug delivery. Thud, WIN-68209

particles wee stabilized by PEG-DSPE stabilizer.

- AN 2005:472002 HCAPLUS <<LOGINID::20080702>>
- DN 143:13359
- ΤI Nanoparticle compositions comprising antibodies for targeted delivery TN
- Liversidge, Elaine; Cunningham, James PA Elan Pharma International Ltd., Ire.
- SO PCT Int. Appl., 95 pp.
- CODEN: PIXXD2
- Patent LA English

FAN.	CMT	1																	
	PA:	TENT :	NO.			KIN	D	DATE			APPL	ICAT	ION	NO.		D	ATE		
							_									-			
PI	WO	2005	0490	91		A2		2005	0602	1	WO 2	004-1	US37:	246		2	0041	109 <	-
	WO	2005	0490	91		A3		2006	1109										
		W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,	
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,	

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

```
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
            SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
            NE, SN, TD, TG
    US 20050147664
                         A1
                               20050707
                                          US 2004-979792
                                                                  20041103 <--
    CA 2545856
                         A1
                              20050602 CA 2004-2545856
                                                                 20041109 <--
                         A2 20060816
    EP 1689442
                                        EP 2004-810555
                                                                 20041109 <--
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
            HR, IS, YU
                                          JP 2006-539722
    JP 2007511513
                               20070510
                                                                 20041109 <--
PRAI US 2003-519251P
                              20031113 <--
    WO 2004-US37246
                               20041109
                         W
```

- L11 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- ΤI Polysaccharide compositions and methods for hydrophobic drug delivery AB Disclosed herein are compns. and methods for the delivery and targeting of therapeutics using nanometer sized polysaccharide structures. The methods and compns. described herein afford improved efficacy for pharmaceuticals such as antitumor drugs on metastatic tumor. The methods described herein are applicable to all chemotherapeutic agents and are especially useful for poorly soluble (hydrophobic) drugs which when formulated with the present compns. render them deliverable in physiol. fluids. The methods and compns. described herein also improve the efficacy of pharmaceutical agents by targeting carbohydrate receptors specific to tumors that mediate endocytosis or enhance delivery of the drug to the ultimate site of action. For example, a paclitaxel-modified galactomannan (6 mg/kg/60 mg/kg) complex was administered i.v. once a day for 5 days to mice implanted with human colon cancer. While control untreated tumors grew well in all mice and reach about 600 mg in 30 days, the tumor in treated mice reach less than 200 mg in 30 days, a 200% reduction in tumor size
 - vs. untreated control animals. 2005:71073 HCAPLUS <<LOGINID::20080702>>
- DN 142:162618

ΔN

- TI Polysaccharide compositions and methods for hydrophobic drug delivery
- IN Platt, David; Zomer, Eliezer; Klyosov, Anatole
- PA Pro-Pharmaceuticals, Inc., USA
- SO PCT Int. Appl., 32 pp.
- CODEN: PIXXD2
- DT Patent LA English
- LA English FAN.CNT 1

	PATENT	NO.			KIN	D	DATE			APPL	ICAT	ION :	NO.		D	ATE	
PI	WO 2005 WO 2005 WO 2005	0071	10		A2 A9 A3		2005 2005 2005	0728		WO 2	004-	US22	375		2	0040	712 <
	W:						AU,										
							DE,										
							ID,										
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NA,	NI,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
		TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
		AZ,	BY,	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,
		SI,	SK,	TR,	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,
		SN,	TD,	TG													

	US	2005	0043	272		A1	2	2005	0224	Ţ	JS 2	004-	8895.	55		2	0040	712	<
	EP	1643	969			A2	- 2	2006	0412	1	EP 2	004-	7780	75		2	040	712	<
		R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
			IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	PL,	SK,	HR
	CN	1838	942			A	2	2006	0927	(CN 2	004-	8002	4080		2	040	712	<
	JP	2007	53169	97		T	- 2	2007	1108		JP 2	006-	5202	60		2	040	712	<
PRAI	US	2003	-4863	338P		P	- 2	2003	0711	<	-								
	WO	2004	-US22	2375		W	2	2004	0712										

- L11 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- TT Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
- AB Disclosed is a medicinal oral preparation to be delivered to the large intestine comprising a core containing a pharmacol. active ingredient, an inner layer containing one or more cationic polymers and an outer layer containing

one or more anionic polymers whereby the core is coated, which is designed so that, in a disintegration test successively consisting of a vertical movement for 2 h in a first solution of pH 1.2, a vertical movement for 2 h in a second solution of pH 7.4 and a vertical movement in a third solution of

На

- 6.4, the average disintegration initiation point and the average disintegration completion point each falls within a period from 35 min to 130 min after starting the vertical movement in the third solution Namely, disclosed is a medicinal oral preparation to be delivered to the large intestine, a medicinal oral preparation for treating colon cancer and a medicinal oral preparation for treating colitis which would not disintegrate in the stomach or small intestine but begin to disintegrate after attaining the large intestine and surely complete the disintegration while remaining in the large intestine. A core composition containing 5-fluorouracil 25.6, lactose 48.4, crystalline cellulose 20, low-substituted hydroxypropylcellulose (LH-21) 5, and magnesium stearate 1 % was coated with an inner coating material containing Eudragit E 7, ethanol 70, water 19.5, and talc 3.5 %, and then with an outerlayer coating material containing Eudragit S 7, ethanol 70, water 18.8, talc 3.5, and polyethylene glycol 6000 0.7 % to obtain a tablet for delivery to large intestine.
- AN 2004:857365 HCAPLUS <<LOGINID::20080702>>
- DN 141:337753
- ΤТ Medicinal oral preparations for colon delivery, medicinal oral
- preparations for treating colon cancer and medicinal oral preparations for treating colitis IN
- Sato, Shuji; Goto, Takeshi; Tanida, Norifumi; Meno, Tatsuya; Yoshinaga, Takaaki; Yonemura, Keishi
- PA Hisamitsu Pharmaceutical Co., Inc., Japan
- PCT Int. Appl., 35 pp. SO
- CODEN: PIXXD2
- Patent DT
- LA Japanese

FAN.	CNT	1																
	PA'	TENT NO.			KIN	D [DATE		2	APPL	ICAT:	ION	NO.		D	ATE		
															-			
PI	WO	2004087	109		A1	2	2004	1014	7	NO 2	003-3	JP38	04		2	0030	327	<
		W: CA	, US															
		RW: AT	, BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	
		IT	, LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR							
	EP	1607087			A1	2	2005	1221	1	SP 2	003-	7154	85		2	0030	327	<
		R: AT	, BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		IE	, SI,	FI,	RO,	CY,	TR,	BG,	CZ,	EE,	HU,	SK						
	US	2006018	8563		A1	2	2006	0824	Ţ	JS 2	005-5	5505	86		2	0050	922	<
PRAI	WO	2003-JP	3804		W	2	2003	0327	<	_								

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L11 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Preclinical studies of anticancer efficacy of 5-fluorouracil when co-administered with the 1,4- β -D- galactomannan
- AB Soluble 1,4-β-D- galactomannan (GM) was obtained from a plant source by controlled acid hydrolysis and further purification under Good Manufacturing Practice (GMP) conditions. Co-administration of the GM along

with

5-Fluorouracil (5-FU) by i.v. injection to mice bearing human colon tumors (COLO 205 and HT-29) significantly increased efficacy of the 5-FU. This article describes the principal results of three sep. preclin. studies, employing (i) COLO 205-bearing mice at one dose of GM and 5-FU (ii) COLO 205-bearing mice at escalating GM doses in combination with 5-FU; and (iii) HT-29-bearing mice at two GM doses in combination with 5-FU with and without leucovorin. The studies have shown a GM dose-related effect with a maximum efficacy at 120 mg/kg/dose of GM. Effect of an addnl. oral administration of leucovorin was minimal. Combination of the GM with 5-FU, compared to 5-FU alone, resulted in the decrease in median tumor volume to 17\$-65\$ and an increase in mean survival time (days) to 150\$-190\$, resp.

- AN 2004:151188 HCAPLUS <<LOGINID::20080702>>
- DN 141:184724
- TI Preclinical studies of anticancer efficacy of 5-fluorouracil
- when co-administered with the 1,4- β -D- galactomannan
- AU Klyosov, Anatole A.; Platt, David; Zomer, Eliezer CS Pro-Pharmaceuticals, Newton, MA, USA
- CS Pro-Pharmaceuticals, Newton, MA, USA SO Preclinica (2003), 1(4), 175-183, 186
- CODEN: PRECC8; ISSN: 1542-9431
- PB Eaton Publishing
- DT Journal
- LA English
- RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L11 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Medical goods comprising heparin or chitosan-based hemocompatible coating
- AB The invention relates to oligo- and polysaccharides containing the sugar structural element N-acylglucosamine or N-acylgalactosamine, in addition to the use thereof for producing hemocompatible surfaces and to methods for coating surfaces in a hemocompatible manner with said oligo- and polysaccharides, which constitute the common biosynthetic precursor substances of heparin, heparan sulfates and chitosan. The invention also relates to methods for producing the oligo- and/or polysaccharides, in addition to diverse application options involving hemocompatible surfaces. The invention specifically relates to the use of the oligo- and/or polysaccharides on stents involving at least one hemocompatible coating that has been applied according to the invention and that contains an anti-proliferative, anti-inflammatory and/or athrombogenic active ingredient, to methods for producing said stents and to the use of the latter for preventing restenosis. Thus desulfated and reacetylated heparin was prepared; the Ac-heparin product was used for coating coronary metal stents. The stents were implanted in swines; after four weeks the animals were anesthetized and the artery segments removed for histomorphometric anal.
- AN 2003:913055 HCAPLUS <<LOGINID::20080702>>
- DN 139:399770
 - I Medical goods comprising heparin or chitosan-based hemocompatible coating
- IN Horres, Roland; Linssen, Marita Katharina; Hoffmann, Michael; Faust, Volker; Hoffmann, Erika; Di Biase, Donato

PA Hemoteq G.m.b.H., Germany PCT Int. Appl., 93 pp. SO

CODEN: PIXXD2 DT Patent

T.A. German FAN.CNT 2

KIND DATE APPLICATION NO. DATE PATENT NO. WO 2003094990 A1 20031120 WO 2003-DE1253 20030415 <--PΙ W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GM, ML, MR, NE DE 10221055 B4 2007-10221055 B4 2007-10221055 B4 2007-10221055 B4 2007-10221055 B4 2007-1025 B5 10261986 B4 2008131 B2 2007-10261986 B4 2008131 AU 2003240391 A1 20031111 AU 2003-240391 AU 2003240391 B2 20070517 AU 2003-2484269 A1 20031120 CA 2003-2484269 CN 1543362 A 20041103 CN 2003-800770 BP 1501565 B1 20061102 FP 2003-729829 B1 501565 B1 20061102 FP 2003-729829 B1 2003-729829 B1 20061102 FP 2003-729829 B1 2003-729829 B1 20061102 FP 2003-729829 B1 20 20020510 <--20020510 <--20030415 <--20030415 <--20030415 <--20030415 <--R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, BR 2003011446 A 2005015 BR 2003-11446 20030415 <-CN 1665554 A 20050907 CN 2003-815926 20030415 <-CN 1665554 A 20050907 CN 2003-815926 20030415 <-JP 2005334724 T 20051117 JP 2004-503070 20030415 <-AT 344064 T 20061115 AT 2003-729829 20030415 <-ES 2276065 T3 20070616 ES 2003-729829 20030415 <-ES 2276065 T3 20070616 ES 2003-729829 20030415 <-ES 2276065 A 20070831 NZ 2003-536331 20030415 <-IN 2004MN00606 A 200505218 IN 2004-MM606 20041028 <-ZA 2004008791 A 20050527 ZA 2004-8791 20041028 <-ZA 2004008787 A 20050531 ZA 2004-8791 20041028 <-US 20050176678 A1 2005011 US 2004-513982 20041102 <-MX 2004PA11112 A 200509174 MX 2004-PA11112 20041109 <-IN 2005MN01451 A 20070706 IN 2005-MN1451 20051230 <-EPRAI US 2002-798676P P 20020509 <-DE 2002-10221055 A 20030510 <--IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK DE 2002-10221 WO 2003-DE1253 W 20030415 <--A3 20041028 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN

TΙ

Multiplex drug delivery system suitable for oral administration AB A multiplex drug delivery system suitable for oral administration containing at least two distinct drug dosage packages, which exhibit equivalent dissoln. profiles for an active agent when compared to one another and when compared to that of the entire multiplex drug delivery unit, and substantially enveloped by a scored film coating that allows the separation of the multiplex drug delivery system into individual drug dosage packages can provide a convenient and cost effective drug delivery unit, particularly for patients with a regimen of prescribed dosages that varies during their treatment period. Formulation of an isosorbide-5-mononitrate

tablet containing immediate-release and extended-release layers is disclosed.

- 2003:603864 HCAPLUS <<LOGINID::20080702>> AN
- DN 139:154899
- TT Multiplex drug delivery system suitable for oral administration
- IN Ting, Richard; Hsiao, Charles
- PA Impax Pharmaceuticals Inc., USA
- SO U.S., 9 pp. CODEN: USXXAM
- Patent
- T.A English

FAN.CNT 1

		TENT :						DATE				LICAT				D	ATE		
PI	US WO	6602 2000 2000	521 0184	47		B1 A2		2000	0406		US I	L998- L999-	1646	42				929 913	
	wo	W:	AE, CZ, IN, MG, SL, GH, RU, LU,	AL, DE, IS, MK, TJ, GM, TJ, MC,	AM, DK, JP, MN, TM, KE, TM,	AT, DM, KE, MW, TR, LS, AT, PT,	AU, EE, KG, MX, TT, MW, BE,	AZ, ES, KP, NO, UA, SD, CH,	BA, FI, KR, NZ, UG, SL, CY,	GB, KZ, PL, UZ, SZ, DE,	GD, LC, PT, VN, UG, DK,	BR, GE, LK, RO, YU, ZW, ES, CI,	GH, LR, RU, ZA, AM, FI,	GM, LS, SD, ZW AZ, FR,	HR, LT, SE, BY, GB,	HU, LU, SG, KG, GR,	ID, LV, SI, KZ, IE,	IL, MD, SK, MD, IT,	
		1416 1416	920			A2					EP 1	1999-	9481	82		1	9990	913	<
		R:				DE, LV,						IT,	LI,	LU,	NL,	SE,	MC,	PT,	
	TW	2278 2289 2003	97			В		2005	0311		TW I	1999- 1999- 2003-	8811	5834		1	9990	913 · 914 · 512 ·	<
	US WO	1998 1999	-164 -US2	642 0807		A W		1998 1999	0929 0913	<-	-								

THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L11 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- In vivo pharmacokinetics in human volunteers: oral administered
- quar qum-based colon-targeted 5-fluorouracil tablets
 - The objective of the present study is to compare the quar gum-based colon-targeted tablets of 5-fluorouracil against an immediate release tablet by in vitro dissoln. and in vivo pharmacokinetic studies in human volunteers. Twelve healthy volunteers participated in the study. 5-Fluorouracil was administered at a dose of 50 mg both in immediate release tablet and colon-targeted tablet. On oral administration of colon-targeted tablets, 5-fluorouracil started appearing in the plasma at $\hat{6}$ h, and reached the peak concentration (Cmax of 216±15 ng/mL) at 7.6±0.1 h (Tmax), whereas the immediate release tablets produced peak plasma concentration (Cmax of 278±21 ng/mL) at 0.6±0.01 h (Tmax). The AUC0-∞ for 5- fluorouracil from colon-targeted tablet and immediate release tablet were found to be 617±39 and 205±21 ng/mL/h, resp. Colon-targeted tablets showed delayed tmax, delayed absorption time (ta), decreased Cmax and decreased absorption rate constant when compared to the immediate release tablets. The results of the study indicated that the guar gum-based colon-targeted formulation did not release the drug in stomach and small intestine, but delivered it to the colon resulting in a slow absorption of the drug and making it available for local action in colon.
- AN 2003:598184 HCAPLUS <<LOGINID::20080702>>
- DN 140:204939

- TI In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets
- AU Krishnaiah, Y. S. R.; Satyanarayana, V.; Dinesh Kumar, B.; Karthikeyan, R. S.; Bhaskar, P.
- ${\tt CS}$ $\,$ Department of Pharmaceutical Sciences, Andhra University, Visakhapatnam, 530 003, India
- SO European Journal of Pharmaceutical Sciences (2003), 19(5), 355-362
- CODEN: EPSCED; ISSN: 0928-0987
- PB Elsevier B.V.
- DT Journal
- LA English
- RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L11 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Oral pharmaceutical formulations for colon delivery, colon cancer treatment, and colitis treatment
- AB The oral pharmaceutical formulations for colon delivery have coating layers including an inner layer containing ≥1 cationic polymer and an outer layer containing ≥1 anionic polymer. In disintegration test involving up-and-down movements in a lst solution (pH 1.2) for 2 h, up-and-down movements in a 2nd solution (pH 7.4) for 2 h, and up-and-down movements in a 3rd solution (pH 6.4), both of the average disintegration initiation time and average disintegration termination time of the pharmaceutical formulations are within 35-130 min after initiation of up-and-down movements in the 3rd solution Core tablets containing m203 5.13, lactose 68.62, crystalline cellulose 20.00, low-substituted hydroxypropyl cellulose 5.03, citric acid 0.26, and Mg stearate 0.97 weight part were spray-coated with a composition containing Eudragit E (Me methacrylate-Bu methacrylate-dimethylaminoethyl methacrylate copolymer) 7, EtOH 70, H2O 19.5, and talc 3.5 weight parts and then with a composition containing
- 19.5, and talc 3.5 weight parts and then with a composition containing Eudragit S

(methacrylic acid-Me methacrylate copolymer) 7.0, EtOH 70.0, H2O 18.8, talc 3.5, and polyethylene glycol 0.7 weight part to give coated placebo tablets showing average disintegration initiation time and average

termination time in the 3rd solution (pH 6.4) of 47 and 61 min, resp. It was observed by gamma scintigraphy that 100% of the Sm-containing coated tablets were

- delivered to the colon when orally administered to humans.
- AN 2003:550199 HCAPLUS <<LOGINID::20080702>>
- DN 139:106464
- TI Oral pharmaceutical formulations for colon delivery, colon cancer treatment, and colitis treatment
- IN Sato, Shuji; Goto, Takeshi; Tanida, Nobufumi; Meno, Tatsuya; Yoshinaga, Takaaki; Yonemura, Keiji
- PA Hisamitsu Pharmaceutical Co., Ltd., Japan
- SO Jpn. Kokai Tokkyo Koho, 14 pp.
- CODEN: JKXXAF
- DT Patent
- LA Japanese
- FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2003201256	A	20030718	JP 2001-399310	20011228 <
PRAI JP 2001-399310		20011228	<	

- L11 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Malleable protein matrix and uses thereof
- AB The present invention relates to a malleable protein matrix (MPM) which is

the reaction product of the agglomeration of proteins after a fermentation process, exhibits biol. activities and is suitable for the incorporation (or encapsulation) of various hydrophilic or lipophilic substances. The present invention also relates to the process for the preparation of the malleable protein matrix and its uses in food, drug, medical and cosmetic products.

- AN 2003:511049 HCAPLUS <<LOGINID::20080702>>
- DN 139:84363
- TI Malleable protein matrix and uses thereof
- IN Simard, Eric: Pilote, Dominique: Dupont, Claude: Lajoie, Nathalie: Paquet, Marcel; Lemieux, Pierre; Goyette, Philippe
- Technologies Biolactis Inc., Can.
- PCT Int. Appl., 92 pp. CODEN: PIXXD2
- DТ Patent
- English LA
- ביתרים ומגים

SO

FAN.		1 FENT	NO.			KIN	D	DATE			APPL	ICAT	ION	NO.		D.	ATE	
ΡI	WO	2003 2003 2003	0531	58		A3		2003	0828		WO 2	002-	CA19	88		2	0021	220 <
			CO, GM, LS, PL, UA,	CR, HR, LT, PT, UG,	CU, HU, LU, RO, US,	CZ, ID, LV, RU, UZ,	DE, IL, MA, SC, VC,	AU, DK, IN, MD, SD, VN, MZ,	DM, IS, MG, SE, YU,	DZ, JP, MK, SG, ZA,	EC, KE, MN, SK, ZM,	EE, KG, MW, SL, ZW	ES, KP, MX, TJ,	FI, KR, MZ, TM,	GB, KZ, NO, TN,	GD, LC, NZ, TR,	GE, LK, OM, TT,	GH, LR, PH, TZ,
			KG, FI, CF,	KZ, FR, CG,	MD, GB, CI,	RU, GR, CM,	TJ, IE, GA,	TM, IT, GN,	AT, LU, GQ,	BE, MC, GW,	BG, NL, ML,	CH, PT, MR,	CY, SE, NE,	CZ, SI, SN,	DE, SK, TD,	DK, TR, TG	EE, BF,	ES, BJ,
		2470																220 <
		1458																220 <
	LP																	PT,
			IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	SK		
																		220 <
												005-	4993	13		2	0050	224 <
PRAI		2001 2002						2001 2002										

- L11 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- Co-administration of a polysaccharide with a chemotherapeutic agent for TI the treatment of cancer
- Methods and compns. for treating cancer with a formulation are provided in which a polysaccharide, galactomannan, is co-administered with a therapeutic agent to a subject to reduce toxicity and/or enhance efficacy of the agent for the subject. Co-administration of galactomannan (120 mg/kg/dose) and 5-FU (75 mg/kg/dose) on a q4d+3 schedule brought a remarkable effect in NCr-nu athymic nude mice s.c. implanted with COLO 205 human colon tumors. It caused a significant delay in quadrupling of tumor weight, from 12.5 days for untreated animals (control) and 23.7 and 15.5 days for 5-FU alone and galactomannan alone, resp., to 56.0 days for their combination. Mean survival time shifted from 14.2 days (control, untreated animals) and 23.7 days (5-FU treatment) to 44.2 days for a combination treatment. Galactomannan was isolated and purified from seeds of Gleditsia triacanthos.
- AN 2003:261019 HCAPLUS <<LOGINID::20080702>>
- 138:281098 DN
- Co-administration of a polysaccharide with a chemotherapeutic agent for

the treatment of cancer

- IN Klyosov, Anatole; Platt, David
- PA Pro-Pharmaceuticals, Inc., USA
- SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 818,596.
- CODEN: USXXCO
- DT Patent
- LA English FAN.CNT 2

11111		PENT				KIN	D	DATE			APPL						ATE	
PI	US	2003	0064	957				2003	0403		US 2							327 <
		7012 6645						2006 2003				0.01	0105				0010	327 <
		2004						2003										827 <
		6914		933		B2		2004			05 2	005-	0491	30			0030	02/ <
		2004		916				2004			IIS 2	003-	6491	31		2	0030	827 <
		6982		510		B2		2006	0220		05 2	005-	0421	J1		-	0030	02/ <
		2005		0.0		A2		2005	0310		WO 2	004-	IIS27	291		2	0040	823 <
		2005				A3		2005								_		
					AL.			AU,		BA,	BB.	BG,	BR.	BW.	BY.	BZ.	CA.	CH,
								DE,										
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
			NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
			ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
		RW:	BW,	GH,	GM,	KE,	LS,	MW,	ΜZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
								RU,										
								GR,										
						BF,	ΒJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,
				TD,														
		2005									WO 2	004-	US27	292		2	0040	824 <
	WO	2005																
		W:						AU,										
								DE,										
								ID,										
								LV,										
								PL,										
		DM.						TZ,										
		Kw.						RU,										
								GR,										
								CF,										
				TD,		DI,	ъ,	CI,	CO,	C1,	CII,	Ori,	OI1,	00,	On,	1111,	1111,	NL,
PRAT	IIS	2001				A2		2001	0327	<-	_							
r war	IIS	2001	-317	092P		P		2001	0904	~-	_							
	US	2003	-649	130		Ā		2003	0827	₹-	_							
	US	2001 2003 2003	-649	131		A		2003	0827	<-	_							

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L11 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
- AB Methods and compns. for treating cancer with a formulation are provided in which a polysaccharide, galactomannan is coadministered with a chemotherapeutic agent to a subject to reduce toxicity and/or to enhance efficacy of the agent for the subject.
- AN 2002:754226 HCAPLUS <<LOGINID::20080702>>
- DN 137:257637
- ${\tt TI}$ $\;\;$ Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer

```
IN
    Klyosov, Anatole; Platt, David
```

CODEN: PIXXD2

DT Patent LA English

	TENT				KIN		DATE			APPL						ATE	
	2002 W:				A1		2002			WO 2							327 -
	RW:		BE, SE,		CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,
US	6645		,		В1		2003	1111		US 2	001-	8185	96		2	0010	327 -
EP	1383	516			A1		2004	0128		EP 2	002-	7311	78		2	0020	327 -
	R:	AT,	BE,	CH,	DE.	DK,	ES,	FR.	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		IE,	FI,	CY,	TR												
JP	2004	5251	43		T		2004	0819		JP 2	002-	5749	87		2	0020	327 -
US	2004	0038	935		A1		2004	0226		US 2	003-	6491	30		2	0030	827 -
US	6914	055			B2		2005	0705									
US	2004	0038	916		A1		2004	0226		US 2	003-	6491	31		2	0030	827 -
US	6982	255			B2		2006	0103									
WO	2005	0209	00		A2		2005	0310		WO 2	004-	US27	291		2	0040	823 -
WO	2005	0209	00		A3		2005	0915									
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
			TM,				TZ,										
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
		AZ,	BY,	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,
		SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,
		SN,	TD,	TG													
WO	2005	0209	01		A2		2005	0310		WO 2	004-	US27	292		2	0040	824 -
WO	2005				A3		2005										
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
							DE,										
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KΡ,	KR,	ΚZ,	LC,
							LV,										
							PL,										
			TM,				TZ,										
	RW:						MW,										
							RU,										
							GR,										
					BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,
			TD,	TG													
	2001				A		2001										
	2001				P		2001		<-								
	2002				W		2002		<-								
	2003				A		2003		<-								
					A		2003	nx27	<-	_							
	2003						REFE										

L11 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN

PA Pro-Pharmaceuticals, Inc., USA PCT Int. Appl., 34 pp. SO

TΙ In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil

I.v. administration of 5-fluorouracil for colon cancer therapy produces severe systemic side-effects due to its cytotoxic effect on

normal cells. The broad objective of the present study was to develop novel tablet formulations for site-specific delivery of 5fluorouracil to the colon without the drug being released in the stomach or small intestine using guar gum as a carrier. Fast-disintegrating 5-fluorouracil core tablets were compression coated with 60% (FHV-60), 70% (FHV-70) and 80% (FHV-80) of guar qum, and were subjected to in vitro drug release studies. The amount of 5fluorouracil released from the compression-coated tablets in the dissoln. medium at different time intervals was estimated by a HPLC method. Guar gum compression-coated tablets released only 2.5-4% of the 5fluorouracil in simulated GI fluids. When the dissoln, study was continued in simulated colonic fluids (4% w/v rat cecal content medium) the compression-coated FHV-60, FHV-70 and FHV-80 tablets released another 70, 55 and 41% of the 5-fluorouracil resp. The results of the study show that compression-coated tablets containing 80% (FHV-80) of guar gum are most likely to provide targeting of 5fluorouracil for local action in the colon, since they released only 2.38% of the drug in the physiol. environment of the stomach and small intestine. The FHV-80 formulation showed no change either in phys. appearance, drug content or dissoln. pattern after storage at 40°/RH 75% for 6 mo. The differential scanning calorimetric study showed that 5-fluorouracil did not interact with the formulation excipients used in the study.

- AN 2002:546865 HCAPLUS <<LOGINID::20080702>>
- DN 138:260264
- TI In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil
- AU Krishnaiah, Y. S. R.; Satyanarayana, V.; Dinesh Kumar, B.; Karthikeyan, R.
- CS College of Engineering, Department of Pharmaceutical Sciences, Andhra University, Visakhapatnam, 530 003, India
- SO European Journal of Pharmaceutical Sciences (2002), 16(3), 185-192
- CODEN: EPSCED; ISSN: 0928-0987
- PB Elsevier Science Ltd.
- DT Journal
- LA English
- RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L11 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Preparation of aqueous clear solution dosage forms with bile acids
- AB Compns. for pharmaceutical and other uses comprise clear aqueous solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aqueous solution The compns. comprise (i) water, (ii) a bile acid component in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and (iii) either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a

range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition may further contain

a pharmaceutical compound, such as insulin, heparin, bismuth compds., amantadine and rimantadine. For example, solution dosage forms that did not show any precipitation at any pH were prepared containing ursodeoxycholic acid (UDCA) 22

g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g, bismuth citrate 4 g, citric acid or lactic acid as needed, and purified water to make 1 L.

AN 2002:185616 HCAPLUS <<LOGINID::20080702>>

```
DN
    136:252482
```

LA English

FAN.CNT	5
---------	---

PATENT NO.								DATE			APPLICATION NO.										
PI	US	20020	031	558		A1			0314			2001-						0010	205	<	
	US	73037 62514 20030 71662	128			B1			0626		US	1999-	-357	1549			19	9990	720	<	
	US	20030	186	933		A1		2003	1002			2002-						0021	204	<	
	US	71662	299			B2			0123												
	US	20050	158	408		A1		2005						20041124 <							
		20043								AU 2004-325203											
		25881				A1						2004-									
	EP	18193							0822			2004-									
		R:										, ES,					GR,	HU,	IE,		
	011	10100	15,	TT,	ьI,	LU,	MC,	NL,	PL,	PT,	RU	, SE,	21	., SK	, 1	R		20.41	104		
	CIN	10106	271	1.0		A		2007	1031		CN	2004-	-800	14446	'		21	JU41.	124		
	BK	20040	1192	13		A		2007	1718		BK	2004-	-192	:13			21	JU41	124		
	JP	20085	218	00		Т		2008	0626		JP	2007-	-543	1006			20	0041	124		
	AU	10106 20040 20085 20062	2033	15		AI		2006	0824		AU	2006-	-203	315			20	0060	803		
	05	20070	10 /2	828		AI		2007	0329		US	2006-	-522	162			21	1060	3 T D	<	
		20070										2007-						0070			
	KR	20070	988	21		A						2007-									
		20080										2007-	-934	1505			20	0071	102	<	
PRAI		1998-							0724												
		1999-							0720												
	US	2000-	-180	268P		P			0204												
		2001-							0205												
		2001-							0205	<-	-										
		2004-							1124												
		2004-							1124												
RE.C	NT	211	TH	ERE	ARE	211	CITE	D RE	FERE	NCES	ΑV	AILAE	BLE	FOR	THI	SF	RECOR	RD			

ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L11 ANSWER 15 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- ΤI Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
- AB A colonic drug delivery composition contains a first polysaccharide and a second polysaccharide wherein both polysaccharides are degradable by colonic enzymes and are mixed at a environmental pH of about 7 or above. A colon selective pharmaceutical composition and dosage form for oral delivery of a drug, nutrient, diagnostic reagent, or mixture thereof includes the drug, nutrient, diagnostic reagent, or mixture thereof in contact with the polysaccharide composition A method of preparing such a colonic drug delivery composition and the colon selective pharmaceutical composition and dosage form are

also disclosed. Capsules filled with budesonide pellets were coated with a composition containing pectin and guar gum at the ratio of 4 to 1 (pH 8), to a thickness of 15 mg/cm2. The capsules were disintegrated in 60 min in simulated colonic fluid, but not disintegrated in simulated gastric or intestinal fluid during 24 h studies.

AN 2000:68148 HCAPLUS <<LOGINID::20080702>>

DN 132:113102

ΤТ Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides

TT Preparation of aqueous clear solution dosage forms with bile acids

TN Yoo, Seo Hong

PA USA

SO U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U.S. 6,251,428. CODEN: USXXCO

Patent

- IN Lee, Seung Seo; Lim, Chang Baeg; Pai, Chaul Min; Lee, Sujung; Park, In; Seo, Moon Gun; Park, Heenam
- PA Samyang Corporation, S. Korea
- SO Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW DT Patent

DT Patent LA Englis

LA English FAN.CNT 1

LIM. CI																				
	PATENT NO.															DATE				
PI I	EΡ	9743	44			A2		2000	0126		EP 1	999-:	3056	00		19990715 <			-	
1	EΡ	9743	44			A3		2000	0301											
I	EP	9743	44			B1		2004	0303											
											GR.	TT.	T.T.	T.II.	NI.	SE.	MC.	PT.		
								RO		,	,	,	,	,	,	,	,	,		
,	KB	2000									KP 1	999-	1466	5		11	agan.	123 <	_	
7	CZ	2226	015			7.1		2000	0223		C2 1	000-	2226	015		19990423 < 19990520 <				
	CA.	2226	015			V.		2000	0203		CA I	222-	2330	013		19990320 <				
	UM	2000	011	2.4		3.1		2003	0007		1.70 1	000	WD OF			19990520 <				
,	WU																			
		W:						AZ,												
								GB,												
								KΖ,												
								PL,					SE,	SG,	SI,	SK,	SL,	TJ,		
								UZ,												
		RW:	GH,	GM,	KE,	LS,	MW,	SD,	SL,	SZ,	UG,	ZW,	BF,	ВJ,	CF,	CG,	CI,	CM,		
			GA,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG									
1	ΑU	9940	627			A		2000	0214		AU 1	999-	4062	7		1	9990!	520 <	-	
2	AU	7441	83			B2		2002	0214											
	JP -	2002	5213	46		Т		2002	0716		JP 2	000-	5609	17		1'	9990:	520 <	-	
	JΡ	4088	420			B2		2008	0521									525 <		
Ţ	US	6413	494			B1		2002	0702		US 1	999-	3185	79		1	9990	525 <	-	
2	AΤ	2606	49			Т		2004	0315		AT 1	999-	3056	00		1	9990	715 <	-	
I	ES	2214	813			Т3		2004	0916		ES 1	999-	3056	0.0		1	9990	715 <	_	
		2001						2001	0804		KR 2	001-	7000	82		2	0010	104 <	-	
		2001																122 <		
PRAI I								1998												
		1999						1999												
		1999		50		W		1999												
										- 1										

- L11 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Polymer-based press-coated, pulsatile drug delivery system suitable for oral administration
 - A press coated, pulsatile drug delivery system suitable for oral administration having an immediate-release compartment, which contains a compressed blend of an active agent and one or more polymers, substantially enveloped by an extended-release compartment, which contains a compressed blend of the active agent and hydrophilic and hydrophobic polymers, can provide a substantially first order delivery of the active agent, interrupted by a timed, pulsed delivery of an increased amount of the active agent; and when the extended-release compartment is substantially enveloped by an optional instant-release compartment, can provide a dose sufficient to exceed the liver's metabolic capacity and to maintain therapeutic levels, preferably throughout a 24-h period. E.g. extended-release tablets of isosorbide 5-mononitrate (ISMN) were prepared The immediate-release compartment contained ISMN mixed with silica and then blended first with microcryst. cellulose and then with croscarmellose sodium and Mg stearate; the powder blend was compressed to obtain a core tablet. The core tablets were then press-coated with a blend containing ISMN, silica, hydroxypropyl Me cellulose, microcryst. cellulose, hydrogenated vegetable oil and Mg stearate. The hardness of the tablets was maintained at 12 ± 4 kp.

- AN 1999:659216 HCAPLUS <<LOGINID::20080702>>
- DN 131:291287
- ΤТ Polymer-based press-coated, pulsatile drug delivery system suitable for oral administration
- TN Ting, Richard; Hsiao, Charles
- PA Impax Pharmaceuticals, Inc., USA
- SO PCT Int. Appl., 34 pp. CODEN: PIXXD2
- DT Patent
- LA English

FAN.CN	IT 2																
P	PATENT	NO.			KIN	D	DATE			APPL	ICAT:	ION	NO.		D	ATE	
-						-											
PI W	10 9951	209			A1		1999	1014		WO 1	999-1	US69:	87		1:	9990	331 <
	W:	ΑE,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,
		DE,	DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,
		JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,
		MN,	MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,
		TM,	TR,	TT,	UA,	UG,	UZ,	VN,	YU,	ZA,	ZW						
	RW:	GH,	GM,	KΕ,	LS,	MW,	SD,	SL,	SZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,	DE,	DK,
		ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,
		CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG					
	IS 6372				B1		2002										402 <
A	U 9932	182			A		1999	1025		AU 1	999-	3218:	2		1	9990:	331 <
	W 2456				В		2005				999-	8810.	5321		1	9990	402 <
PRAI U							1998										
W	70 1999	-US6	987		M		1999	0331	<-	-							
RE.CNT	3	TH	ERE	ARE	3 CI	ΓED	REFE	RENC	ES A	VAIL	ABLE	FOR	THI	S RE	CORD		

- L11 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
- Solid pharmaceutical compositions for oral administration with prolonged TΙ gastric residence

ALL CITATIONS AVAILABLE IN THE RE FORMAT

- AB The title compns. comprise an active ingredient characterized by erratic gastrointestinal absorption, a high d. inorg. substance, such as BaSO4, Fe, Mg trisilicate, and a bioadhesive polymer, such as cellulose ethers and acrylate copolymers. For example, a tablet was formulated containing nifedipine with micronized crosslinked PVP (1:5) 240, BaSO4 235, Methocel A4C 155, Aerosil 200 5, xanthan gum 30, galactomannan 30, and Mg stearate 5 mg.
- 1993:154582 HCAPLUS <<LOGINID::20080702>>
- 118:154582
- OREF 118:26399a,26402a
- TI Solid pharmaceutical compositions for oral administration with prolonged gastric residence
- IN Esposito, Pierandrea; Carli, Fabio
- PA Vectorpharma International S.p.A., Italy
- SO Eur. Pat. Appl., 20 pp. CODEN: EPXXDW
- DT Patent
- LA English

FAN.	CNT 1				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 526862	A1	19930210	EP 1992-113187	19920803 <
	EP 526862	В1	19960214		
	R: AT, BE, CH,	DE, DK,	ES, FR, GB,	GR, IE, IT, LI, LU,	MC, NL, PT, SE
	AT 134134	T	19960215	AT 1992-113187	19920803 <
	ES 2086029	T3	19960616	ES 1992-113187	19920803 <
PRAI	IT 1991-MI2212	A	19910806 <-	-	

```
L11 ANSWER 18 OF 18 HCAPLUS COPYRIGHT 2008 ACS on STN
    Antitumor activity of xanthan gum
TT
    Xanthan qum [11138-66-2] was the most effective antitumor agent among 11
AB
     food additives tested in mice implanted with Ehrlich ascites tumor;
     xanthan gum was effective when given i.p. before or after tumor
     implantations. In S-180 tumor-bearing mice, a synergistic effect was
     observed between xanthan qum and 5-fluorouracil [51-21-8] or
     bleomycin [11056-06-7], but no synergism was noted when xanthan gum was
     combined with cyclophosphamide [50-18-0].
AN
     1987:131313 HCAPLUS <<LOGINID::20080702>>
DN
   106:131313
OREF 106:21255a, 21258a
ΤI
    Antitumor activity of xanthan gum
ΔU
     Oda, Munehiro
CS
    Meiji Inst. Health Sci., Japan
SO.
    Yakuri to Chiryo (1973-2000) (1985), 13(10), 5743-50
     CODEN: YACHDS; ISSN: 0386-3603
DT
     Journal
LA
    Japanese
=> d his
     (FILE 'HOME' ENTERED AT 18:00:00 ON 02 JUL 2008)
     FILE 'HCAPLUS' ENTERED AT 18:01:21 ON 02 JUL 2008
          13810 S GUAR OR GALACTOMANNAN
T. 1
L2
             79 S FLUOROURACIL OF FLUORODEOXYURIDINE OR FLUOROPYRIMIDINE OF CIS
L3
           2637 S LEUCOVORIN
L4
              0 S L1 AND L2
L5
              0 S L1 AND L2 AND L3
L6
              0 S L4 AND (PY<2004 OR AY<2004 OR PRY<2004)
L7
              0 S L5 AND (PY<2004 OR AY<2004 OR PRY<2004)
     FILE 'STNGUIDE' ENTERED AT 18:01:32 ON 02 JUL 2008
     FILE 'HCAPLUS' ENTERED AT 18:02:04 ON 02 JUL 2008
L8
          22775 S FLUOROURACIL OR FLUORODEOXYURIDINE OR FLUOROPYRIMIDINE OF CIS
L9
             38 S L1 AND L8
L10
              6 S L1 AND L8 AND L3
L11
             18 S L9 AND (PY<2004 OR AY<2004 OR PRY<2004)
L12
              2 S L10 AND (PY<2004 OR AY<2004 OR PRY<2004)
     FILE 'STNGUIDE' ENTERED AT 18:02:11 ON 02 JUL 2008
     FILE 'HCAPLUS' ENTERED AT 18:02:19 ON 02 JUL 2008
     FILE 'STNGUIDE' ENTERED AT 18:02:21 ON 02 JUL 2008
=> log hold
COST IN U.S. DOLLARS
                                                 SINCE FILE
                                                                 TOTAL
                                                               SESSION
                                                      ENTRY
FULL ESTIMATED COST
                                                       0.06
                                                                61.05
DISCOUNT AMOUNTS (FOR OUALIFYING ACCOUNTS)
                                                 SINCE FILE
                                                                TOTAL
                                                      ENTRY
                                                               SESSION
CA SUBSCRIBER PRICE
                                                        0.00
                                                                 -14.40
```

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 18:02:23 ON 02 JUL 2008

Welcome to STN International! Enter x:X

LOGINID: SSPTAEX01623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * * * SESSION RESUMED IN FILE 'STNGUIDE' AT 18:08:11 ON 02 JUL 2008 FILE 'SINGUIDE' ENTERED AT 18:08:11 ON 02 JUL 2008 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS FULL ESTIMATED COST	SINCE FILE ENTRY 0.06	TOTAL SESSION 61.05
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) CA SUBSCRIBER PRICE	SINCE FILE ENTRY 0.00	TOTAL SESSION -14.40
=> file hcaplus COST IN U.S. DOLLARS FULL ESTIMATED COST	SINCE FILE ENTRY 0.18	TOTAL SESSION 61.17
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) CA SUBSCRIBER PRICE	SINCE FILE ENTRY 0.00	TOTAL SESSION -14.40

FILE 'HCAPLUS' ENTERED AT 18:09:45 ON 02 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jul 2008 VOL 149 ISS 1 FILE LAST UPDATED: 1 Jul 2008 (20080701/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

^{=&}gt; s interferon or interleukin

83968 INTERFERON

179098 INTERLEUKIN
L13 235409 INTERFERON OR INTERLEUKIN

=> s 11 and 113

L14 38 L1 AND L13

=> s 11 and 13 and 113

L15 3 L1 AND L3 AND L13

=> s 114 and (PY<2004 or AY<2004 or PRY<2004)

23986121 PY<2004 4778946 AY<2004 4249769 PRY<2004

L16 23 L14 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s 115 and (PY<2004 or AY<2004 or PRY<2004)

23986121 PY<2004 4778946 AY<2004 4249769 PRY<2004

L17 1 L15 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS SINCE FILE TOTAL SESSION ENTRY FULL ESTIMATED COST 2.69 63.86 DISCOUNT AMOUNTS (FOR OUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE 0.00 -14.40

FILE 'STNGUIDE' ENTERED AT 18:09:53 ON 02 JUL 2008 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 27, 2008 (20080627/UP).

=> d 116 1-23 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y) /N:Y

L16 ANSWER 1 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Nonsteroidal immunomodulating kit and composition and uses thereof
B A composition and therapeutic kit including an aerosol packaging assembly
including a container accommodating a pressurized product and an outlet
capable of releasing a foamable composition, including a nonsteroidal
immunomodulating agent as a foam. The pressurized product includes a
foamable composition including; a) a container accommodating a pressurized
product; and b) an outlet capable of releasing the pressurized product as
a foam; wherein the pressurized product comprises a foamable composition
including: i. a nonsteroidal immunomodulating agent; ii. at least one organic

carrier selected from the group consisting of a hydrophobic organic carrier,

a polar solvent, an emollient and mixts. thereof, at a concentration of about

to about 50% by weight; iii. a surface-active agent; iv. about 0.1% to about 5% by weight of a therapeutically active foam adjuvant, selected from the group consisting of a fatty alc., a fatty acid, a hydroxy fatty acid; and mixts. thereof; v. about 0.01 % to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; vi. water; and vii. liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition

AN 2005:1132617 HCAPLUS <<LOGINID::20080702>>

DN 143:393082

2%

TI Nonsteroidal immunomodulating kit and composition and uses thereof

IN Tamarkin, Dov; Eini, Meir; Friedman, Doron

PA Foamix Ltd., Israel

SO U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. Ser. No. 911,367. CODEN: USXXCO

DT Patent LA English

FAN.CNT 26

FAN.	PA:	Z6 TENT NO.			KIND DATE				APPL	ICAT	ION	мо.		DATE				
PI	US WO	20050232 20040372 20040372	869 25				2005	1020 0506		US 2	005-	7890	2		2	0050	311 < 024 <	
	wo	W: AE, CO, GM, LS, PL,	AG, CR, HR, LT, PT, UG,	CU, HU, LU, RO,	AM, CZ, ID, LV, RU,	AT, DE, IL, MA, SC,	AU, DK, IN, MD, SD,	AZ, DM, IS, MG, SE,	DZ, JP, MK, SG,	EC, KE, MN, SK,	EE, KG, MW, SL,	ES, KP, MX,	FI, KR, MZ,	GB, KZ, NO,	GD, LC, NZ,	GE, LK, OM,	GH, LR, PH,	
	US	FI,	KZ, FR, BJ,	MD, GB, CF,	RU, GR,	TJ, HU, CI,	TM, IE, CM,	AT, IT,	BE, LU, GN,	BG, MC, GQ,	CH, NL, GW,	CY, PT, ML,	CZ, RO, MR,	DE, SE, NE,	DK, SI, SN,	SK, TD,	ES, TR, TG	
	WO	20050032 20070072 20070072	08		A2 20070118 A3 20070830				WO 2006-IB2755									
		GE, KZ, MZ, SG,	AG, CO, GH, LC, NA, SK, YU,	CR, GM, LK, NG, SL,	CU, HR, LR, NI, SM,	CZ, HU, LS, NO, SY,	DE, ID, LT, NZ,	DK, IL, LU, OM,	DM, IN, LV, PG,	DZ, IS, LY, PH,	EC, JP, MA, PL,	EE, KE, MD, PT,	EG, KG, MG, RO,	ES, KM, MK, RU,	FI, KN, MN, SC,	GB, KP, MW, SD,	GD, KR, MX, SE,	
		RW: AT, IS, CF, GM,		BG, LT, CI, LS,	CH, LU, CM, MW,	CY, LV, GA, MZ,	MC, GN, NA,	NL, GQ, SD,	PL, GW, SL,	PT, ML, SZ,	RO, MR, TZ,	SE, NE,	SI, SN,	SK, TD,	TR, TG,	BF, BW,	BJ, GH,	
	EP	1863447 R: AT, IS,	BE, IT, HR,	BG,	CH, LT,	CY,	2007 CZ,	1212 DE,	DK,	EP 2	006- ES,	FI,	FR,		GR,		IE,	
PRAI	US US US IL	20062018 20070253 20070292 20080044 2002-152 2002-429	78 911 359 444 486		A1 A1 A1 A1		2007 2007 2008 2002	0927 1101 1220 0221 1025 1129	<-		007- 007-	7178 8111	97 40		2	0070	504 < 313 < 607 < 705 <	

```
US 2003-492385P P 20030804 <--

WO 2003-IB5527 A2 20031024 <--

US 2004-911367 A2 20040804
US 2003-497648P
                          P 20030825 <--
                          P
                                   20031216 <--
US 2003-530015P
US 2003-530015P P 20040428
US 2004-835505 A2 20040428
US 2004-922358 A2 20040820
US 2005-48902 A 20050311
US 2005-124676 A2 20050509
US 2005-696878P P 20050509
                         P 20050719
A2 20051222
US 2005-700702P
US 2005-532618
WO 2006-IB2755
                          W
                                   20060310
                         P 20060313
P 20060607
P 20060705
A2 20060706
A2 20060719
A2 20070112
US 2006-781868P
US 2006-811627P
US 2006-818634P
US 2006-481596
US 2006-488989
US 2007-653205
                          P
US 2007-897638P
                                    20070126
                           P
US 2007-899176P
                                    20070202
US 2007-717897
                            A2
                                    20070313
```

- L16 ANSWER 2 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
- Compositions and methods for treating burns
- AB The present invention provides compns. and methods for treating burns comprising administering to a burn area of a subject in need thereof of a therapeutically effective amount of a composition comprising an anti-cytokine

anti-inflammatory agent or a functional derivative thereof; and a pharmaceutically acceptable excipient. For example, for example, a topical composition HR341g was prepared by mixing dicalcium phosphate dihydrate 1150 g, insol. sodium metaphosphate 700 g, sorbitol syrup (70% solution) 1250 g, guar gum 225 g, xanthan gum 90 g, monosodium phosphate 15 g, sodium monofluorophosphate 477 g, aminopterin 80 g, titanium dioxide 30 g, sodium dodecylbenzene sulfate 25 g, water 1200 g, trimagnesium phosphate 40 g, and hydroxethyl cellulose 157.5. A patient suffering from 2nd and 3rd degree burns was treated with HR341g applied to the burn areas. Edema was substantially reduced at the burn site. There was some inflammation, which was necessary for proper healing, but there were no excessive reactions. The patient suffered min. associated disease responses, because the environment a burn wound needed for microorganisms to proliferate was altered with HR431g.

- AN 2005:324001 HCAPLUS <<LOGINID::20080702>>
- DN 142:379383
- ΤТ Compositions and methods for treating burns
- IN Hicks, Terry; Kohutka, Jeffrey
- PA Kohi Corporation, USA
- PCT Int. Appl., 78 pp. SO
- CODEN: PIXXD2
- Patent

or

LA English FAN.CNT 1

	PATENT	NO.			KIND DATE				APPLICATION NO.						DATE			
						_									-			
PI	WO 2005	0324	70		A2		2005	0414		WO 2004-US31917 20							930 <	-
	WO 2005032470				A3		2005	0602										
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,	

```
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
        TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YY, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004277977
                         A1
                               20050414
                                          AU 2004-277977
                                                                  20040930 <--
                               20050414 CA 2004-2540742
     CA 2540742
                         A1
                                                                  20040930 <--
     EP 1667648
                         A2
                              20060614
                                         EP 2004-789212
                                                                  20040930 <--
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     CN 1886128
                     A
                              20061227
                                         CN 2004-80035410
                                                                  20040930 <--
     JP 2007507512
                        т
                               20070329
                                         JP 2006-534052
                                                                  20040930 <--
                              20051222 US 2004-12210
     US 20050281820
                        A1
                                                                  20041216 <--
    MX 2006PA03573
                        A
                              20060831 MX 2006-PA3573
                                                                  20060330 <--
     IN 2006CN01090
                        A
                               20070817
                                          IN 2006-CN1090
                                                                  20060330 <--
PRAI US 2003-506745P
                        P
                              20030930 <--
     WO 2004-US31917
                        W
                              20040930
```

- L16 ANSWER 3 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
- AB Disclosed herein are compns. and methods for treating diseases such as cancer. The compns. comprise polysaccharides in an admixt. with one or more therapeutic agents. This admixt. can be administered to a subject in need thereof using any known method of administration. The therapeutic agent, if administered alone, can cause undesirable side-effects in the subject. The polysaccharide component (e.g., galactomannan) minimizes or eliminates these side effects. The compns. described herein
 - effectuate an enhanced therapeutic effect along with reduced toxicity. 5-FU and galactomannan worked synergistically.
- AN 2005:219721 HCAPLUS <<LOGINID::20080702>>
- DN 142:285217
- TI Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
- IN Zomer, Eliezer; Platt, David
- PA USA
- SO U.S. Pat. Appl. Publ., 30 pp. CODEN: USXXCO
- DT Patent
- LA English
- FAN.CNT 1

	PATENT	NO.	KI	KIND DATE		AE	APPLICATION NO.					DATE			
PI	US 2005	0053664	A	1 :	20050310	US	S 2003-	65750	8		20030908 <				
	AU 2004	272022	A	1 :	20050324	At	U 2004-	27202	22		20040907 <				
	WO 2005	025501	A	2 :	20050324	WC	0 2004-	US28	383		20040907 <				
	WO 2005	025501	A	A3 20050519											
	W:	AE, AG,	AL, AM	, AT,	AU, AZ,	BA, E	BB, BG,	BR,	BW,	BY,	BZ,	CA,	CH,		
		CN, CO,	CR, CU	, CZ,	DE, DK,	DM, D	DZ, EC,	EE,	EG,	ES,	FI,	GB,	GD,		
		GE, GH,	GM, HR	, HU,	ID, IL,	IN, I	IS, JP,	KE,	KG,	KP,	KR,	KZ,	LC,		
		LK, LR,	LS, LT	, LU,	LV, MA,	MD, N	MG, MK,	MN,	MW,	MX,	MZ,	NA,	NI,		
		NO, NZ,	OM, PG	, PH,	PL, PT,	RO, E	RU, SC,	SD,	SE,	SG,	SK,	SL,	SY,		
		TJ, TM,	TN, TR	, TT,	TZ, UA,	UG, U	US, UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW		
	RW:	BW, GH,	GM, KE	, LS,	MW, MZ,	NA, S	SD, SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,		
		AZ, BY,	KG, KZ	, MD,	RU, TJ,	TM, A	AT, BE,	BG,	CH,	CY,	CZ,	DE,	DK,		
		EE, ES,	FI, FR	, GB,	GR, HU,	IE, I	IT, LU,	MC,	NL,	PL,	PT,	RO,	SE,		
		SI, SK,	TR, BF	, BJ,	CF, CG,	CI, C	CM, GA,	GN,	GQ,	GW,	ML,	MR,	NE,		
		SN, TD,	TG												
	EP 1662	874	A	2 2	20060607	E	P 2004-	7832	11		20	00409	907 <		

```
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
    BR 2004013410
                                                               20040907 <--
                       A
                             20061010 BR 2004-13410
    CN 1867252
                                                              20040907 <--
                        А
                             20061122
                                        CN 2004-80030017
    JP 2007505041
                        Т
                            20070308 JP 2006-525488
                                                              20040907 <--
PRAI US 2003-657508
                            20030908 <--
                        Α
    WO 2004-US28883
                        TAT
                            20040907
```

- L16 ANSWER 4 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
- TΙ Dissolvable backing layer for use with a transmucosal delivery device A water-dissolvable drug delivery device is designed so as to reliably maintain a drug or active agent within a defined region against a mucosal surface. The drug delivery device comprises a water-dissolvable backing layer, an adhesive layer adjacent to at least a portion of the backing layer, and an active layer that is circumscribed by the backing layer and adhesive layer. The backing layer may optionally include a water-dissolvable hydrophilic region and a non-hydrophilic region at least partially encapsulated within the hydrophilic region that inhibits migration of water, drugs, or other active agents through the backing layer. The adhesive layer may be water-activated or it may have a peelable cover layer that, when removed, exposes the adhesive material. The active layer may comprise any drug or other active agent, either alone or in combination with (i) an enhancer that increases the ability of the drug or other active agent to diffuse through a mucosal membrane and/or (ii) a matrix material such as an alginate to hold the active layer together. A patch contained an active layer comprising Na alginate interferon $\alpha 2b$, Na taurocholate, and water; an adhesive layer comprising PEG, polyacrylic acid, and water; and a backing layer comprising gelatin, glycerin, dodecyltrimethylammonium bromide, and water.

Dissolvable backing layer for use with a transmucosal delivery device

- AN 2004:964611 HCAPLUS <<LOGINID::20080702>>
- DN 141:400935
- IN Zhang, Hao
- PA Cephalon, Inc., USA
- SO U.S. Pat. Appl. Publ., 14 pp.
- CODEN: USXXCO
- DT Patent

ΤI

- LA English
- FAN.CNT 1

FAN.	CNT	1																
		TENT				KIN	D	DATE			APPL	ICAT	ION :	NO.		D.	ATE	
							-											
PI		2004		007					1111		US 2	004-	8418	92		2	0040	507 <
	US	7276	246			B2		2007	1002									
	CA	2523	787			A1		2004	1202		CA 2	004-	2523	787		2	0040	510 <
	WO	2004	1033	41		A2		2004	1202		WO 2	004-	US14	555		2	0040	510 <
	WO	2004	1033	41		A3		2005	0421									
		W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
			CN.	co.	CR.	CU.	CZ.	DE.	DK,	DM.	DZ.	EC.	EE.	EG.	ES.	FI.	GB,	GD,
									IL,									
									MA,									
									PT,									
									UA,									
		pw.							MZ,									
									TJ,									
									HU,									
						Br,	BJ,	CF,	CG,	CI,	CM,	GA,	GIN,	GQ,	GW,	PIL,	MK,	NE,
				TD,														
	EP	1626	704			A2		2006	0222		EP 2	004-	7517	81		2	3040	510 <
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
																		SK, HR
	JP	2006	5289	75		T		2006	1228		JP 2	006-	5329	13		2	0040	510 <

MX 2005PA12010 A 20060831 MX 2005-PA12010 20051108 <--PRAI US 2003-469497P P 20030509 <--20040507 US 2004-841892 A WO 2004-US14555 W

20040510

RE.CNT 107 THERE ARE 107 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

Use of compounds for the prevention of drug-induced cell toxicity TI

AB The present invention relates to the use of compds, for the manufacture of a medicament for the prophylaxis and/or treatment of induced cell toxicity, such as nephrotoxicity and ototoxicity, in particular where the cell toxicity is induced by a medical treatment. In a preferred embodiment the compds. have at least two nitrogen atoms, more preferably at least two amino groups. The compds. according to the invention are capable of blocking binding of cell toxic compds. to the megalin receptor, and thereby inhibiting uptake of the cell toxic compds. into cells. The invention further relates to novel compds. for use in said treatment, as well as a method for reducing the cell toxicity of cell toxic compds.

AN 2004:817689 HCAPLUS <<LOGINID::20080702>>

DN 141:325783

TI Use of compounds for the prevention of drug-induced cell toxicity

IN Nykiaer, Anders

PA Arhus Universitet, Den.; Receptioon Aps

SO PCT Int. Appl., 55 pp. CODEN: PIXXD2

Patient DT

English LA FAN.CNT 1

E	PATI	ENT 1	١0.			KIN		DATE				ICAT				D.	ATE		
								2004 2004			WO 2	004-	DK20	5		2	0040	325 <	
			CN, GE, LK, NO, TJ, BW, BY, ES, SK,	CO, GH, LR, NZ, TM, GH, KG, FI, TR,	CR, GM, LS, OM, TN, GM, KZ, FR,	CU, HR, LT, PG, TR, KE, MD, GB,	CZ, HU, LU, PH, TT, LS, RU, GR,	AU, DE, ID, LV, PL, TZ, MW, TJ, HU, CG,	DK, IL, MA, PT, UA, MZ, TM, IE,	DM, IN, MD, RO, UG, SD, AT, IT,	DZ, IS, MG, RU, US, SL, BE, LU,	EC, JP, MK, SC, UZ, SZ, BG, MC,	EE, KE, MN, SD, VC, TZ, CH, NL,	EG, KG, MW, SE, VN, UG, CY, PL,	ES, KP, MX, SG, YU, ZM, CZ, PT,	FI, KR, MZ, SK, ZA, ZW, DE, RO,	GB, KZ, NA, SL, ZM, AM, DK, SE,	GD, LC, NI, SY, ZW AZ, EE, SI,	
E C C C C C C C C C C C C C C C C C C C	CA :	25609 1610 R: 20040 17949 20069 20050 20050 2003	522 773 AT, IE, 00869 52076 PA100 0004 CN02	BE, SI, 99 61 143 727	CH, LT,	A1 A2 DE, LV, A A T A A1 A	DK, FI,	2004 2006 ES, RO, 2006 2006 2006 2006 2007	1007 0104 FR, MK, 0328 0628 0914 0317 0104 0525 0326	GB, CY,	CA 2 EP 2 GR, AL, BR 2 CN 2 JP 2 MX 2 US 2 IN 2	004- 004- TR, 004- 004- 006- 005- 005-	2560: 7231: LI, BG, 8699: 8001: 5043: PA10: 5504:	522 68 LU, CZ, 4657 37 143	NL, EE,	21 SE, HU, 21 21 22 21	MC, PL, 0040: 0040: 0040: 0040: 0050:	325 < 325 < 325 < PT, SK 325 < 325 < 325 < 325 < 326 < 326 <	

L16 ANSWER 6 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Autologous ghrelin and encoding nucleic acid and foreign T cell epitope conjugates for vaccination against obesity and excess body fat increase or

loss in human and animal

- AB Disclosed are novel methods that generally rely on immunization against autologous ghrelin. Immunization is preferably effected by administration of analogs of autologous ghrelin, said analogs being capable of inducing antibody production against the autologous ghrelin polypeptides. Especially preferred as an immunogen is autologous ghrelin, which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against ghrelin and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogs and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.
- AN 2004:252369 HCAPLUS <<LOGINID::20080702>>
- DN 140:269531
- ТΤ Autologous ghrelin and encoding nucleic acid and foreign T cell epitope conjugates for vaccination against obesity and excess body fat increase or loss in human and animal
- IN Boving, Tine Elisabeth Gottschalk; Klysner, Steen
- PA Pharmexa A/s, Den.
- SO PCT Int. Appl., 83 pp. CODEN: PIXXD2
- DT Patent

LA	Eng	Ιli	sh
FAN	.CNT	1	

FAN.																			
		TENT 1				KIN		DATE				ICAT:				Di	ATE		
PI		20040														21	00300	912 d	
L 1	WO																		
		W:						AU,											
								DK,											
								IL,											
								MA,											
			OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	ΤJ,	TM,	
			TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW			
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	
			KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	
			FI.	FR.	GB,	GR,	HU,	IE.	IT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR.	
			BF.	BJ.	CF.	CG.	CI.	CM,	GA.	GN.	GO,	GW.	ML.	MR.	NE.	SN.	TD.	TG	
	CA	24981						2004											<
	AU	20032	2631	50		A1		2004	0430		AU 2	003-	2631	50		20	00309	912 <	<
		15392																	
								ES,											
								RO,											
	CN	1694						2005										912 4	<
		2006																912 <	
	MX	2005	2012	699		Δ		2005	0920		MY 2	005-1	PA26	99		21		310 <	
		20051				A		2006										323 <	
		20050						2005										411 4	
		20050						2006										411 <	
DDAT		2002-						2002									0000		•
FIVAL		2002				D D		2002											
		2003-						2002											
	wU	2000		24		1/1		2003	U 2 I Z	<-	_								

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L16 ANSWER 7 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
- Inhalation compositions containing buffers and anti-inflammatory agents Bronchodilating concs. and diluted compns., methods of use thereof, and processes for making the concs. and diluted compns., are provided. The compns. are intended for administration as a nebulized aerosol. Methods for treatment, prevention, or amelioration of one or more symptoms of

bronchoconstrictive disorders using the compns. provided herein are also provided. Thus, a composition contained Fluticasone propionate 150 μ g/mL, TPGS 4, propylene glycol 1.67, glycerin 2, NaCl 0.1, and water 92.1% by weight, and buffer 2 mM.

AN 2004:100805 HCAPLUS <<LOGINID::20080702>>

DN 140:151959

TI Inhalation compositions containing buffers and anti-inflammatory agents IN Banerjee, Partha S.; Malladi, Ramana R.; Chaudry, Imtiaz A.

PA Dev, L.P., USA

SO U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

- DT Patent
- LA English
- FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI PRAI	US 20040023935 US 2002-212573	A1	20040205 20020802	US 2002-212573 <	20020802 <

- L16 ANSWER 8 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Medical goods comprising heparin or chitosan-based hemocompatible coating
 AB The invention relates to oligo- and polysaccharides containing the sugar
 - The invention relates to oligo- and polysaccharides containing the sugar structural element N-acylglucosamine or N-acylgalactosamine, in addition to the use thereof for producing hemocompatible surfaces and to methods for coating surfaces in a hemocompatible manner with said oligo- and polysaccharides, which constitute the common biosynthetic precursor substances of heparin, heparan sulfates and chitosan. The invention also relates to methods for producing the oligo- and/or polysaccharides, in addition to diverse application options involving hemocompatible surfaces. The invention specifically relates to the use of the oligo- and/or polysaccharides on stents involving at least one hemocompatible coating that has been applied according to the invention and that contains an anti-proliferative, anti-inflammatory and/or athrombogenic active ingredient, to methods for producing said stents and to the use of the latter for preventing restenosis. Thus desulfated and reacetylated heparin was prepared; the Ac-heparin product was used for coating coronary metal stents. The stents were implanted in swines; after four weeks the animals were anesthetized and the artery segments removed for histomorphometric anal.

2003:913055 HCAPLUS <<LOGINID::20080702>>

DN 139:399770

AN

TI Medical goods comprising heparin or chitosan-based hemocompatible coating IN Horres, Roland; Linssen, Marita Katharina; Hoffmann, Michael; Faust,

Volker; Hoffmann, Erika; Di Biase, Donato PA Hemoteg G.m.b.H., Germany

SO PCT Int. Appl., 93 pp.

CODEN: PIXXD2

- DT Patent
- LA German
- FAN CNT 2

FAN.	CNT	2																	
	PAT	ENT I	.00			KIN	D	DATE			APPL	ICAT:	ION I	NO.		D	ATE		
							-												
PI	WO	2003	0949	90		A1		2003	1120		WO 2	003-	DE12.	53		2	0030	415 <-	-
		W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FΙ,	GB,	GD,	GE,	GH,	
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NI,	NO,	NZ,	OM,	
			PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	
			TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW						
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	
			KG,	KZ,	MD,	RU,	TJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	

```
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
               BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
      DE 10221055
                             A1 20031127
                                                  DE 2002-10221055
      DE 10221055
                             B4
                                    20071025
      DE 10261986
                            A1 20040318 DE 2002-10261986
                                                                             20020510 <--
      DE 10261986
                            B4 20080131
                           A1 20031111 AU 2003-240391
B2 20070517
      AU 2003240391
                                                                             20030415 <--
      AU 2003240391
                            A1 20031120 CA 2003-2484269
                                                                             20030415 <--
      CA 2484269
      CN 1543362
                            A
                                   20041103 CN 2003-800770
                                                                             20030415 <--
                            A1 20050202 EP 2003-729829
B1 20061102
      EP 1501565
                                                                            20030415 <--
      EP 1501565
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                                   20050315 BR 2003-11446
      BR 2003011446 A
                                                                            20030415 <--
      CN 1665554
                                    20050907 CN 2003-815926
                                                                             20030415 <--
CN 1665554 A 20050907 CN 2003-815926
JP 2005534724 T 20051117 JP 2004-503070
AT 344064 T 20051115 AT 2003-729829
ES 2276065 T 3 20070616 ES 2003-729829
NZ 536331 A 20070831 NZ 2003-536331
IN 2004MN00606 A 20050218 IN 2004-80606
ZA 2004008791 A 20050527 ZA 2004-8791
ZA 2004008757 A 20050531 ZA 2004-8791
US 20050176678 A1 20050631 US 2004-8796
MX 2004PA11112 A 20050811 US 2004-71112
IN 2005M01451 A 20050714 MX 2004-711112
PRAI US 2002-378676P P 20020509 <---
DE 2002-10221055 A 20020510 <---
WO 2003-DE1253 W 20030415 <---
                             A
                                                                            20030415 <--
                                                                            20030415 <--
                                                                             20030415 <--
                                                                             20030415 <--
                                                                             20041028 <--
                                                                            20041028 <--
                                                                            20041028 <--
                                                                            20041108 <--
                                                                             20041109 <--
                                                                             20051230 <--
      WO 2003-DE1253
                             W
                                   20030415 <--
      IN 2004-MN606
                             A3 20041028
               THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
                ALL CITATIONS AVAILABLE IN THE RE FORMAT
L16 ANSWER 9 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Nanoparticulate compositions of angiogenesis inhibitors
AB Nanoparticulate compns. comprising at least one poorly soluble angiogenesis
      inhibitor and at least one surface stabilizer are described. The
      nanoparticulate compns. have an average particle size of less than about 2000
      nm. The invention also describes methods of making and using such compns.
      For example, a nanoparticulate dispersion was prepared by milling a mixture
      containing 5% 2-methoxyestradiol, 1% hydroxypropyl cellulose of low viscosity
      (HPC-SL), and 0.05% docusate sodium (DOSS). The mean particle size of the
      nanoparticulate dispersion of 2-methoxyestradiol was 153 nm, with 50% <
      144 nm, 90% < 217 nm, and 95% < 251 nm. After 2 wk storage at 5°,
      the nanoparticulate dispersion of 2-methoxyestradiol had a mean particle
      size of 195 nm.
     2003:777565 HCAPLUS <<LOGINID::20080702>>
AN
     139:296972
DN
ΤI
     Nanoparticulate compositions of angiogenesis inhibitors
IN
     Merisko-Liversidge, Elaine; Bosch, H. William; Cary, Greta G.; Pruitt,
      John; Ryde, Tuula; Jain, Rajeev; Walters, Amy
PA
     Elan Pharma International Ltd., USA
      PCT Int. Appl., 72 pp.
SO
```

FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI MO 2003080027 Al 20031002 WO 2003-US8546 2003320 <-W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CODEN: PIXXD2 Patent English

```
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
            TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2479665
                        A1
                             20031002 CA 2003-2479665
                                                                20030320 <--
    AU 2003230691
                        A1
                              20031008 AU 2003-230691
                                                                20030320 <--
    US 20040033267
                        A1
                              20040219
                                        US 2003-392403
                                                                20030320 <--
    EP 1490030
                        A1
                             20041229
                                         EP 2003-723781
                                                                 20030320 <--
    EP 1490030
                        В1
                              20061025
           AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                         T
                             20051013
                                        JP 2003-577857
                                                                20030320 <--
    JP 2005530712
    AT 343376
                              20061115
                                          AT 2003-723781
                                                                 20030320 <--
                                          EP 2006-22201
    EP 1800666
                         A1
                               20070627
                                                                 20030320 <--
        R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR
    US 20080050461
                    A1
                              20080228
                                         US 2007-928250
                                                                 20071030 <--
                                          US 2007-928278
    US 20080107741
                        A1
                              20080508
                                                                20071030 <--
                        P
PRAI US 2002-365540P
                              20020320 <--
                       P
    US 2002-366542P
                              20020325 <--
                       A3
                             20030320 <--
    EP 2003-723781
    US 2003-392403
                        A3
                               20030320
    WO 2003-US8546
                        ToT
                              20030320 <--
RE.CNT 9
             THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
             ALL CITATIONS AVAILABLE IN THE RE FORMAT
L16 ANSWER 10 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
    Effect of amphotericin B treatment on kinetics of cytokines and parameters
    of fungal load in neutropenic rats with invasive pulmonary aspergillosis
AB
    The kinetics of various parameters of fungal load and cytokines were
    investigated, to acquire insight into the pathogenesis of invasive
    pulmonary aspergillosis (IPA) during antifungal treatment with
    amphotericin B. Neutropenic rats with left-sided IPA received either
    treatment with amphotericin B or remained untreated. At 0, 4, 8, 16, 24,
    48, 72 and 120 h after fungal inoculation, the rats were dissected. The
    size of the macroscopic pulmonary lesions, the number of cfu and amts. of
    chitin were determined in the infected left lung. Galactomannan
```

concns. were measured both in the left lung and serum. The cytokines tumor necrosis factor (TNF)- α , interleukin (IL)-1 β , IL-6, interferon (IFN)-γ, IL-4, IL-10, and the chemokines macrophage inflammatory protein (MIP)-2 and monocyte chemoattractant protein (MCP)-1 were determined quant. by ELISA in the infected left lung, uninfected right lung and serum. Amphotericin B treatment of IPA resulted in changed aspect of pulmonary lesions and significantly reduced levels of left lung chitin (72 and 120 h), left lung galactomannan (72 and 120 h) and serum galactomannan (120 h), but not left lung cfu, compared with untreated infected rats. In addition, amphotericin B treatment resulted in a significant decrease in levels of left lung IL-6 (at 72 and 120 h), MIP-2 (at 120 h) and MCP-1 (at 120 h). No local or systemic increases in TNF- α , IL-1 β or IFN- γ were observed during infection. It is concluded that treatment with amphotericin B results in decreased fungal load in the infected lung. This reduction in fungal load probably results in a decreased local inflammatory response, as measured by decreased levels of IL-6, MIP-2 and MCP-1 in the infected lung. 2003:726072 HCAPLUS <<LOGINID::20080702>>

- Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis
- Becker, Martin J.; de Marie, Siem; Fens, Marcel H. A. M.; Verbrugh, Henri AII A.; Bakker-Woudenberg, Irma A. J. M.
- Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center Rotterdam, Rotterdam, 3015 GE, Neth.
- SO Journal of Antimicrobial Chemotherapy (2003), 52(3), 428-434 CODEN: JACHDX; ISSN: 0305-7453
- PB Oxford University Press
- DT Journal
- T.A English
- RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L16 ANSWER 11 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
- ΤТ Silver-containing antimicrobial compositions
- AB The present invention comprises methods and compns. for making a silver-containing antimicrobial hydrophilic material. More particularly, the present invention comprises methods and compns. for stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide, and an active agent. The matrix may be formed into any desired shape for its desired uses. The incorporation of the antimicrobial agent, penicillin G, into the matrix was evaluated by dissolving 1+106 units of penicillin G powder into 50 mL of water. Acrylamide, methylenebisacrylamide, glycerol, and a guar gum/isopropyl alc. mixture were added 900 mL water and mixed for 2 h. The penicillin solution was then added along with TEMED dissolved in 25 mL water. After thorough mixing, ammonium persulfate in 25 mL water was added and mixed thoroughly. The mixture was then poured into sheet molds and allowed to gel. The sheets of semi-solid gel material were stripped from the mold and dehydrated to approx. 7% their original water content for storage. Disks of 0.7 cm diameter were cut from the sheets. These results demonstrate the release of active penicillin G after its incorporation into the matrix.
- 2003:622578 HCAPLUS <<LOGINID::20080702>> AN
- DN 139:169330
- TΙ Silver-containing antimicrobial compositions
- IN Gibbins, Bruce L.; Hopman, Lance D.
- PA Acrymed, USA SO U.S., 29 pp., Cont.-in-part of U.S. Ser. No. 191,223.
 - CODEN: USXXAM
- DT Patent LA English

FAN.CNT						
PA	TENT NO.	KIND	DATE	API	PLICATION NO.	DATE
PI US	6605751	B1	20030812	US	2000-675892	20000929 <
US	6355858	B1	20020312	US	1998-191223	19981113 <
US	20040010215	A1	20040115	US	2003-441275	20030519 <
US	6897349	B2	20050524			
US	20050226931	A1	20051013	US	2004-978556	20041101 <
PRAI US	1997-971074	A2	19971114	<		
US	1998-191223	A2	19981113	<		
US	1999-157000P	P	19991001	<		
US	2000-212455P	P	20000619	<		
US	2000-675892	A1	20000929	<		
US	2003-441275	A1	20030519	<		
RE.CNT	17 THERE ARE	17 CITE	REFERENCE	ES AV	ATLABLE FOR THIS B	RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

- TI Effects of a lichen galactomannan and its vanadyl (IV) complex on peritoneal macrophages and leishmanicidal activity
- AB A galactomannam (GMPOLY) isolated from lichen Ramalina celastri was complexed with vanadyl ion (IV,VO) forming the complex GMPOLY-VO. Both GMPOLY-VO diminished the superoxide anion production by macrophages triggered with PMA, the complex giving rise to this effect at concns. 100 times lower than GMPOLY. Macrophages treated with GMPOLY enhanced the nitric oxide production (40%), this effect not being observed when interferon-y (IFM-y) or IFM-y plus lipopolysaccharide (LPS) were present. No effect on nitric oxide production was observed by treatment of macrophage with GMPOLY-VO. Both GMPOLY and

lipopolysaccharide (LPS) were present. No effect on nitric oxide production was observed by treatment of macrophage with GMPOLY-VO. Both GMPOLY and GMPOLY-VO exhibited leishmanicidal effects on the amastigote form of Leishmania amazonesis, but only GMPOLY-VO inhibited the growth of promastigote form.

- AN 2002:543306 HCAPLUS <<LOGINID::20080702>>
- DN 137:92613
- TI Effects of a lichen galactomannan and its vanadyl (IV) complex on peritoneal macrophages and leishmanicidal activity
- AU Noleto, Guilhermina R.; Merce, Ana Lucia R.; Iacomini, Marcello; Gorin, Philip A. J.; Soccol, Vanete Thomaz; Oliveira, Maria Benigna M.
- CS Departamento de Bioquimica, Universidade Federal do Parana, Curitiba, Brazil
- SO Molecular and Cellular Biochemistry (2002), 233(1&2), 73-83
- CODEN: MCBIB8; ISSN: 0300-8177
- PB Kluwer Academic Publishers
- DT Journal
- LA English
- RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L16 ANSWER 13 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Polymer-based matrixes for wound dressing devices containing antimicrobial agents
- AB The present invention comprises methods and compns. for treating wounds. More particularly, the present invention comprises methods and compns. for wound dressing devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide having active agents, such as wound healing agents, incorporated therein. The matrix may be formed into any desired shape for the treatment of wounds. The incorporation of the antimicrobial agent, penicillin G, into the matrix was evaluated by dissolving 1+106 units of penicillin G powder into 50 mL water. Acrylamide, methylenebisacrylamide, glycerol, and a guar gum/isopropyl alc. mixture were mixed for 2 h. The penicillin solution was then added to an aqueous solution of TEMED and after thorough mixing, ammonium persulfate in water was added and mixed thoroughly. The mixture was then poured into sheet molds and allowed to gel. The sheets of semi-solid gel material were stripped from the mold and dehydrated to approx. 7% their original water content for storage. Prior to testing, the sheets were placed in a humidified environment until the sheet weight had increased to approx. 118-122% the storage weight Disks were cut and placed onto the surfaces of agar plates that had previously been seeded with various strains of microorganisms (Staphylococcus aureus; Escherichia coli; Candida albicans; Pseudomonas aeruginosa). Zones of inhibition were measured around the penicillin containing matrix but not the control matrix on the S. aureus, E. coli, and P. aeruginosa plates. The results demonstrated the release of active penicillin G after its incorporation into the matrix.
- AN 2002:182217 HCAPLUS <<LOGINID::20080702>>
- DN 136:236843
- TI Polymer-based matrixes for wound dressing devices containing antimicrobial agents

- IN Gibbins, Bruce L.
- PA AcryMed, Inc., USA
- SO U.S., 14 pp., Cont.-in-part of U.S. 5,928,174.
- CODEN: USXXAM
- DT Patent LA English
- FAN.CNT 4

TIME CHAIN				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6355858	B1	20020312	US 1998-191223	19981113 <
US 6605751	B1	20030812	US 2000-675892	20000929 <
US 20040010215	A1	20040115	US 2003-441275	20030519 <
US 6897349	B2	20050524		
US 20050226931	A1	20051013	US 2004-978556	20041101 <
PRAI US 1997-971074	A2	19971114	<	
US 1998-191223	A2	19981113	<	
US 1999-157000P	P	19991001	<	
US 2000-212455P	P	20000619	<	
US 2000-675892	A1	20000929	<	
US 2003-441275	A1	20030519	<	

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L16 ANSWER 14 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates
- AB A stable cosmetic, dermatol., or pharmaceutical composition comprising: (a) about 0.001-99.9%, by weight, of at least one metal complex of an oxidized carbohydrate, wherein the metal complex of an oxidized carbohydrate is
- neither zinc gluconate, manganese gluconate, nor lithium gluconate; and (b) about 0.1-99.99%, by weight, of a vehicle, wherein the vehicle comprises at least about 5%, by weight of the composition, of propylene glycol. The
- composition is administered orally, parenterally or topically. For example, a topical composition was prepared containing zinc lactobionate 5.0%, zinc gluconate 3.0%.
 - minoxidil 2.5%, propylene glycol 8.0%, dimethylisosorbide 19.0%, and ethanol and minors up to 100%.
- AN 2002:89809 HCAPLUS <<LOGINID::20080702>>
- DN 136:139844
- TI Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates
- IN Gardlik, John Michael; Severynse-Stevens, Diana; Comstock, Bryan Gabriel PA The Procter & Gamble Company, USA
- SO PCT Int. Appl., 47 pp.
- CODEN: PIXXD2
- DT Patent
- LA English

E MIN .	CIVI																	
	PATENT	NO.			KIN	D	DATE			APPL	ICAT	ION	NO.		D.	ATE		
						_									_			
PI	WO 200	20077	00		A2		2002	0131		WO 2	001-	US23	425		2	0010	725 <	
	WO 200	20077	0.0		A8		2003	1030										
	WO 200	20077	00		A3		2002	0829										
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE.	ES,	FI,	GB,	GD,	GE,	GH,	
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PL,	PT,	
		RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	UG,	UZ,	
		VN,	YU,	ZA,	ZW													

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,

```
KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
       IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
       GQ, GW, ML, MR, NE, SN, TD, TG
                                     US 2001-909440
US 20020119174
                    A1
                          20020829
                                                             20010719 <--
```

PRAI US 2000-220756P 20000726 <--P

L16 ANSWER 15 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN Method of regulating hair growth using metal complexes of oxidized

carbohydrates A method for regulating the growth of hair comprising administering to a mammal, an effective amount of a composition comprising: (a) about 0.001-99.9%, by weight, of at least one metal complex of an oxidized carbohydrate, wherein the metal complex of an oxidized carbohydrate is neither zinc gluconate nor manganese gluconate; and (b) about 0.1-99.999%, by weight, of a vehicle. The composition is administered orally, parenterally, or topically. For example, a topical composition contained zinc lactobionate 5.0%, zinc gluconate 1.0%, zinc pyrithione 1.0%, Tween 20 1.0%, propylene glycol 10.0%, dimethylisosorbide 18.0%, EtOH 30.0%, and water and minors up to 100%. Also, tablets were prepared containing zinc lactobionate 100 mg, Crospovidone

mg, lactose 200 mg, microcryst. cellulose 80 mg, and magnesium stearate 5

2002:89795 HCAPLUS <<LOGINID::20080702>> AN

DN 136:139843

15

Method of regulating hair growth using metal complexes of oxidized carbohydrates

Gardlik, John Michael; Severynse-Stevens, Diana; Comstock, Bryan Gabriel TN

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent LA English

FAN.	CNT	1																
		ENT :				KIN	D	DATE			APPL:					D	ATE	
PI		2002				A2	_	2002	0131			001-				2	0010	725 <
	WO	2002	0076	85		A8		2003	1030									
	WO	2002	0076	85		A3		2002	0829									
		W:						ΑU,										
								DK,										
			GM,	HR,	ΗU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KΡ,	KR,	ΚZ,	LC,	LK,	LR,
								MD,										
			RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ΤJ,	TM,	TR,	TT,	TZ,	UA,	UG,	UZ,
				YU,														
		RW:						ΜZ,										
								ΑT,										
								PT,			BF,	ΒJ,	CF,	CG,	CI,	CM,	GA,	GN,
								SN,										
		2002						2002										719 <
		2001						2002				001-	8077	9		2	0010	725 <
PRAI		2000																
	WO	2001	-US2	3424		W		2001	0725	<-	-							

L16 ANSWER 16 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

Silver-containing compositions, devices and methods for making them

The present invention comprises methods and compns. for making a silver-containing antimicrobial hydrophilic material. More particularly, the present invention comprises methods and compns. for stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a non-gelable polysaccharide, and an active agent. The matrix may be formed into any desired shape for its desired uses.

```
AN 2001:265285 HCAPLUS <<LOGINID::20080702>> DN 134:300843
```

II Silver-containing compositions, devices and methods for making them

IN Gibbins, Bruce L.; Hopman, Lance D.

PA Acrymed, USA

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DT Patent

LA English FAN.CNT 4

		TENT :				KIN		DATE						NO.			ATE		
PI	WO	2001	0248	39				2001	0412									929 <	
								AU,			BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
			CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	
			HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	
			LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PL,	PT,	RO,	RU,	
			SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	UG,	US,	UΖ,	VN,	
			YU,	ZA,	ZW														
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,	
			DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	BJ,	
								GN,											
	EP	1216	065			A1		2002	0626		EP 2	000-	9705:	22		2	00009	929 <	
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
								RO,											
PRAI		1999																	
		2000																	
		2000																	
RE.CI	NT	8						REFE						THI	S RE	CORD			

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 17 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

II Immunoglobulin production regulating activity of dietary fibers

AB In rats fed some types of dietary fat, class specific increases or
decreases of serum Igs (lg), changes in 1g productivity of spleen and
mesenteric lymph node (MLN) lymphocytes, changes in T cell populations of
splenocytes, and changes in cytokine productivity in MLN lymphocytes have
been reported. In comparison with the water-insol. dietary fiber
cellulose the soluble forms pectin, glucomannan and chitosan enhanced the
production of IGA and IGG, but inhibit the production of IGE. The proportion

CD8 cells in rats fed these dietary fibers are significantly lower than rats fed cellulose and the proportion of CD4 cells is significantly elevated. In addition, production of interferon-y and tissue necrosis factor-a by MLN lymphocytes is significantly enhanced by pectin as compared with cellulose. These results suggest that dietary fibers in the diet affect Ig production by influencing T cell differentiation and cytokine synthesis. Though similar Ig production regulating activity is observed galactomannan guar gum, enzymically degraded guar gum exerts lower activity. When MLN lymphocytes are cultured in the presence of glucomannan, galactomannan, or their structural sugars, no change in the Ig productivity has been observed These results suggest that the above effects are not due to the direct interaction of dietary fibers or their metabolites on the Ig production system.

AN 2000:418862 HCAPLUS <<LOGINID::20080702>>

DN 133:281020

of

TI Immunoglobulin production regulating activity of dietary fibers

AU Yamada, Koji

CS Lab. Food Chem., Div. Bioresource Bioenvironmental Sci., Grad. Sch. Kyushu

```
Univ., Fukuoka, 812-8581, Japan
```

Foods & Food Ingredients Journal of Japan (2000), 186, 26-32 SO

CODEN: FFIJER; ISSN: 0919-9772

PR FFI Janaru DT Journal.

LA Japanese

L16 ANSWER 18 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Improved wound dressing device and methods

AB The present invention comprises methods and compns. for treating wounds. More particularly, the present invention comprises methods and compns. for wound dressing devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide having active agents, such as wound healing agents, incorporated therein. The matrix may be formed into any desired shape for treatment of wounds. A mixing tank was charged with 161.4 kg water and 9.1894 kg acrylamide, and 0.10347 kg of methylenebisacrylamide and 9.3046 kg glycerol were added and mixed. Then, 1.0213 kg quar qum was dispersed in a mixture containing 0.9770 kg isopropanol and 2 kg water. The solution of guar gum was dispersed into the acrylamide mixture After suitable mixing, 0.1042 kg TEMED was added and polymerization was catalyzed with 0.0999 kg ammonium persulfate.

While

the batch was still liquid, it was poured into molds to form sheets. After gelling had occurred, sheets were transferred to a desiccator and dehydrated to form a stable sheet.

```
AN
     1999:350613 HCAPLUS <<LOGINID::20080702>>
```

DN 130:357215

Improved wound dressing device and methods

IN Gibbins, Bruce L.

PA USA SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

Patent DT

LA English

FAN.	PA	TENT N				KINI		DATE			APPL	ICAT	ION 1	. OF			ATE	
PI	WO	99253	395			A2					WO 1	998-	US24:	272				113 <
		W:	AL, DK, KP,	AM, EE, KR,	AT, ES, KZ,	AU, FI, LC,	AZ, GB, LK,	BA, GD, LR,	BB, GE, LS,	BG, GH, LT,	GM, LU,	HU, LV,	ID, MD,	IL, MG,	IS, MK,	JP, MN,	KE, MW,	KG, MX,
								RU, YU,		SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,
		RW:						SD, IT,										
	AU							MR, 1999					1699	1		1	9981	113 <
		10306									EP 1	998-	9617	33		1	9981	113 <
			AT, IE,		CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
DDST		29248						2005 1997				998-	9617	33		1	9981	113 <
PRAI		1997-																
1.16	AN:	SWER 1	19 01	F 23	HC:	APLIIS	3 0	OPYR	TGHT	200	8 AC	S on	STN					

- L16 ANSWER 19 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
- Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
- Gas and gaseous precursor filled microspheres, and foams provide novel topical and s.c. delivery vehicles for various active ingredients,

including drugs and cosmetics. Gas and gaseous precursor filled microcapsules were prepared from dipalmitoylphosphatidylcholine.

AN 1998:207280 HCAPLUS <<LOGINID::20080702>>

DN 128:275101

OREF 128:54369a,54372a

- TI Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
- IN Unger, Evan C.; Matsunaga, Terry O.; Yellowhair, David
- Imarx Pharmaceutical Corp., USA PA
- U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 307,305. SO
- CODEN: USXXAM
- Patent
- LA English FAN.CNT 21

PAN.C	NI ZI						
1	PATENT NO. US 5733572		KIND	DATE	APPLICATION NO.		DATE
PI I	TC 5722572		7.	100000221	TIC 1004-246426		100/11/20
EI !	33 3733372			19900331	03 1334-340420		19941129 <
1	JS 5088499		A	19920218	US 1990-569828		19900820 <
1	WO 9109629		A1	19910711	US 1994-346426 US 1990-569828 WO 1990-US7500		19901219 <
	W: CA,	.TD					
				no no	OD OD TM 111 111	0.77	
	RW: AT,	BE,	H, DE, L	DK, ES, FR,	GB, GR, IT, LU, NL,	SE	
	JP 05502675		T	19930513	JP 1991-503276		19901219 <
	JP 3309356		B2	20020729			
	AT 180170			10000015	3T 1001 0020E7		10001210 *
	MI 1001/0		1	19990013	A1 1991-902037		19901219 <
	ES 2131051		T3	19990716	ES 1991-902857		19901219 <
	CA 2069759		С	20070116	CA 1990-2069759		19901219 <
1	JS 5228446		ā	19930720	HS 1991-717084		19910618 <
	WO 9222247		3.1	10001000	WO 1002 W02615		10020221
,	NO 9222241		AI	19921223	WU 1992-US2615		19920331 <
	W: AU,	CA, J	P		GB, GR, IT, LU, NL, JP 1991-503276 AT 1991-902857 ES 1991-902857 CA 1990-2069759 US 1991-717084 WO 1992-US2615 GB, GR, IT, LU, MC,		
	RW: AT.	BE. C	H. DE. D	OK. ES. FR.	GB, GR, IT, LU, MC,	NI	SE
	NII 0220020	,	,,	10020112	AU 1002 20020	,	10020221 <
	MO 5220020		m n	19930112	AU 1992-20020		19920331 <
	AU 667471		B2	19960328			
	JP 06508364		T	19940922	AU 1992-20020 JP 1993-500847 EP 1992-912456		19920331 <
	TP 3456584		B2	20031014			
	D C1C500		3.1	10031011	ED 1000 010156		100000001
	FL 010208		AI	19940928	EP 1992-912456		19920331 <
1	EP 616508		B1	20010718			
1	EP 616508		B2	20040929			
	D. 3T	DF C	ם ספ ד	W EC ED	GB, GR, IT, LI, LU,	140	NT CP
	N. MI,	DE,	n, DE, L	M, ES, EN,	GB, GR, IT, LIT, LU, AT 1992-912456 ES 1992-912456 CA 1992-912456 US 1993-76239 US 1993-76250 US 1993-8268 US 1993-160232 US 1993-15987 US 1994-199462 WO 1994-US5633	PIC,	NL, SE
	AT 203148		T	20010815	AT 1992-912456		19920331 <
1	ES 2159280		T3	20011001	ES 1992-912456		19920331 <
	CA 2110491		С	20070724	CA 1992-2110491		19920331 <
	10 5/6005/		7	10051120	HC 1002-76220		10020611
	33 3403034			19931120	03 1993-76239		19930011 <
	JS 5580575		A	19961203	US 1993-76250		19930611 <
1	JS 5348016		A	19940920	US 1993-88268		19930707 <
1	TS 5542935		A	19960806	HS 1993-160232		19931130 <
	10 5505112		7	10061217	TIC 1002 150607		10021120 <
	JS JJ6J112		Α.	19901217	03 1993-139007		19931130 <
1	JS 5769080		A	19980623	US 1994-199462		19940222 <
1	WO 9428874		A1	19941222	WO 1994-US5633		19940519 <
	W: AU,	CA. C	NTP				
				N EC ED	GB, GR, IE, IT, LU,	140	NI DT CE
	KW: AI,	BE,	H, DE, L	M, ES, FK,	GB, GR, IE, II, LU,	MC,	NL, PI, SE
1	US 5773024 CA 2177713		A	19980630	US 1994-307305 CA 1994-2177713		19940916 <
	CA 2177713		A1	19950608	CA 1994-2177713		19941130 <
1	WO 9515118		A1	19950608	WO 1994-US13817		19941130 <
		03 0	N, JP	13330000	"0 1334-0513017		15511150 <
	RW: AT,	BE, C	H, DE, D	OK, ES, FR,	GB, GR, IE, IT, LU,	MC,	NL, PT, SE
1	EP 740528		A1	19961106	EP 1995-908414		19941130 <
	EP 740528 EP 740528		B1				
	R: AT,	BE, C	H, DE, D	DK, ES, FR,	GB, GR, IE, IT, LI,	LU,	MC, NL, PT, SE
	JP 09506098		T	19970617	JP 1995-515763 AT 1995-908414 US 1995-468056		19941130 <
	AT 235228		т	20030415	AT 1995-908414		19941130 <
	TO EE21402		2	10061105	TIC 1005 400050		10050000
	JS 33/149/		A	13301102	05 1335-468056		13330000 <

CN 1102045 US 6001335 A 19991214 US 1996-665719 US 5935553 A 19990810 US 1997-818179 US 5985246 A 19991116 US 1997-841169 19970429 US 5985246 A 19991116 US 1997-841169 19970429 AU 9886271 A 19980507 AU 1998-65271 19980224 AU 713127 B2 19991125 AU 9888405 A 19981203 AU 1998-88405 A1 20000420 HK 1013625 AU 731072 B2 20010322 HK 1013625 AU 731072 B2 20010322 HK 1013625 AU 7990043 AU 1999-114978 B1991125 AU 9910043 AU 1999-10043 B19910044 AU 1999-10043 B1990-10043 B1990-10044 B1990-10043 B1990-10044 B1990-10043 B1990-10044 B1990-10043 B1990-10044 B1990-10043 B1990-10044 B1990-10044 B1990-10043 B1990-10044 B1990-10	CN	1180310	A	19980429	CN	1996-193069	19960327 <
US 5935553 A 19900810 US 1996-758179 19961125 <			В	20030226			
US 6743779 US 5985246 A 19991116 US 1997-884126 1997008 < AU 9856271 A 19980507 AU 1998-56271 19980224 < AU 713127 B2 19991125 AU 9888405 A 19981203 AU 1998-88405 19981012 < AU 731072 B2 20010322 HK 1013625 A1 20000420 HK 1998-114978 19981223 < AU 9910043 A 19990304 AU 1999-10043 19991004 AU 1999-10043 19991004 GR R 3036877 T3 20020131 GR 2001-401740 20011011 < PRAI US 1989-455707 B2 19891222 US 1991-716899 B2 19910618 US 1993-76250 A2 19930611 US 1993-76250 A2 19930611 US 1993-76250 A2 19930611 US 1993-159674 B2 1993130 US 1993-159677 B2 1993130 US 1993-150687 A2 1993130 US 1993-150687 A2 1993130 US 1991-716793 A 19910618 US 1993-156687 A2 1993130 US 1993-156687 A2 1993130 US 1993-15687 A2 1993130 US 1993-160232 A2 19930130 US 1991-716783 A 19910618 US 1992-US2615 A 19930130 US 1992-US2615 A 19930130 US 1993-16783 A 19910618 US 1993-16783 A 19910618 US 1993-16886 A3 19930217 US 1993-16783 A3 19910619 US 1993-16783 A3 19910619 US 1993-16783 A3 19930217 US 1993-1688 A3 19930217 US 1993-86608 A3 19930217 US 1993-86608 A3 19930217 US 1993-1683 A3 19930217 US 1993-1683 A3 19950218 US 1994-0131817 W 19941130 US 1994-0131817 W 19941130 US 1995-395683 A3 19950266 US 1995-460055 A3 19950606 US 1995-788661 B2 1997017 US 1995-788661 B2 1997017 US 1996-640554 B2 1997017 US 1996-665719 B3 199901017			A	19991214	US	1996-665719	19960618 <
US 5985246 A 19991116 US 1997-888426 19970708 <	US	5935553	A	19990810	US	1996-758179	19961125 <
AU 9856271 A 19980507 AU 1998-56271 19980224 < AU 713127 B2 19991125 AU 9888405 A 19981203 AU 1998-88405 19981012 < AU 731072 B2 20010322 HK 1013625 A1 20000420 HK 1998-114978 19981223 < AU 9910043 A 19990304 AU 1999-10043 19990104 < GR 3036877 T3 20020131 GR 2001-401740 20011011 < PRAI US 1989-455707 B2 19891222 < US 1990-569828 A2 19900820 < US 1991-716899 B2 19910618 < US 1993-76250 A2 19930611 < US 1993-76250 A2 19930611 < US 1993-76250 A2 19930611 < US 1993-195687 A2 1993130 < US 1993-19688 < US 1993-19688 A3 19910219 < US 1992-052615 A 19910618 < US 1992-052615 A 19921027 < US 1993-19688 A3 19930217 < US 1993-19688 A3 19930212 < US 1993-19688 A3 19930212 < US 1993-19688 A3 19930212 < US 1993-85608 A3 19930212 < US 1993-85608 A3 19930210 < US 1993-8268 A3 19930217 < US 1993-8268 A3 19930210 < US 1993-8268 A3 19930217 < US 1993-8268 A3 19930030 < US 1993-8268 A3 19930030 < US 1993-8268 A3 199300707 < US 1994-013317 W 19941130 < US 1994-013317 W 19941130 < US 1994-013317 W 19941130 < US 1995-468056 A3 19950606 < US 1995-788661 B2 19990117 <	US	6743779	B1	20040601	US	1997-841169	19970429 <
AU 713127 AU 988405 AU 9888405 AU 19981203 AU 1998-88405 AU 19981203 AU 1998-88405 AU 19981203 AU 1998-88405 AU 1998-88405 AU 1999-10043 AU 19910043 AU 1999-10043 AU 1990-56828 AU 1990-822 AU 1990-822 AU 1991-71689 AU 1991-71689 AU 1991-71689 AU 1991-71689 AU 1993-76250 AU 1993-10618 AU 1993-76250 AU 1993-10618 AU 1993-199674 AU 1993-1993-1004 AU 1993-1993-1004 AU 1993-1993-1004 AU 1993-1993-1004 AU 1993-1993-1004 AU 1994-007305 AU 19940916 AU 1991-716793 AU 1991-716793 AU 1991-716793 AU 1991-716793 AU 1991-716793 AU 1991-71683 AU 1992-82615 AU 1992-82615 AU 1993-85608 AU 1993-85608 AU 1993-85608 AU 1993-85608 AU 1993-85608 AU 1993-8268 AU 1994-7016 AU 1994-7016 AU 1994-7016 AU 1994-7016 AU 1995-21850 AU 1994-304626 AU 1995-480056 AU 1995-480056 AU 1995-785661 BU 1999-788661	US	5985246	A	19991116	US	1997-888426	19970708 <
AU 9888405 AU 731072 BZ 20010322 HK 1013625 AI 20000420 HK 1998-18476 AU 9910043 A 19990304 AU 1999-10043 AI 20000420 HK 1998-114978 19981223 < GR 3036877 T3 20020131 GR 2001-401740 20011011 < PRAI US 1989-455707 BZ 19891222 US 1990-569828 AZ 19900820 US 1991-716899 BZ 19910618 US 1993-76239 AZ 19930611 US 1993-76250 AZ 19930611 US 1993-195687 AZ 1993130 US 1993-195687 AZ 1993130 US 1993-195687 AZ 1993130 US 1993-195687 AZ 1993130 US 1993-195687 AZ 19930108 AD 1994-307305 AZ 19940168 US 1993-19688 AZ 1993130 US 1993-19688 AZ 19930130 US 1993-19688 AZ 19930130 US 1992-818069 AZ 19930130 US 1992-82615 AZ 19930217 US 1993-1683 AZ 19930217 US 1993-1683 AZ 19930217 US 1993-85608 AZ 19930077 US 1993-8268 AZ 19930077 US 1993-8268 AZ 19930077 US 1993-8268 AZ 19930077 US 1993-1683 AZ 19930077 US 1993-1683 AZ 19940311 US 1994-70416 AZ 19940311 AU 1994-70416 AZ 1994130 US 1994-70416 AZ 1994130 US 1994-12553 AZ 1994130 US 1994-12553 AZ 1994130 US 1994-12553 AZ 19940311 AU 1994-70416 AZ 1994130 US 1994-70416 AZ 1994130 US 1994-12553 AZ 19940311 AU 1995-21850 AZ 1994130 US 1995-468056 AZ 19950606 US 1995-468055 AZ 19950606 US 1995-468055 AZ 19950606 US 1995-788661 BZ 19970117	AU	9856271	A	19980507	AU	1998-56271	19980224 <
AU 7310/2 HK 1013625 Al 20000420 HK 1998-114978 19981223 < AU 9910043 A 19990304 AU 1999-10043 19990104 < GR 3036877 T3 20020131 GR 2001-401740 20011011 < US 1990-569828 A2 19900820 US 1991-716899 B2 19910618 US 1991-716899 A2 19930611 US 1993-76250 A2 19930611 US 1993-19674 B2 1993130 US 1993-19679 B2 1993130 US 1993-19679 B2 1993130 US 1993-19679 B2 1993130 US 1993-19679 B3 1993130 US 1993-19679 B4 1993130 US 1994-307305 B4 1993130 US 1994-307305 B4 19910618 US 1995-79687 B4 1993130 US 1992-818069 B5 19920188 US 1992-818069 B7 19920188 US 1992-818069 B7 19920188 US 1993-17683 B7 19910618 US 1993-17683 B7 19910618 US 1992-818069 B7 1990019 B7 190019 B7 1900104 B			B2	19991125			
HK 1013625 AU 9910043 AU 1999-10043 AU 1999-10043 BE 1998-145707 BE 1998-145707 BE 1998-145707 BE 1998-145707 BE 1998-145707 BE 19980220 C- US 1991-716899 BE 199910618 C- US 1991-717084 AU 19990-66500 BE 199930611 C- US 1993-76250 AU 199930611 C- US 1993-159677 BE 19993130 C- US 1993-159678 BE 19993130 C- US 1993-159678 AU 19993130 C- US 1993-159679 AU 19990-1000 BE 19991130 C- US 1993-15000 BE 19991130 C- US 1993-160232 AU 19991130 C- US 1991-716793 AU 19910-716793 AU 19910-716793 AU 19910-716793 AU 19910-716793 AU 1991-716793 AU 1991-716793 AU 1991-716793 AU 1991-716793 AU 1991-716793 AU 1991-71683 AU 1993-17683 AU 1993-17683 AU 1993-17683 AU 1993-18112 BB 199300217 C- US 1993-1683 AU 1993-1683 AU 1993-1683 AU 1993-1683 AU 1994-70416 AU 1994-70416 AU 1994-70416 AU 1994-70416 AU 1995-21850 AU 1994-70416 AU 1994-70416 AU 1994-70416 AU 1994-70416 AU 1994-	AU	9888405	A	19981203	AU	1998-88405	19981012 <
AU 9910043 GR 3036877 T3 20020131 GR 2001-401740 20011011 < PRAI US 1989-455707 B2 19891222 < US 1990-569828 A2 199010618 < US 1991-716899 B2 19910618 < US 1993-76239 A2 19930611 US 1993-76250 A2 19930611 US 1993-199674 B2 19931130 < US 1993-199677 B2 19931130 < US 1993-199677 B2 19931130 < US 1993-199677 B2 19931130 < US 1993-19678 B2 19931130 < US 1993-19678 B2 19931130 < US 1993-19679 B2 19931130 < US 1993-19678 B2 19931130 < US 1993-19678 B3 19931130 < US 1994-307305 B3 19940916 C US 1994-807305 B3 19940916 C US 1991-716793 B3 19910618 C US 1992-818069 B3 19920108 C US 1992-818069 B3 19920108 C US 1992-95615 B3 19920217 C US 1993-17683 B3 19930217 C US 1993-85608 B3 19930217 C US 1993-85608 B3 19930217 C US 1993-8268 B3 19930207 C US 1994-0416 B3 1995-480056 B3 19950066 C US 1995-480056 B3 19950001 C US 1995-480056 B3 19950001 C US 1995-480056 B3 19950001 C US 1996-640554 B2 19990017 C US 1996-640554 B2 19990017 C US 1996-640554 B2 19990017 C US 1997-788661 B2 1997017 C			B2				
GR 3036B77 T3 20020131 GR 2001-401740 20011011 < PRAT US 1989-455707 B2 19891222 < US 1990-569828 A2 19990820 < US 1991-716899 B2 19910618 < US 1991-716899 A2 19930611 < US 1993-76239 A2 19930611 < US 1993-76250 A2 19930611 < US 1993-159674 B2 1993130 < US 1993-159674 B2 1993130 < US 1993-159677 A2 1993130 < US 1993-159687 A2 1993130 < US 1993-159687 A2 1993130 < US 1993-150687 A2 1993130 < US 1991-716793 A 19910618 < US 1991-716793 A 19910618 < US 1991-750877 A3 19910826 < US 1992-818069 A3 1992031 < US 1992-818069 A3 1992031 < US 1993-1683 A3 19930217 < US 1993-1683 A3 19930217 < US 1993-1688 A3 19930217 < US 1993-8268 A3 1993027 < US 1993-8268 A3 19930070 < US 1993-8268 A3 19930070 < US 1993-8268 A3 19930070 < US 1994-212553 B2 19940311 < US 1995-395683 A3 19950066 < US 1995-480056 A3 19950028 < US 1995-480056 A3 19950006 < US 1995-480056 B2 19960501 < US 1995-480056 B2 19960501 < US 1995-48661 B2 19970117 <			A1				
PRAI US 1989-455707 B2 19901222 < US 1991-716899 B2 19910618 < US 1991-717084 A2 19910618 < US 1991-717084 A2 19910618 < US 1993-76239 A2 19930611 < US 1993-76250 A2 19930611 < US 1993-76250 A2 19930611 < US 1993-76250 A2 19931130 < US 1993-15967 A2 19931130 < US 1993-15967 A2 19931130 < US 1993-16022 A2 19931130 < US 1994-707500 W1 19901219 < US 1994-707500 W1 19901219 < US 1991-716793 A 19910618 < US 1991-716793 A 19910618 < US 1992-818069 A3 19920108 < US 1992-818069 A3 19920108 < US 1992-818069 A3 1992027 < US 1993-7683 A3 1993027 < US 1993-7683 A3 1993027 < US 1993-85608 A3 1993027 < US 1993-85608 A3 1993027 < US 1993-8608 A3 1993027 < US 1993-8608 A3 1993027 < US 1993-8268 A3 19930707 < US 1993-8268 A3 19930707 < US 1993-8268 A3 19930707 < US 1994-70416 A3 1994031 < US 1994-70416 A3 1994031 < US 1994-70416 A3 1994130 < US 1994-91618 A3 1994031 < US 1994-70416 A3 1994031 < US 1994-91618 A3 1994031 < US 1994-91650 < US 1995-91665719 A3 19950606 < US 1995-865719 A3 19950606 < US 1995-865719 A3 19950606 < US 1996-640554 B2 19970117 < US 1997-788661 B2 19970	AU	9910043	A	19990304			19990104 <
US 1990-569828 A2 19900820 US 1991-716899 B2 19910618 US 1991-716899 B2 19910618 US 1993-76239					GR	2001-401740	20011011 <
US 1991-716899 B2 19910618 < US 1993-76239 A2 19930611 < US 1993-76250 A2 19930611 < US 1993-76250 A2 19930611 < US 1993-199674 B2 19931130 < US 1993-199674 B2 19931130 < US 1993-195687 A2 19931130 < US 1994-107305 A2 19940916 < US 1991-716793 A 19910618 < US 1991-716793 A 19910618 < US 1992-US2615 A 19920108 < US 1992-US2615 A 19920108 < US 1992-107683 A3 1992027 < US 1993-17683 A3 19930217 < US 1993-17683 A3 19930217 < US 1993-85608 A3 19930217 < US 1993-85608 A3 19930207 < US 1993-8608 A3 19930207 < US 1994-20153 B2 19940311 < US 1994-70416 A3 19940519 < US 1994-70416 A3 19940519 < US 1994-1013817 W 19941130 < AU 1994-70416 A3 19940519 < US 1994-1013817 W 19941130 < AU 1995-28566 A3 19950066 < US 1995-480056 A3 19950606 < US 1995-471250 A3 19950606 < US 1995-640554 B2 19960618 < US 1996-640554 B2 19960618 < US 1997-785661 B2 19970117 <	PRAI US	1989-455707		19891222	<		
US 1991-717084 A2 19910618 < US 1993-76239 A2 19930611 < US 1993-76250 A2 19930611 < US 1993-159674 B2 199313130 < US 1993-159677 B2 199313130 < US 1993-159687 A2 19931330 < US 1993-160232 A2 19931330 < US 1994-107305 A2 19940916 < US 1991-75000 W 19901219 < US 1991-716793 A 19910618 < US 1991-716793 A 19910618 < US 1992-818069 A3 19920108 < US 1992-818069 A3 19920108 < US 1992-967974 A3 19920107 < US 1993-7683 A3 19930212 < US 1993-7683 A3 19930212 < US 1993-82668 A3 19930217 < US 1993-82688 A3 19930707 < US 1993-82688 A3 19930707 < US 1993-82688 A3 19930707 < US 1993-8268 A3 19930707 < US 1994-212553 B2 19940311 < US 1994-212553 B2 19940311 < AU 1994-70416 A3 19940519 < US 1994-346426 A 19941129 < AU 1995-21850 A3 19931206 < US 1994-31817 W 19941130 < US 1995-395683 A3 19950228 < US 1995-480056 A3 19950066 < US 1995-480056 A3 19950066 < US 1995-480056 B2 19960011 <					<		
US 1993-76239 A2 19930611 < US 1993-76250 A2 19930611 < US 1993-76250 A2 19930611 < US 1993-76250 A2 19931130 < US 1993-159687 A2 19931130 < US 1993-150687 A2 19931130 < US 1994-307305 A2 19940916 < US 1991-716793 A 19910618 < US 1991-716793 A 19910618 < US 1991-716793 A 19910618 < US 1992-052615 A 19920108 < US 1992-052615 A 19920108 < US 1993-17683 A3 19930217 < US 1993-17683 A3 19930217 < US 1993-1688 A3 19930217 < US 1993-85608 A3 19930217 < US 1993-85608 A3 19930217 < US 1993-85608 A3 19930200 < US 1993-4010 A3 19940311 < US 1993-46426 A3 19940311 < US 1994-70416 A3 19940311 < US 1994-70416 A3 1994031 < US 1995-395663 A3 19950606 < US 1995-460056 A3 19950066 < US 1995-460056 A3 19950606 < US 1995-460056 B2 19960011 < US 1996-640554 B2 19960011 <	US	1991-716899	B2		<		
US 1993-16250 A2 19930611							
US 1993-159674 B2 19931130 < US 1993-159687 A2 19931130 < US 1993-159687 A2 19931130 < US 1994-307305 A2 19940916 < WO 1990-US7500 W 19901219 < US 1991-716793 A 19910618 < US 1991-716793 A 19910618 < US 1992-B18069 A3 19920108 < US 1992-B18069 A3 19920108 < US 1992-B8069 A3 19921027 < US 1993-17683 A3 19930217 < US 1993-17683 A3 19930217 < US 1993-B5608 A3 19930217 < US 1993-B8060 A3 19930217 < US 1993-B8268 A3 19930217 < US 1993-B8268 A3 19930217 < US 1993-B8268 A3 19930201 < US 1993-B8268 A3 19930707 < US 1993-B8268 A3 19930707 < US 1994-70416 A3 19940311 < AU 1994-70416 A3 19940311 < AU 1994-70416 A3 1994019 < US 1994-70416 A3 1994019 < US 1994-19550 A3 19941129 < AU 1995-21850 A3 19941130 < US 1995-395683 A3 19950228 < US 1995-468056 A3 19950606 < US 1995-468055 A3 19950606 < US 1995-640554 B2 19960510 < US 1996-640554 B2 19960510 < US 1996-640554 B2 19960618 < US 1997-785661 B2 19970117 <				19930611	<		
US 1993-195687 A2 19931130 < US 1994-210522 A2 19931130 < US 1994-307305 A2 19940916 < WO 1990-US'5500 W 19901219 < US 1991-716793 A 19910618 < US 1991-716793 A 19910618 < US 1991-216877 A3 19910626 < US 1992-818069 A3 19920108 < US 1992-US2615 A 19920103 < US 1992-967974 A3 19921027 < US 1993-16812 B3 19930212 < US 1993-8112 B3 19930217 < US 1993-80608 A3 19930217 < US 1993-80608 A3 19930630 < US 1993-8268 A3 19930630 < US 1993-8268 A3 1993017 < US 1993-4012553 B2 19940311 < AU 1994-70416 A3 19940519 < US 1994-212553 B2 19940311 < AU 1994-70416 A3 19940519 < US 1994-346426 A 19941129 < AU 1995-21850 A3 19931206 < US 1995-395683 A3 19950228 < US 1995-395683 A3 19950228 < US 1995-480056 A3 19950006 < US 1995-480056 B2 19960011 < US 1995-640554 B2 19960011 < US 1996-660554 B2 19960011 < US 1996-660554 B2 199900117 <					<		
US 1993-160232 A2 19931130							
US 1994-307305 A2 19940916 < WO 1990-US'7500 W 19901219 < US 1991-T16793 A 19910618 < US 1991-T16793 A 19910618 < US 1991-T50877 A3 19910626 < US 1992-US2615 A 19920108 < WO 1992-US2615 A 19920107 < US 1992-US2615 A 19920107 < US 1993-17683 A3 19930212 < US 1993-18112 B3 19930217 < US 1993-18112 B3 19930217 < US 1993-8608 A3 19930630 < US 1993-8608 A3 19930630 < US 1993-8608 A3 19930630 < US 1993-403053 B2 19940311 < AU 1994-70416 A3 19940519 < WS 1994-212553 B2 19940311 < AU 1994-70416 A3 19940519 < US 1994-346426 A 19941129 < AU 1995-21850 A3 19930206 < US 1995-395683 A3 19950228 < US 1995-480056 A3 19950028 < US 1995-460056 A3 19950066 < US 1995-460554 B2 19960618 < US 1996-660554 B2 19960618 < US 1996-660554 B2 19990017 <					<		
WO 1990-US7500 W 19901219 < US 1991-716793 A 19910818 < US 1991-716793 A 19910826 < US 1992-818069 A3 19920108 < US 1992-82615 A 19920331 < US 1992-967974 A3 19921027 < US 1993-17683 A3 19930212 < US 1993-85608 A3 19930217 < US 1993-88268 A3 1993027 < US 1993-88268 A3 1993027 < US 1993-893030 A3 19931206 < US 1993-160303 A3 19931206 < US 1994-70416 A3 19940311 < AU 1994-70416 A3 19940519 < US 1994-346426 A 19941129 < AU 1995-21850 A3 19941120 < US 1994-31850 A3 19941120 < US 1994-31850 A3 19941130 < US 1995-395683 A3 19950228 < US 1995-468056 A3 19950228 < US 1995-468056 A3 19950606 < US 1995-468055 B2 19960510 < US 1995-640554 B2 19960510 < US 1995-640554 B2 19960510 < US 1996-640554 B2 19960618 < US 1997-785661 B2 19970117 <	US	1993-160232	A2	19931130	<		
US 1991-716793 A 19910618 < US 1991-750877 A3 19910626 < US 1992-818069 A3 19920108 < US 1992-818069 A3 19920108 < US 1992-92615 A 19920103 < US 1992-967974 A3 19920107 < US 1993-17683 A3 19930217 < US 1993-8112 B3 19930217 < US 1993-88268 A3 19930217 < US 1993-88268 A3 19930707 < US 1993-85039 A3 19930707 < US 1993-813039 A3 19930707 < US 1993-4212513 B2 19940311 < US 1994-7016 A3 19940519 < US 1994-346426 A 19941130 < US 1994-346426 A 19941130 < US 1995-395683 A3 19950228 < US 1995-480056 A3 19950028 < US 1995-480056 A3 19950066 < US 1995-480056 B2 19960618 < US 1996-640554 B2 19960618 < US 1996-65719 A3 19950606 < US 1996-640554 B2 19970117 <							
US 1991-750877 A3 19910826 < US 1992-818069 A3 19920108 < WO 1992-0182615 A 19920331 < US 1992-967974 A3 19921027 < US 1993-1683 A3 19930212 < US 1993-8112 B3 19930217 < US 1993-88268 A3 19930630 < US 1993-88268 A3 19930707 < US 1993-163039 A3 19931206 < US 1994-122553 B2 19940311 < AU 1994-70416 A3 19940519 < US 1994-346426 A 19941129 < AU 1995-21850 A3 19941130 < US 1994-1850 A3 19941130 < US 1994-1850 A3 19941130 < US 1995-395683 A3 19950228 < US 1995-488066 A3 19950066 < US 1995-468056 B2 19960510 < US 1995-640554 B2 19960510 < US 1996-660554 B2 19960618 < US 1996-665719 A3 19950606 < US 1996-685719 A3 19950606 < US 1997-785661 B2 19970117 <			W		<		
US 1992-818069 A3 19920108 < WO 1992-US2615 A 19920311 < US 1992-US2615 A 19921027 < US 1993-17683 A3 19930212 < US 1993-17683 A3 19930212 < US 1993-8112 B3 19930217 < US 1993-88268 A3 19930207 < US 1993-88268 A3 19930707 < US 1993-82503 B2 19940311 < US 1994-212533 B2 19940311 < US 1994-7016 A3 19931206 < US 1994-346426 A 19941129 < AU 1995-21850 A3 19931409 < US 1995-395683 A3 19950228 < US 1995-395683 A3 1995028 < US 1995-480056 A3 19950066 < US 1995-6400554 B2 19960618 < US 1996-665719 A3 19950606 < US 1996-68056 B2 19970117 <			A	19910618	<		
WO 1992-US2615 A 19920331 US 1992-967974 A3 1992027 US 1993-17683 A3 19930212 US 1993-81812 B3 19930217 US 1993-85608 A3 199300707 US 1993-163039 A3 199310706 US 1994-122553 B2 19940311 AU 1994-70416 A3 1994011 AU 1995-21850 A3 19941129 AU 1995-21850 A3 19941130 WO 1994-W1313817 W 19941130 US 1995-395683 A3 19950228 US 1995-468056 A3 19950606 US 1996-640554 B2 1996051 US 1996-6605719 A3 19960618 US 1997-785661 B2 19970117							
US 1992-967974 A3 19921027 < US 1993-17683 A3 19930212 < US 1993-17683 A3 19930212 < US 1993-85608 A3 19930217 < US 1993-85608 A3 19930707 < US 1993-163039 A3 19931206 < US 1994-212553 B2 19940311 < AU 1994-70416 A3 19940519 < US 1994-346426 A 19941129 < AU 1995-21850 A3 19941130 < US 1995-959683 A3 19950228 < US 1995-959683 A3 19950228 < US 1995-48056 A3 19950606 < US 1995-640554 B2 19960618 < US 1996-665719 A3 19950606 < US 1996-656719 A3 19950606 < US 1996-656719 A3 19950606 < US 1996-68056 B2 19970117 <			A3				
US 1993-17683 A3 19930212 < US 1993-18112 B3 19930217 < US 1993-85608 A3 19930630 < US 1993-86268 A3 19930707 < US 1993-163039 A3 19931206 < US 1994-70416 A3 19940311 < AU 1994-70416 A3 19940519 < US 1994-746426 A 19941130 < AU 1995-21850 A3 19941120 < AU 1995-21850 A3 19941130 < US 1994-746426 A 19941130 < US 1995-395683 A3 19950228 < US 1995-395683 A3 19950228 < US 1995-395683 A3 19950606 < US 1995-646056 A3 19950606 < US 1995-6460554 B2 19960510 < US 1996-640554 B2 19960618 < US 1997-785661 B2 19970117 <							
US 1993-18112 B3 19930217 US 1993-85608 A3 19930630 < US 1993-85608 A3 19930707 < US 1993-163039 A3 19931206 < US 1994-212553 B2 19940311 AU 1994-70416 A3 19940319 < US 1994-346426 A 19941129 < AU 1995-21850 A3 19941130 < WO 1995-41850 A3 19941130 < US 1995-480056 A3 19950228 < US 1995-480056 A3 19950066 < US 1995-471250 A3 19950606 < US 1996-640554 B2 19960618 < US 1996-65719 A3 19950606 < US 1996-658719 A3 19950606 < US 1996-68056 B2 19970117 <							
US 1993-85608 A3 19930630 < US 1993-8268 A3 1993077 < US 1993-8268 A3 19931206 < US 1994-70416 A3 19940311 < AU 1994-70416 A3 19940519 < US 1994-70416 A3 19941120 < AU 1995-21850 A3 19941130 < US 1995-21850 A3 19941130 < US 1995-395683 A3 19950228 < US 1995-471250 A3 19950606 < US 1995-471250 A3 19950606 < US 1996-640554 B2 19960511 < US 1996-65719 A3 19950608 < US 1996-65719 A3 19950608 < US 1997-785661 B2 1997017 <							
US 1993-88268 A3 19930707 < US 1993-163039 A3 19931206 < US 1994-212553 B2 19940311 < AU 1994-70416 A3 19940519 < US 1994-346426 A 19941129 < AU 1995-21850 A3 19941130 < WO 1994-US13817 W 19941130 < US 1995-395683 A3 19950228 < US 1995-48056 A3 19950606 < US 1995-471250 A3 19950606 < US 1996-640554 B2 19960510 < US 1996-65719 A3 19950606 < US 1996-656719 A3 19950606 < US 1996-68056 B2 19970117 <							
US 1993-163039 A3 19931206 < US 1994-212553 B2 19940311 < AU 1994-70416 A3 19940519 < US 1994-346426 A 19941130 < AU 1995-21850 A3 19941130 < US 1995-395683 A3 19950228 < US 1995-395683 A3 19950228 < US 1995-471250 A3 19950606 < US 1995-471250 A3 19950606 < US 1996-640554 B2 1996051 < US 1996-65719 A3 19950618 < US 1997-785661 B2 19970117 <							
US 1994-212553 B2 19940311 AU 1994-70416 A3 19940519 US 1994-346426 A 19941129 AU 1995-21850 A3 19941130 WO 1994-US13817 W 19941130 US 1995-395683 A3 19950228 US 1995-480056 A3 19950606 US 1995-471250 A3 19950606 US 1996-640554 B2 19960510 US 1996-665719 A3 19950618 US 1997-785661 B2 19970117							
AU 1994-70416 A3 19940519 < US 1994-346426 A 19941129 < AU 1995-21850 A3 19941130 < US 1995-4813817 W 19941130 < US 1995-395683 A3 19950228 < US 1995-468056 A3 19950606 < US 1995-471250 A3 19950606 < US 1996-640554 B2 19960501 < US 1997-785661 B2 19970117 <							
US 1994-346426 A 19941129 < AU 1995-21850 A3 19941130 < WO 1994-US13817 W 19941130 < US 1995-395683 A3 19950228 < US 1995-468056 A3 19950606 < US 1995-471250 A3 19950606 < US 1996-640554 B2 19960510 < US 1996-65719 A3 19950618 < US 1997-785661 B2 19970117 <							
AU 1995-21850 A3 19941130 < WO 1994-US13817 W 19941130 < US 1995-395683 A3 19950228 < US 1995-468056 A3 19950606 < US 1995-471250 A3 19950606 < US 1996-640554 B2 19960501 < US 1996-665719 A3 19950618 < US 1997-785661 B2 19970117 <							
WO 1994-US13817 W 19941130 < US 1995-395683 A3 19950228 < US 1995-468056 A3 19950606 < US 1995-471250 A3 19950606 < US 1996-640554 B2 19960501 < US 1996-65719 A3 19960618 < US 1997-785661 B2 19970117 <							
US 1995-395683 A3 19950228 < US 1995-471250 A3 19950606 < US 1995-471250 A3 19950606 < US 1996-640554 B2 19960501 < US 1996-665719 A3 19960618 < US 1997-785661 B2 19970117 <							
US 1995-468056 A3 19950606 < US 1995-471250 A3 19950606 < US 1996-640554 B2 19960501 < US 1996-65719 A3 19960618 < US 1997-785661 B2 19970117 <							
US 1995-471250 A3 19950606 < US 1996-640554 B2 19960501 < US 1996-665719 A3 19960618 < US 1997-785661 B2 19970117 <							
US 1996-640554 B2 19960501 < US 1996-665719 A3 19960618 < US 1997-785661 B2 19970117 <							
US 1996-665719 A3 19960618 < US 1997-785661 B2 19970117 <							
US 1997-785661 B2 19970117 <							

RE.CNT 314 THERE ARE 314 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 20 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Glucoamylase gene fusions alleviate limitations for protein production in

Aspergillus awamori at the transcriptional and (post) translational levels AB In this study we have analyzed the effects of a glucoamylase gene fusion on the mRNA levels and protein levels for the human interleukin -6 gene (hil6) and the guar α-galactosidase gene (aglA). Previously it was shown that production of nonfused α-galactosidase and hIL-6 in Aspergillus awamori was limited at transcriptional and (post) translational levels, resp. (R. J. Gouka, P. J. Punt, J. G. M. Hessing, and C. A. M. J. J. van den Hondel, Appl. Environ. Microbiol. 62:1951-1957, 1996). Vectors were constructed which contained either the hil6 or aglA

gene fused to the Aspergillus niger glucoamylase gene (glaA) under control of the efficient 1,4- γ -endoxylanase A promoter and transcription

terminator. For comparison, the vectors were integrated in a single copy at the pyrG locus of A. awamori. A glaA fusion to the 5' end of the hil6 gene resulted in a large increase in hIL-6 yield, whereas with a glaA fusion to the 3' end of the hil6 gene, almost no protein was produced. Nevertheless, the steady-state mRNA levels of both fusions were very similar and not clearly increased compared to those of a strain expressing nonfused hIL-6. Fusions of glaA to the 5' end of the wild-type quar aglA gene resulted in truncated mRNA lacking almost 900 bases (>80%) of the aglA sequence. When the coding sequence of the wild-type aglA gene was replaced by a synthetic aglA gene with optimized Saccharomyces cerevisiae codon usage, full-length mRNA was obtained. Compared to a nonfused synthetic aglA gene, a glaA fusion with the synthetic aglA gene resulted in a 25-fold increase in the mRNA level and, as a consequence, a similar increase in the α -galactosidase protein level. The truncated transcripts derived from the wild-type aglA gene were further analyzed by nuclear run-on transcription assays. These expts. indicated that transcription elongation in the nucleus proceeded at least 400 bases downstream of the site where the truncation was determined, indicating that transcription elongation or premature termination was not the reason for the generation of truncated mRNAs. As the truncated mRNA also contained a poly(A) tail, truncation most likely occurs by incorrect processing of the aglA mRNA in the nucleus.

AN 1997:106774 HCAPLUS <<LOGINID::20080702>>

DN 126:167043

OREF 126:32197a,32200a

TI Glucoamylase gene fusions alleviate limitations for protein production in Aspergillus awamori at the transcriptional and (post) translational levels

AU Gouka, Robin J.; Punt, Peter J.; Van Den Hondel, Cees A.M.J.J.

CS Department of Molecular Genetics and Gene Technology, TNO Nutrition and Food Research Institute, Rijswijk, NL-2280 HV, Neth.

SO Applied and Environmental Microbiology (1997), 63(2), 488-497 CODEN: AEMIDF; ISSN: 0099-2240

PB American Society for Microbiology

DT Journal

LA English

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 21 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Analysis of heterologous protein production in defined recombinant Aspergillus awamori strains

A study was carried out to obtain more insight into the parameters that determine the secretion of heterologous proteins from filamentous fungi. A strategy was chosen in which the mRNA levels and protein levels of a number of heterologous genes of different origins were compared. All genes were under control of the A. awamori 1,4-B-endoxylanase A (exlA) expression signals and were integrated in a single copy at the A. awamori pyrG locus. A Northern (RNA) anal. showed that large differences occurred in the steady-state mRNA levels obtained with the various genes; those levels varied from high values for genes of fungal origin (A. awamori $1,4-\beta-$ endoxylanase A, Aspergillus niger glucoamylase, and Thermomyces lanuginosa lipase) to low values for genes of nonfungal origin (human interleukin 6 and Cyamopsis tetragonoloba [quar] α-galactosidase). With the C. tetragonoloba α-galactosidase wild-type gene, full-length mRNA was undetectable. Surprisingly, small amts. of full-length mRNA could be detected when a C. tetragonoloba a-galactosidase gene with an optimized Saccharomyces cerevisiae preference was expressed. In all cases except human interleukin 6, the protein levels corresponded to the amts. expected on basis of the mRNA levels. For human interleukin 6, very low protein levels were observed, whereas relatively high steady-state mRNA levels were

- obtained. These data suggest that intracellular protein degradation is the most likely explanation for the low levels of secreted human interleukin 6.
- AN 1996:335305 HCAPLUS <<LOGINID::20080702>>
- DN 125:8567
- OREF 125:1971a.1974a
- TI Analysis of heterologous protein production in defined recombinant Aspergillus awamori strains
- AU Gouka, Robin J.; Punt, Peter J.; Hessing, Johanna G. M.; van den Hondel, Cees A. M. J. J.
- CS Dep. Mol. Genetics Gene Technol., TNO Nutrition Food Res. Inst., Rijswijk, 2280 HV, Neth.
- SO Applied and Environmental Microbiology (1996), 62(6), 1951-1957 CODEN: AEMIDF; ISSN: 0099-2240
- PB American Society for Microbiology
- DT Journal
- LA English
- L16 ANSWER 22 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI Monocrystalline iron oxide particles for studying biological tissues
- AB A liquid that contains monocryst. superparamagnetic particles and a method for preparing this liquid are disclosed. Also described are a method of decreasing the NMR relaxation times of water protons in contact with biol. tissue by using this liquid and an in vitro method for obtaining information from biol. tissue or components thereof using this liquid
- AN 1996:184265 HCAPLUS <<LOGINID::20080702>>
- DN 124:283285
- OREF 124:52347a,52350a
- TI Monocrystalline iron oxide particles for studying biological tissues
- IN Weissleder, Ralph
- PA The General Hospital Corporation, USA
- SO U.S., 36 pp., Cont. of U.S. Ser. No. 725,060, abandoned. CODEN: USXXAM
- DT Patent
- LA English
- FAN.CNT 1

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	US 5492814	A	19960220	US 1992-970942	19921103 <
PRAI	US 1992-970942	B1	19921103	<	
	US 1991-725060	B2	19910703	<	
	US 1990-549434		19900706	<	

- L16 ANSWER 23 OF 23 HCAPLUS COPYRIGHT 2008 ACS on STN
- TI An interferon-like substance induced by mannans
- AB An interferon-like substance was detected in the serum of mice 2 hrs. after an i.v. inoculation of mannan (100 γ) obtained from Candida albicans. A galactomannan from Lipomyces starkeyi had a lower interferoninducing ability in cell cultures.
- AN 1967:409818 HCAPLUS <<LOGINID::20080702>>
- DN 67:9818
- OREF 67:1835a,1838a
- TI An interferon-like substance induced by mannans
- AU Borecky, L.; Lackovic, V.; Blaskovic, Dionyz; Masler, Ladislav; Sikl, Dobroslav
- CS Ceskoslov. Akad. Ved., Bratislava, Czech.
- SO Arerugi (1967), 11(3), 264-6 CODEN: ARERAM; ISSN: 0021-4884
- DT Journal
- LA English